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Pneumocystis remains the most common opportunistic infection in patients with HIV/AIDS and 
can cause a life-threatening fulminant pneumonia. Pneumocystis pneumonia is re-emerging in 
the HIV-negative population, as immunosuppressive medications have greater use clinically. As 
the at-risk population increases, understanding the underlying host responses that can lead to 
protection against Pneumocystis becomes imperative. To that end, we characterized the early 
CD4+ T-cell dependent eosinophilic response to Pneumocystis murina. Importantly, we 
demonstrated that eosinophils have potent anti-Pneumocystis activity both in vitro and in vivo.  
However, eosinophils in the lung can also lead to pathology as seen in allergic airway 
inflammation in asthma. We therefore compared Pneumocystis to the common airway allergen, 
house dust mite, and demonstrated that the immune response to both pathogens was highly 
similar. Pneumocystis antigen exposure resulted in increased airway hyperresponsiveness and 
mucus production in a Th2-dependent and eosinophil-independent manner. From a translational 
standpoint, a subset of patients with severe asthma had increased anti-Pneumocystis IgG and IgE 
antibodies. Patients with high anti-Pneumocystis IgG levels had worsened cough and lung 
function as measured by spirometry, suggesting that Pneumocystis exposure may be correlated 
with worsened disease.  
As Pneumocystis infection induces such a potent adaptive immune response, we next 
examined local immunity to Pneumocystis. Inducible bronchus associated lymphoid tissue 
(iBALT) has been characterized in several models of lung infection and contributes to protection. 
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Pneumocystis infection and exposure in a co-housing model resulted in the formation of iBALT 
structures in a CXCL13-dependent manner. Importantly, CXCL13 regulation appeared to be 
dependent on both Th2 and Th17 CD4+ T-cells in vivo and in pulmonary fibroblasts in vitro.   
The host response to Pneumocystis is limited in patients with global immunosuppression 
and the identification of novel drug and vaccine targets is lacking. Towards that end, we 
annotated the Pneumocystis genome and as proof-of-principle, demonstrated that the kinome 
(specifically VPS34) was druggable in vitro. Additionally, we utilized various –omics techniques 
to identify Meu10 and GSC-1 as novel vaccine targets capable of providing partial protection 
against Pneumocystis. Together, these studies identified novel protective and pathologic immune 
responses to Pneumocystis and enabled a top-down approach of anti-Pneumocystis therapeutic 
development. 
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PREFACE 
“If we knew what we were doing, it wouldn’t be called research.” 
-Albert Einstein
While this quote may seem like an inauspicious one to begin a dissertation defense with, I have 
two primary reasons for its selection. The first is that this quote reminds me of one of the many 
important lessons my mentor, Dr. Jay Kolls, imprinted on me during my time in his laboratory. 
Dr. Kolls continually reminded me to follow the data, as opposed to searching for results that 
would support a predetermined outcome. That philosophy led to at least two hours per week 
spent with Dr. Kolls, critically pouring over data and designing the next steps. This process led 
to the multiple successful projects contained within this defense and dozens of others that never 
got off the ground. But, it never mattered if my hypothesis was spot on or dead wrong. Instead, 
he taught me to evaluate every possible avenue that could explain the data and begin the next 
experiments. Find the phenotype, and chase it. That’s what I have spent the last three and half 
years doing, and while the chase invariably led to many exhilarating and frustrating twists and 
turns, I am incredibly thankful for the journey and all he has taught me. It was truly an honor to 
work with such a brilliant scientific mind over the past three years.  
Of course, Dr. Kolls was not the only mentor I have encountered over my training. I 
would like to thank Dr. Brian Campfield, a faculty member in the Kolls’ lab, for seldom acting 
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like a faculty member. Dr. Campfield was an excellent role model on how to live a balanced life 
as a physician scientist and his advice, humor, and guidance throughout my PhD years were 
unbelievably important to my training. I also need to acknowledge Dr. Waleed Elsegeiny, a 
former graduate Student in the Kolls’ lab. Waleed was always a willing teammate on our projects 
and his collaborations and training were instrumental in my development as a scientist. I would 
also like to acknowledge Dr. Kong Chen, William Horne, Dr. Pawan Kumar, Dr. Derek Pociask, 
and Dr. Mingquan Zheng. As past and present faculty members in the Kolls’ lab, I always felt 
like I had a place I could to turn for guidance. To all the members of the Kolls’ lab and my 
dissertation committee, thank you for pushing me to grow as a scientist.  
 Additionally, my training over the past three years was not limited to the bench top. I will 
forever be grateful to Dr. Allyson Larkin and Dr. Geoff Kurland for their clinical mentorship. 
Their efforts in guiding and relentlessly encouraging my growth as a physician scientist gave me 
confidence to pursue a lot of the work presented here. I would also like to thank Dr. Richard 
Steinman and the MSTP administration, past and present, for their continuing support. 
The second reason for selecting the quote at the top of this preface dates back to when I 
first entered the University of Pittsburgh-Carnegie Mellon MSTP. My parents gave me a gift to 
celebrate my accomplishments, and it was a small, framed cartoon of Albert Einstein with that 
quote transcribed on the bottom. This cartoon sat on my desk and served as a reminder to stay 
patient and driven even as the science slowed down or got frustrating. More importantly 
however, it was a daily reminder of the loving support of my mom, dad, and brother, who never 
hesitated in their excitement for my training, even as I entered an eight-year program. To my 
friends and family, thank you for the fun trips, parties, and events over the past five years as 
when I look back in thirty years, I’m sure those will be the moments that I remember first. And 
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last but not least, I would like to thank my beautiful fiancé Dr. Katie Ryan. I realize that 
Pneumocystis is not a common topic at the dinner table in most households, but it certainly was 
in ours over the past three years. She has proofread more pages devoted to my research than she 
probably would ever care to. But her encouragement and support were unwavering. I thank you 
for all you do from the bottom of my heart.  
It is only because of the people listed above, and many more, that these past three years 
have been as exciting, challenging, and fun as they were. In all sincerity, I thank you all.  
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1.0  INTRODUCTION 
The title of this dissertation is probably shorter and more vague than most. However, it 
accurately reflects my dissertation studies in the Kolls’ lab. I studied how Pneumocystis interacts 
with the host, and how the host appropriately—and sometimes inappropriately—responds to the 
fungus. This dissertation will discuss novel findings in the area of protective and pathologic 
immunity to Pneumocystis, the development of antifungals, and antigen discovery to prevent 
Pneumocystis infection (Figure 1-1). Each chapter will begin with a more host-centric or in-
depth analysis of the prior work that led to that particular project. However, as the chapters 
contained within this dissertation cover a wide range of topics, this introduction will focus on the 
unifying theme of this project: Pneumocystis.  
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Figure 1-1. Visual outline of the host-pathogen interactions studied within this dissertation. 
 
 
The majority of this introduction has been published in the following places:  
Eddens T., Kolls J.K. 2015. Pathological and protective immunity to Pneumocystis infection. 
Semin Immunopathol 37:153-162. 
Eddens, T., Kaloti, A. and Kolls, J.K. 2015. Pathogenesis of Pneumocystis jirovecii Pneumonia. 
In: Singh, S. K. ed. Human Emerging and Re-emerging Infections. Hoboken, NJ, USA: 
John Wiley & Sons, Inc., pp. 953–966. 
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1.1 PNEUMOCYSTIS: THE PATHOGEN 
1.1.1 Epidemiology 
The epidemiology of Pneumocystis can be categorized into the HIV and non-HIV populations. 
As described above, Pneumocystis first emerged as a common opportunistic infection in the 
HIV/AIDS population. As a result, anti-Pneumocystis prophylaxis was recommended for any 
individual with low CD4+ T cell counts (<200 cells/μL), which led to a reduction in the incidence 
of infection (1). This reduction was furthered by the implementation of combined anti-retroviral 
therapy (cART) regimens (1). Within three years of the use of cART, Pneumocystis incidence (as 
measured by infection rates per 1,000 person-years) decreased by approximately half (1). 
Although the incidence of Pneumocystis has been reduced, a study by Walzer et al. demonstrated 
that the mortality of Pneumocystis pneumonia has largely been unchanged by the implementation 
of antiretroviral therapy (2). Prior to cART, mortality rates of Pneumocystis pneumonia in HIV 
patients were 10.1%; following cART, mortality rates were modestly reduced to 9.7% (2).  
Despite the use of cART and anti-Pneumocystis prophylaxis, Pneumocystis pneumonia 
remains the most common serious opportunistic infection in HIV patients in the United States (1, 
3, 4). One study reported 322 cases of Pneumocystis pneumonia in 2,622 patients with AIDS-
defining events (3). Unsurprisingly, most cases of Pneumocystis in the developed world are in 
patients unaware of their HIV-positive status and/or patients not receiving prophylaxis or 
antiretroviral therapy (4).  
In the developing world, Pneumocystis pneumonia is a common complicating factor in 
the HIV-positive population. Pneumocystis was detected in the bronchoalveolar lavage (BAL) 
fluid of 33% of HIV-infected patients presenting with a diffuse pneumonia in southern Africa 
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(5). Furthering those findings, additional studies in Africa have shown that HIV-positive patients 
with symptoms (e.g. cough/dyspnea) of pneumonia are likely to have Pneumocystis infection; the 
incidence of Pneumocystis in such populations were found to be between 37.2% and 48.6% in 
South Africa and Kenya, respectively (6, 7). Asian countries, such as Thailand, India, and 
Malaysia, also have high incidences of Pneumocystis infection in the HIV-positive population 
with diagnosis rates between 12.2-25% (8–10). Developing countries in South America, such as 
Chile and Venezuela, also report high incidences of Pneumocystis in HIV-positive patients with 
respiratory symptoms (~37%) (11, 12). More alarming than any individual percentage, the above 
studies all further the point that Pneumocystis remains a global clinical concern for patients with 
HIV/AIDS where prophylaxis and/or cART use is limited for a variety of reasons.  
Pneumocystis is also re-emerging in developed countries in the HIV-negative population. 
A study conducted in Sweden demonstrated that 75% of patients presenting to the hospital with 
Pneumocystis pneumonia were HIV-negative (13). Another study conducted in the United 
Kingdom between 2000-2010 found that the number of hospital episodes of Pneumocystis 
pneumonia more than doubled during the study period, with transplant and hematologic 
malignancy patients representing the highest risk groups (14). In addition to malignancy and 
transplantation, several other conditions including autoimmune conditions and inherited 
immunodeficiencies have been implicated as emerging risk factors for Pneumocystis infection 
(Table 1) (3, 15–27).   
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Table 1-1. Conditions, procedures, and therapeutic agents that have been implicated in increasing the 
patient’s risk for developing Pneumocystis pneumonia. 
Conditions/procedures associated with 
Pneumocystis infection  
Therapeutic agents associated with 
Pneumocystis infection 
HIV 
Hematologic malignancy  
Solid tumors 
Hematopoietic stem cell transplantation 
Solid organ transplantation 
Rheumatoid arthritis 
Severe combined immunodeficiency 
Hyper-IgM syndrome 
Wegener’s granulomatosis 
Inflammatory Bowel Disease 
Collagen vascular disorders 
Corticosteroids 
Alkylating agents (e.g. 
cyclophosphamide) 
Antimetabolite chemotherapeutics (e.g. 
methotrexate) 
TNF inhibitors (e.g. Etanercept) 
Azathioprine 
Alemtuzumab 
Rituximab 
Sirolimus/Tacrolimus 
Cyclosporine 
 
Although there are several immunologic changes associated with each of the above 
conditions, the immunosuppressive therapy for each disease undoubtedly contributes to the risk 
of developing Pneumocystis pneumonia (Table 1). One such example is the use of Rituximab, a 
monoclonal antibody against the B-cell marker CD20, for the treatment of hematological 
malignancies such as diffuse large B-cell lymphoma. Martin-Garrido et al. found that 
approximately 30% of patients receiving Rituximab went on to develop Pneumocystis 
pneumonia over the course of the study period (28). Perhaps more troubling, acute respiratory 
failure was seen in 40% of patients with Rituximab-associated Pneumocystis, while mortality in 
these patients was as high as 30% (28). Although several other agents can increase a patient’s 
risk for Pneumocystis (Table 1-1), this example of Rituximab highlights two important points. 
First, the use of these targeted immunosuppressive agents has lead to a greater understanding of 
the immune response required to protect against Pneumocystis (see Immunity against 
Pneumocystis section). Rituximab selectively targets B-cells and leaves the often-implicated 
CD4+ T cells intact; however, these patients are exquisitely susceptible to Pneumocystis to the 
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point where universal prophylaxis is being discussed. Second, similar to the findings described 
above with Rituximab, non-HIV cases of Pneumocystis tend to have increased morbidity (e.g. 
higher mechanical ventilation rates) and mortality than HIV-positive cases (29, 30). At this time, 
it remains unclear if the direct cause of the increased mortality is due to changes in the disease or 
differences in clinical management. 
Since the first noticed cases of human Pneumocystis pneumonia (PCP) among 
malnourished children and preterm infants in Germany, there has been remarkable progression in 
our understanding of the pathogenesis of pediatric PCP. Maternal to fetal transmission of HIV 
led to an upshot in PCP diagnoses among infants and pediatric population in the pre-HAART 
and PCP prophylaxis era in the US. Currently, organ transplant and childhood hematological 
malignancies constitute the major risk factors for the development of PCP. Saltzman et al. (2012) 
conducted a retrospective review of 80 pediatric patients with PCP at Children’s Hospital of 
Philadelphia admitted from 1996-2006 (31). In this cohort, HIV was the single most common 
associated underlying condition, accounting for 39% of the cases overall, but only in 15% of the 
cases since 1998. Transplant recipients and oncology patients together comprised another 39% of 
the cases, while another 9% of cases were attributed to primary immune deficiency. The 
remaining 9% of cases were associated with less well-recognized causes of susceptibility. High 
mortality was noted in the HIV and organ transplant groups. The probability of ICU admission 
and tracheal intubation was greater than 50% in all cases, although there was no increase in 
mortality associated with ICU admission or tracheal intubation in patients with underlying cancer 
or primary immune deficiency when compared to HIV-positive PCP. The cause of this 
discrepancy is unclear, although HIV patients could have had more complicating factors (31). 
Saltzman et al., (2012) also noted that prophylaxis provided incomplete protection in the 
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pediatric population, irrespective of the underlying condition, although they particularly noted 
the failure of prophylaxis among HIV patients (31). Pediatric HIV associated PCP is also a 
common problem in Argentina, which had the 6th largest pediatric AIDS population and a very 
high PCP attack rate (32, 33). 
1.1.2 Clinical Features 
Pneumocystis pneumonia in the HIV-positive population is generally characterized by a sub-
acute onset of low-grade fever, nonproductive cough, and progressive dyspnea (34). Further 
nonspecific findings, such as tachypnea and tachycardia, can be found on physical exam, while 
the lung exam may range from normal to diffuse crackles upon auscultation (34). While the 
above characteristic presentation of Pneumocystis pneumonia is common in HIV-positive 
patients, HIV-negative patients can present much differently. Typically, the HIV-negative 
patients will have a more acute or fulminant presentation with substantial dyspnea, fever, and 
chills (15, 16). Furthermore, HIV-negative patients have a wider alveolar-arterial oxygen 
gradient and are more likely to require mechanical ventilation (15, 16).  
1.1.3 Diagnosis 
Radiologic methods are a useful first step in making a diagnosis of Pneumocystis, as most 
patients presenting with fever and dyspnea will receive a chest x-ray (CXR). The classic CXR of 
patients with Pneumocystis shows diffuse, bilateral interstitial and alveolar infiltrates (Figure 1-
2A). Less common findings, such as pneumatoceles, lobar infiltrates, and pneumothoraxes have 
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been reported (15, 16). Some patients presenting with Pneumocystis will have near normal or 
unimpressive radiographic findings, in which case higher resolution radiologic approaches are 
recommended, such as high-resolution chest CT (4, 16). Chest CT most commonly demonstrates 
ground glass opacity with relative peripheral sparing, although mosaic and diffuse patterns can 
be observed (35). Notably, the findings described above are not specific for Pneumocystis and a 
broad differential for opportunistic pneumonias (e.g. Aspergillus, Mycobacterium avium-
complex) should be maintained (4).  
It is also important to interpret radiologic findings in the context of the underlying 
immunosuppression. HIV-negative patients with Pneumocystis tend to have a greater extent of 
ground-glass opacity on chest CT (35). Moreover, HIV-negative Pneumocystis patients are more 
likely to have lung consolidations, perhaps reflecting a more robust host immune response (35).  
Although radiologic methods, coupled with the appropriate clinical context, can highly 
suggest a diagnosis of Pneumocystis, the gold standard of diagnosis remains harvesting organism 
from bronchoalveolar lavage (BAL) fluid. Several stains can be utilized to identify Pneumocystis 
microscopically: Gomori-methenamine silver stain (GMS) (Figure 1-2B), Wright-Giemsa, 
toluidine blue O, or Calcofluor white (34). Monoclonal antibodies conjugated to a fluorescent 
marker are also available to stain Pneumocystis. In fact, these conjugated monoclonal antibodies 
have greater sensitivity and specificity for detecting Pneumocystis than most non-
immunofluorescent stains (34). In addition to BAL sampling, induced sputum samples can also 
be analyzed for Pneumocystis by the above stains, with monoclonal antibodies again having the 
highest sensitivity and specificity (15, 16). Importantly, HIV-negative patients with suspected 
Pneumocystis infection may have a negative induced sputum sample, as HIV-negative patients 
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tend to have a lower organism burden than their HIV-positive counterparts (15, 16). In HIV-
negative patients, BAL is recommended (15, 16).  
Figure 1-2. Radiographic and microbiologic diagnosis of Pneumocystis. A. Chest radiograph of child with X-
linked severe combined immunodeficiency showing bilateral ground glass infiltrates and air bronchograms 
consistent with Pneumocystis pneumonia. B. Gomori-methenamine silver stain (GMS) on Pneumocystis infected 
mouse lung, showing lung architecture (green) with Pneumocystis organisms (black) filling the alveolar spaces. 
Several molecular techniques have been tested as a means to diagnose Pneumocystis from 
BAL or sputum samples. One such method developed in the 1990’s was the use of a single-
round polymerase chain reaction (PCR) to amplify the mitochondrial small subunit rRNA of 
Pneumocystis (36, 37). Since that time, the use of nested-PCR (two round PCR) has been used 
on several gene targets, such as dihydropteroate synthase (DHPS), dihydrofolate reductase 
(DHFR), major surface glycoprotein (MSG), and loci within the region coding for rRNAs (37). 
While using the nested approach increases sensitivity to nearly 100%, this often comes at the 
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cost of decreasing specificity due to the ability to detect colonized individuals who may not have 
active Pneumocystis pneumonia (37). 
Newer techniques include the use of quantitative real-time PCR (qPCR) on many of the 
same targets described above. In addition to reduced turnaround times, qPCRs provide semi-
quantitative data to discriminate the cases of colonized individuals from the truly infected 
individuals. As such, qPCRs for Pneumocystis tend to have high sensitivities, along with 
increased specificities when compared to nested techniques (37). One study that illustrates this 
point was conducted by Flori et al. and examined the diagnostic value of a qPCR test on MSG 
(38). In this study, which examined both HIV-positive and HIV-negative patients, the MSG 
qPCR test had a sensitivity of 100% and specificity of 98.6% (38). While this indicates such 
diagnostic tests can be optimized to have value in the clinical setting, implementing a qPCR test 
requires validating the gradations of Pneumocystis PCR product to distinguish colonization from 
infection in the heterogeneous population of the immunocompromised (37). At this time, this 
challenge still persists in the field and limits the clinical use of such tests.   
Two serum markers, β-1,3-glucan and KL-6, have been evaluated as diagnostics for 
Pneumocystis. β-1,3-glucan is a component of the fungal wall, particularly of the ascus (see 
Microbiology of Pneumocystis below) and can enter the serum upon active infection. One study 
demonstrated that serum β-1,3-glucan above 100 pg/mL had a sensitivity of 100% and a 
specificity of 96.4% for diagnosing Pneumocystis pneumonia using a retrospective analysis (39). 
However, specificity for serum β-1,3-glucan testing is difficult to establish, as this test does not 
discriminate between fungal species. As such, serum β-1,3-glucan is often used as an adjunct to 
clinical suspicion and other diagnostic tests to confirm a Pneumocystis infection rather than a 
stand alone diagnostic. Similarly, KL-6, a glycoprotein expressed on pneumocytes, can enter the 
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serum in the setting of infectious lung disease. One study has shown that KL-6 levels are 
elevated in HIV-positive cases of Pneumocystis, but the generalizability of serum KL-6 to the 
HIV-negative population has yet to be demonstrated (40). 
1.1.4 Microbiology of Pneumocystis 
In the 1980’s, molecular evidence began to arise that supported the notion that Pneumocystis 
belonged in the group Fungi as opposed to being classified as a protozoan. Edman et al. were the 
first to molecularly confirm the homology of Pneumocystis to fungi, such as Saccharomyces 
cerevesiae, by using alignments of the 16S rRNA (41). Several other groups corroborated the 
homology of the 16S rRNA to fungi and established homology between Pneumocystis and 
fungal mitochondrial gene sequences as well (42–44). Furthermore, one group demonstrated the 
presence of elongation factor-3 (EF-3), a protein specific to fungi, in Pneumocystis (45). 
Although more molecular evidence was uncovered, perhaps the most substantial evidence came 
in the context of the Pneumocystis genome project, when Cushion et al. made cDNA libraries of 
Pneumocystis carinii and subsequently sequenced the contigs; the vast majority of these 
sequences aligned to fungal species such as S. cerevesiae and Schizosaccharomyces pombe as 
opposed to protozoa (46).  
Along with reclassifying the genus Pneumocystis into the group Fungi, researchers also 
discovered that genetic diversity existed between species of Pneumocystis isolated from different 
hosts. Originally, Pneumocystis was believed to be transmitted in a zoonotic fashion, until 1976 
when Frenkel proposed that each Pneumocystis species was host-specific (47). After several 
other studies validated this theory, the genus Pneumocystis grew to contain several species. The 
genus Pneumocystis encompasses five named species: P. carinii, P. wakefieldiae, P. murina, P. 
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oyrctolagi, and P. jirovecii (48). P. carinii, which is isolated from rats, was the first to be 
discovered and is the most extensively studied organism within the genus. P. wakefieldiae is also 
isolated from rats and is the most genetically similar to P. carinii. P. murina, P. oyctolagi, and P. 
jirovecii appear to be the sole species found in mice, rabbits, and humans, respectively (as 
reviewed in (48).  Interestingly, the amount of genetic variation between P. carinii and P. 
jirovecii suggests that these organisms diverged over 90-100 million years ago around the time 
of rodent-primate molecular divergence, which may explain why host-specificity appears to be 
so paramount to these organisms (49).  In addition, several other unnamed species appear to have 
been isolated from other hosts such as non-human primates, ferrets, and horses (50–52).  
One of the unique features shared by all the Pneumocystis species is the multiphasic life 
cycle that occurs within the alveolar space of the host (Figure 1-3). The ascus (cyst) form of 
Pneumocystis is circular or ovoid in shape and is approximately 4-7 μm in diameter (53, 54). The 
ascus form has a distinctive thick outer wall made of β-1,3-D-glucan, while within the ascus, 
eight ascospores mature (53–55). Following maturation, the ascospores will leave the ascus 
through a small pore and become the troph life form (53, 56). The troph life form appears to be 
the more metabolically active and replicative form of Pneumocystis. Trophs range in size from 2-
8 μm and are more irregular in shape. Trophs are thought to replicate in both an asexual and 
sexual manner. Although most fungal species replicate asexually through a process known as 
“budding,” trophs are thought to propagate via binary fission (57). Two trophs can also conjugate 
via the use of pheromone receptors and replicate sexually by fusing.  Following fusion, the two 
previous trophs are now a single diploid early sporocyte, which divides using meiosis. This 
meiotic process is then followed mitosis, generating the eight ascospores (58). During the 
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division processes, the wall of the sporocyte thickens and hardens and returns the life cycle to the 
ascus stage.  
 
 
Figure 1-3. The Pneumocystis life cycle. Pneumocystis cysts contain eight ascospores, which leave the cyst to 
become trophs. Trophs can reproduce asexually through binary fission, a process that results in two identical troph 
clones. Sexual reproduction can also occur, as two different trophs can fuse to become an early sporocyte. The early 
sporocyte will then undergo meiosis, forming four nuclei within the late sporocyte. The late sporocyte then thickens 
its wall and undergoes mitosis, resulting in a cyst. 
 
One study by Cushion et al. examined the life cycle in vivo; in particular, they examined 
the effects of β-1,3-D-glucan synthase inhibitors on the ascus and troph population within the 
lung (55). Mice treated with anidulafungin had a decrease burden of asci in the lung, while the 
level of trophs remained the same. More importantly, mice depleted of asci were no longer able 
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to aerially transmit infection to immunodeficient mice, implicating the ascus as the infectious 
form. Using in vivo infection, a second study and unpublished data from our laboratory 
demonstrated the adherence of the troph life form to the type I pneumocyte in the lung (53). An 
additional study examined the Pneumocystis life cycle in vitro, despite the fact that a continuous 
axenic culture method for Pneumocystis has yet to be discovered (59). In this study, Martinez et 
al. showed that asci were capable of producing new trophs while the reverse (trophs becoming 
asci) did not occur. These results demonstrated that information regarding the Pneumocystis life 
cycle could be gleamed from in vitro studies, although the viability in culture is undoubtedly a 
confounding variable. Recently, a novel mechanism to grow Pneumocystis jirovecii has been 
reported using differentiated pseudostratified CuFi-8 cells, although the utility of such a culture 
system for propagating infection and/or directed therapy selection has yet to be determined (60). 
Further studies on the Pneumocystis life cycle would be greatly enhanced by any sustainable 
Pneumocystis culture method.  
 
1.1.5 Transmission and Colonization 
The most widely accepted theory of Pneumocystis transmission is that of aerosolized particles 
from host to host (16). However, various models of infection are still debated.  The reactivation 
of latent infection theory postulates that initial infection occurs in infancy or early childhood, 
with reactivation later in life in the context of immune suppression. Pneumocystis DNA has been 
identified in the air surrounding apple orchards and the surface of pond water, indicating that it 
may be a ubiquitous organism in nature (15). Furthermore, seroprevalance of antibodies to 
Pneumocystis is very common among children and has been observed in many parts of the 
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world, thus supporting the theory that children are exposed to Pneumocystis early (16, 61). It is 
thought that in health, the infection is self-contained, but in the case of immunosuppression, the 
infection may reactivate.  
The re-acquisition or de novo infection theory suggests Pneumocystis infection is actually 
re-acquired later in life after early childhood infection clearance, in the context of immune 
suppression. There is considerable evidence in support of this theory. PCP cases are known to 
have geographic clustering in the urban setting and genotypes found in patients with PCP are 
similar to those found in the current patient’s environment but not those from his or her place of 
birth (15). Many studies have shown asymptomatic carrier state, particularly resulting by 
transmission of Pneumocystis from PCP patients to healthy hospital workers (62, 63). Additional 
evidence comes from animal studies that have demonstrated the transmission of Pneumocystis 
between immunocompetent and immunocompromised animals (64). Furthermore, asymptomatic 
carriage state has recently been observed in patients with non-HIV immunosuppression and 
pulmonary disease (65). Although asymptomatic carriage is common to both theories, the biggest 
difference between the de novo infection and the latent infection models is the length of time of 
colonization; in the latent infection model, colonization occurs early and may be stable at a low 
level until immunosuppression, while the de novo infection model suggests that infection is 
acquired after immunosuppression. 
Given the presence of Pneumocystis colonization over time, several groups have begun to 
investigate the relationship between Pneumocystis and chronic lung diseases. Gingo et al. first 
documented respiratory abnormalities such as diffusion impairment and irreversible airway 
obstruction in patients with HIV in the era of combination antiretroviral therapy (66). The 
development of chronic obstructive pulmonary disease (COPD) in non-human primates with 
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persistent Pneumocystis colonization has also been demonstrated (67). Further, infection with 
Pneumocystis has been shown to be associated with the development of COPD in human 
subjects with and without HIV infection (68). These studies demonstrate that Pneumocystis can 
persist asymptomatically in the lung at low-levels (colonization) and that person-to-person 
transmission may result in frequent exposure in the population (64).  
1.1.6 Protective Immunity to Pneumocystis 
Much of what we have learned of the immune response to Pneumocystis has been gleaned from 
acquired and congenital immunodeficiencies leading to susceptibility, and many of these human 
conditions have also been successfully replicated in animal models. High dose corticosteroid 
treatment remains a risk factor and steroid-induced immunosuppression has been a widely used 
tool to induce infection in rodents (69, 70). Prior to the epidemic of the acquired 
immunodeficiency syndrome (AIDS), Pneumocystis infection in humans was associated with 
significant malnutrition or myelosuppressive chemotherapy for acute leukemia (71). When the 
epidemic of Pneumocystis infection was observed in AIDS, it was realized that the prevalence of 
Pneumocystis inversely correlated with the peripheral blood CD4+ T-cell lymphocyte count (72). 
This was recapitulated in a murine model where CD4+ T-cell depletion resulted in Pneumocystis 
pneumonia whereas CD4+ T-cell replete mice cleared the infection (73). Although CD4+ T-cells 
are essential, the specific T-cell subsets required remain unclear. Experimental Pneumocystis 
infection induces Th1, Th2, and Th17 responses in mice. Mice deficient in Th17 immunity have 
delayed clearance of the pathogen but ultimately clear the infection (74). Analogous to these 
findings, patients with STAT3 mutations that have a reduction in the number of antigen-specific 
Th17 cells to Candida albicans (75) rarely develop clinical Pneumocystis infection (76). 
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Interleukin (IL) 21 is a cytokine produced by T-follicular helper cells in the germinal center of 
secondary lymphoid tissues (77) as well as Th17 cells. IL-21 appears to play a key role in 
susceptibility to Pneumocystis as evidenced by a recent patient with an IL-21 receptor mutation 
who subsequently developed clinical Pneumocystis pneumonia (78).   
B-cells also play a key role in susceptibility to infection. B-cell deficient mice are 
susceptible to infection (79), as well as patients with hyper IgM syndrome due to either 
mutations in CD40 or CD40 ligand (80, 81). Consistent with these findings, both Cd40-/- or 
Cd40l-/- mice are also susceptible to Pneumocystis. In addition to obvious effects on antibody 
production, the increased susceptibility of these patients may also be due to the fact that B-cells 
can function as critical antigen presenting cells during the infection (79). Antigen presentation by 
B-cells may also explain the fact that patients with mutations that affect antibody production 
such as common-variable or X-linked agammaglobulinemia can, but rarely, develop clinical 
Pneumocystis pneumonia (82). One caveat to the low incidence of Pneumocystis pneumonia in 
these patients, however, is that intravenous immunoglobulin is typically given prophylactically, 
which may mask some of the susceptibility to Pneumocystis. Despite the ambiguity associated 
with genetic immunodeficiencies, the use of anti-CD20 monoclonal antibodies in humans has 
emerged as a strong risk factor for Pneumocystis pneumonia, which further implicates the B-cell 
as an important cell type for the normal host defense against Pneumocystis (28). Thus the B-cell 
appears to be critical and the dual functions of antigen presentation and antibody production are 
likely important.  
Further evidence suggests antibodies can provide protection against Pneumocystis. It has 
been demonstrated that antibodies can provide protective immunity by passive transfer of serum 
elicited by immunization (83) or of monoclonal antibodies that recognize surface epitopes on the 
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organism to immunodeficient mice (84). Thus, although the role of humoral immunity in 
conferring susceptibility in humans remains unclear, antibodies could still be exploited for 
prevention or therapy.   
It is thought that ultimately macrophages are the key effector cells that actually clear the 
infection. Indeed, macrophage depletion increases organism burden in the lung (85). 
Pneumocystis has also been shown to induce apoptosis of lung macrophages and this could be a 
major host evasion strategy of the organisms (86). Non-opsonic phagocytosis and killing of the 
organism requires the c-type lectin receptor Clec7a (87). This pathway can be bypassed if the 
organism is opsonized with IgG (71). Complement also plays in a role in the antibody-mediated 
control of Pneumocystis, as mice deficient in complement treated with an anti-Pneumocystis 
monoclonal antibody had less protection against Pneumocystis than complement-replete, 
antibody treated mice (88). GM-CSF treatment of macrophages in vitro increases Pneumocystis 
killing (89), while GM-CSF administration in vivo can reduce Pneumocystis burden in 
susceptible mice (90). Moreover, GM-CSF deficient mouse strains develop Pneumocystis 
infection (91) and patients with anti-GM-CSF autoantibodies have increased susceptibility to 
Pneumocystis (92). Recently, it has been demonstrated that macrophages that have an alternative 
activation program have greater fungicidal activity (93).  
In summary, much has been gleaned about the necessary components of the immune 
system required to clear Pneumocystis infection from both clinical studies on patients with 
genetic mutations and murine models using genetically modified mice. Importantly, however, the 
murine knockout models faithfully recapitulate clinical susceptibility conferred by analogous 
genetic mutations (Table 1-2). While no murine model will perfectly translate to human patients, 
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the table below suggests that using mice to study the essential components of immunity against 
Pneumocystis may accurately reflect those requirements in humans.  
 
Table 1-2. Genes associated with Pneumocystis susceptibility in mice and men.  
Loss of function 
Gene Mutation 
Susceptibility to Pneumocystis 
Human Murine 
RAG1 + + 
RAG2 + + 
CD40-CD40L + + 
PRKDC + + 
IL2RG + + 
CD4 + + 
HLA/MHC Class II + + 
IKBKG + N/I 
ICOS + N/I 
BTK + N/I 
STAT3 (polymorphism)* + + 
IL-21R* + + 
Human (+): Clinical diagnosis in patients with mutation. 
Murine (+): Validated using experimental models. 
N/I: Not yet investigated. *: Unpublished observations 
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1.1.7 Treatment 
The first line therapy for active Pneumocystis infection and for Pneumocystis prophylaxis is 
trimethoprim-sulfamethoxazole (TMP-SMX) (Table 1-3). However, TMP-SMX can be 
associated with several side effects (e.g. rash, cytopenia) and is not recommended for patients 
with sulfa allergy (94–96). Interestingly, HIV-infected patients appear to be more likely to 
develop adverse side effects to sulfa drugs, further limiting the efficacy of TMP-SMX in the 
population at-risk for Pneumocystis infection (97). Several other treatments are indicated as 
second line therapies (e.g. pentamidine and dapsone) but such regimens tend to have much 
higher treatment failure rates (94, 95). 
 
Table 1-3. Current treatment regimens for Pneumocystis. 
Regimen Dosage Treatment 
Failure 
Rate 
Common Adverse Effects Mortality 
Trimethoprim-
Sulfamethoxazole (First 
Choice) 
15-20 mg/kg, 
IV or orally 
21% Cytopenia, skin reactions, hepatitis, 
pancreatitis, renal insufficiency, 
anaphylaxis, GI disturbance 
Up to 15% 
Dapsone + 
Trimethoprim 
5mg/kg 3 times 
daily orally 
39% Skin rash, fever, methemoglobinemia, 
GI disturbance 
~20% 
Atovaquone 750 mg 2-3 
times orally 
36% Skin rash, fever, GI disturbance, 
hepatitis 
~20% 
Clindamycin and 
primaquine 
600mg 4 times 
daily IV or 350-
400mg 4 times 
a day orally 
35% Skin rash, fever, neutropenia, GI 
disturbance, hepatitis 
19% 
Pentamidine (Alternate 
choice moderate to 
severe PCP) 
4mg/kg daily 
IV 
40% or higher Hypotension, cardiac arrhythmias, 
calcium, magnesium and potassium 
level disturbance, renal insufficiency, 
pancreatitis, hypoglycemia, 
neutropenia, hepatitis 
>= 24% 
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2.1 INTRODUCTION: BIOLOGY OF EOSINOPHILS 
Eosinophils were first described in 1879, when Dr. Paul Ehrlich noted the presence of a highly 
granular cell in the blood that stained strongly with acidophilic dyes (98). Eosinophils are 
derived from the myeloid lineage and circulate in low abundance in the serum with a very short 
half-life of approximately 18 hours (98, 99). Eosinophils can also enter tissues under homeostatic 
conditions, with the gastrointestinal tract representing the largest repository (100). In states of 
disease or inflammation, eosinophils can be detected in virtually any organ by histologic 
analysis. In addition to the unique morphology of eosinophils, these cells can also be recognized 
by expression of several surface receptors. For one, murine eosinophils express sialic acid-
binding Ig-like lectin-F (SiglecF) while human eosinophils express Siglec-8 (99). In addition to 
being a useful marker for detection of eosinophils by flow cytometry, Siglec-F appears to bind 
mucins in the airway and may play a role in mediating eosinophil homeostasis (101, 102).  
Another key surface receptor expressed by eosinophils is the IL-5 receptor alpha chain 
(IL-5Rα). IL-5, a cytokine released by Th2 and ILC2 cells, can travel through the circulation to 
the bone marrow where it acts on granulocyte/monocyte progenitors and eosinophil progenitors 
to give rise to eosinophils (103). In addition to being required for eosinophilopoiesis, IL-5 is a 
pro-survival factor in mature eosinophils and appears to prevent apoptosis (104).  IL-5 signals 
through a heterodimeric receptor complex comprised of IL-5Rα and CSF2RB, a shared beta 
subunit with cytokines GM-CSF and IL-3 (105, 106). Binding of IL-5 to its receptor activates 
JAK2 and STAT5, in addition to several other proliferative signals such as PI3K and the MAPK 
pathways (105).  
Several other mediators in the development of eosinophils have been discovered and 
exploited for the study of eosinophils in vivo. Eosinophil lineage commitment is dependent on 
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several transcription factors, including GATA1, PU.1, IFN consensus sequence binding protein, 
and C/EBP family members (99). GATA1 appears to be the most important transcription factor 
for eosinophilopoiesis, as deletion of the high-affinity double palindromic GATA1 site in the 
Gata1 promoter leads to the complete ablation of eosinophil development (107). Impressively, 
despite erythroid and megakaryocytic cells requiring GATA1 expression, this deletion appears to 
abrogate eosinophilopoiesis and modify the differentiation of basophils (107, 108). We, along 
with several other groups, have used these mice to explore the role of eosinophils in vivo.  
One key functional component of the eosinophil is the component that allowed for its 
differentiation via staining: the granule. Eosinophil granules contain a number of proteins, 
including major basic protein (MBP), eosinophil peroxidase, eosinophil cationic protein, and 
eosinophil-derived neurotoxin. These four proteins are highly cationic, and once released, are 
thought to cause damage to surrounding cells by damaging both self and non-self membranes 
(109). This lack of specificity has led to the study of the mechanisms of degranulation, as the 
eosinophil was presumed to release its contents completely and without discrimination (98). 
However, more recent studies have demonstrated that eosinophils secrete cytotoxic mediators in 
a more controlled fashion called ‘piecemeal degranulation’ (110, 111). Piecemeal degranulation 
also explains how an eosinophil can release a certain mediator and remain viable and responsive 
to subsequent stimuli (98). This controlled degranulation also explains how eosinophils can help 
modulate the immune system; eosinophils have been shown to secrete CCL17, CCL22 (Th2 
recruitment factors), APRIL (plasmablast survival factor), and IL-4 and IL-13 (cytokines 
promoting alternatively activated macrophage development) (98). Additionally, eosinophils are 
capable of stimulating antigen-specific T-cell responses through MHC class II and CD80/86 
expression (112).  
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 Despite clear interactions with the immune system, the role of eosinophils in mediating 
clearance of pathogens remains somewhat controversial. Historically, eosinophils were thought 
to mediate host defense against helminthic infections, as histologic analysis of infected tissue 
revealed eosinophils and parasites in close proximity (98). Studies using recombinant 
eosinophilic cationic protein and major basic protein in vitro also demonstrated anti-helminthic 
properties against Schistosoma mansoni infection (113, 114). However, as newer genetic tools 
have become available for in vivo manipulation, the role of eosinophils in anti-parasitic defense 
became less clear. For example, eosinophil-deficient GATA1-/- knockout mice fail to develop 
Trichinella spiralis infection and have increased activity of nitric oxide synthase in the local 
macrophage milieu (115, 116). These findings were also recapitulated in a second eosinophil-
deficient mouse model, TgPHIL, which express diphtheria toxin under the control of the 
eosinophil peroxidase promoter (115, 116). While undoubtedly more studies need to be 
performed with different parasitic infections, these more recent studies do raise the possibility 
that the parasite is skewing the immune response towards a Th2-eosinophil axis to allow 
persistence, as opposed to providing protection to the host.  
 However, eosinophils do appear to have beneficial properties in the context of host 
defense against other pathogens. Much like the early studies with parasites, eosinophilic granules 
have antibacterial and antiviral properties in vitro (117, 118). Unlike the parasitic studies, 
however, the protective effects of eosinophils in the setting of bacterial and viral infections were 
replicated in vivo. Transgenic eosinophilic mice overexpressing IL-5 had increased survival 
against a lethal Pseudomonas infection (119). Likewise, IL-5 transgenic mice have increased 
clearance of respiratory syncytial virus (RSV) and increased survival following lethal challenge 
with pneumovirus (98, 120).  
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 Similarly, eosinophils appear to have antifungal properties. One study by Lilly et al. 
demonstrated that eosinophilic granules are fungicidal using a transwell assay with Apsergillus 
fumigatus (121). An additional study found that human eosinophils are capable of recognizing 
and damaging the cell wall of Alternaria, a fungal species associated with asthma and allergic 
airway disease (122). While a large portion of the literature on eosinophils is focused on allergic 
airway disease, here we will discuss protective effects of eosinophils in response to another 
fungal pathogen, Pneumocystis. The role of eosinophils in asthma will be discussed in Chapter 3.   
 
2.2 RATIONALE AND HYPOTHESIS 
The conventional mediators of immunity against Pneumocystis include antibodies and 
macrophages. However, anti-Pneumocystis antibodies form and perform opsonic phagocytosis 
with macrophages after Pneumocystis clearance has already begun, suggestive of a different 
antifungal immunologic mechanism early in infection. To investigate immunologic responses 
that may mediate clearance of Pneumocystis, we used RNA sequencing of whole lung at day 14 
of Pneumocystis murina infection in CD4-depleted (which develop chronic progressive 
infection) and wild type C57BL/6 mice (which clear by 4 weeks). This unbiased approached 
revealed a strong eosinophil signature.  
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2.3 MATERIALS AND METHODS 
Mice 
C57BL/6 mice, Rag1-/- knockout mice on a C57BL/6 background, BALB/c mice, and 
Gata1tm6Sho/J mice were all ordered from The Jackson Laboratory (107). Mice were all 6-8 week 
old females and were bred in the Rangos Research Building Animal Facility. All use of 
laboratory animals was approved and performed in accordance with the University of Pittsburgh 
Institutional Care and Use Committee. 
 
Pneumocystis infection time course and primary infections 
Twenty-five C57BL/6 female mice were CD4-depleted using weekly intraperitoneal 
administration of 0.3 mg of GK1.5 monoclonal antibody per mouse and were subsequently 
challenged with 2.0 x 106/mL Pneumocystis murina cysts using oropharyngeal inoculation as 
previously described (83, 123, 124). Twenty-five age-matched C57BL/6 female mice were 
inoculated at the same time, but were not CD4-depleted. Five mice from each group were then 
sacrificed at day 0, 3, 7, 10, and 14. Four BALB/c and Gata1tm6Sho/J mice were also inoculated 
with Pneumocystis oropharyngeally and sacrificed at day 14. Six uninfected BALB/c mice were 
used as naïve controls.  
 
RNA isolation and qRT-PCR 
Lung RNA was purified using Trizol® Reagent (Life Technologies). Briefly, lungs were 
homogenized and following the addition of chloroform, RNA in the aqueous phase was collected 
and precipitated in isopropanol. Following centrifugation, the RNA was washed with 75% 
ethanol, centrifuged again, and then resuspended in nuclease-free water. Following incubation at 
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55°C, RNA was quantified using a Nanodrop and 1 μg of RNA was converted to cDNA using 
iScript™ cDNA synthesis kit per manufacturer’s instructions (Bio-Rad). PC burden was then 
quantified using SsoAdvanced qRT-PCR universal probes supermix (Bio-Rad) using primers and 
a probe specific for Pneumocystis murina small subunit (SSU) rRNA with a standard curve of 
known Pneumocystis SSU rRNA concentrations. SSU primer and probe sequences are as 
follows:  
F: 5’-CATTCCGAGAACGAACGCAATCCT; R: 5’- TCGGACTTGGATCTTTGCTTCCCA; 
Probe: 5’- TCATGACCCTTATGGAGTGGGCTACA.  Other primers used include: Prg2, Epx, 
Il5, Clca3, Muc5ac, Muc5b, and Il13 (Applied Biosystems). Prior to sequencing, the RNA was 
further purified using a Qiagen RNA cleanup kit with DNAse treatment. 
 
RNA sequencing 
Total RNA from mouse whole lung was used to perform RNA sequencing. Each sample was 
assessed using Qubit 2.0 fluorometer and Agilent Bioanalyzer TapeStation 2200 for RNA 
quantity and quality. Library preparation was done using Illumina TruSeq Stranded mRNA 
sample prep kit. The first step in the workflow involves purifying the poly-A containing mRNA 
molecules using poly-T oligo attached magnetic beads. Following purification, the mRNA was 
fragmented into small pieces using divalent cations. The cleaved RNA fragments were copied 
into first strand cDNA using reverse transcriptase and random primers. Strand specificity was 
achieved by using dUTP in the Second Strand Marking Mix, followed by second strand cDNA 
synthesis using DNA Polymerase I and RNase H. These cDNA fragments then have the 
addition of a single 'A' base and subsequent ligation of the adapter. The products are then 
purified and enriched with PCR to create the final cDNA library. The cDNA libraries are 
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validated using KAPA Biosystems primer premix kit with Illumina-compatible DNA primers 
and Qubit 2.0 fluorometer. Quality is examined using Agilent Bioanalyzer Tapestation 2200.The 
cDNA libraries will be pooled at a final concentration 1.8pM. Cluster generation and 75 bp 
paired read single-indexed sequencing was performed on Illumina NextSeq 500’s. 
Raw reads from an Illumina NextSeq 500 in fastq format were trimmed to remove 
adaptor/primer sequences. Trimmed reads were then aligned using BWA (version 0.5.9, settings 
aln -o 1 -e 10 -i 5 -k 2 -t 8) against the mouse genomic reference sequence. Additional alignment 
and post-processing were done with Picard tools (version 1.58) including local realignment and 
score recalibration (not duplicate marking) to generate a finale genomic aligned set of 
reads. Reads mapping to the genome were characterized as exon, intron, or intergenic (outside 
any annotated gene) using the matched annotation for the genomic reference sequence. The 
remaining unmapped reads from the genomic alignment were then aligned to a splice reference 
created using all possible combinations of known exons (based on annotation described above) 
and then categorizing these as known or novel splice events. This aligned data was then used to 
calculate gene expression by taking the total of exon and known splice reads for each annotated 
gene to generate a count value per gene. For each gene there was also a normalized expression 
value generated in two ways: 1) Reads per Mapped Million (RPM), which was calculated by 
taking the count value and dividing it by the number of million mapped reads, 2) Reads per 
Mapped Million per Kilobase (RPKM), which was calculated by taking the RPM value and 
dividing it by the kilobase length of the longest transcript for each gene. The RPM values are 
subsequently used for comparing gene expression across samples to remove the bias of different 
numbers of reads mapped per sample. RPKM values were subsequently used for comparing 
relative expression of genes to one another to remove the bias of different numbers of mapped 
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reads and different transcript lengths. In addition to gene expression measurements, nucleotide 
variation was also detected using the GATK (version 1.3-25, -dcov 2000 -stand_call_conf 30.0 -
stand_emit_conf 10.0 -A DepthOfCoverage -A BaseCounts -A AlleleBalance), which identified 
single nucleotide and small insertion/deletion (indel) events using default settings. Mapped 
exonic reads per WT sample: 44,291,011; 23,432,350; 41,004,408; and 41,308,864. Mapped 
exonic reads per GK1.5 sample: 23,305,058; 43,821,698; 122,834,770; and 29,805,804. Data 
were then filtered on a quality score of 20 and probed for eosinophil associated genes: Ear11, 
Ear5, Ccl8, Ccl24, Ccr3, Prg2, Ccl11, Ccl7, Il13, Ear10, Il5ra, Ear2, Csf2rb, Ccl5, Il5, Ear1, Il4 
(did not pass quality filter), and Epx (did not pass quality filter).  
 
Data Availability 
The RNA sequencing data contained in this paper is publicly available through the Sequence 
Read Archive BioProject number: PRJNA276259. Further information can be found at: 
http://www.ncbi.nlm.nih.gov/bioproject/. 
 
Bronchoalveolar lavage 
Wild type C57BL/6, and GK1.5 treated mice infected with Pneumocystis were anesthetized at 
day 14 post-infection and a 20g Exel Safelet Catheter (Exel International Co.) was inserted in the 
cricoid cartilage. The needle was then removed and 1 mL aliquots were inserted and removed 
from the lung using a 1 mL syringe (10 mL total). Bronchoalveolar lavage (BAL) cells were then 
spun at 300xg for 10 minutes, resuspended in PBS, and counted using Trypan Blue stain. 1x106 
cells were then transferred to a round bottom 96-well plate for staining and the remainder of cells 
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was transferred to Trizol® Reagent for RNA isolation (as described above). Naïve (uninfected) 
mice were also examined as a control. 
 
IL-5 and Eotaxin-1 Luminex on lung homogenate 
Lung was collected in PBS containing protease inhibitors (Roche) and homogenized. We used a 
Bio-Plex Pro™ Assay (23-plex, Bio-Rad) according to the manufacturers recommendations.  
Briefly, the plate was treated with Bio-Plex assay buffer, followed by vortexing and two washes. 
Lung homogenates (undilulted), standards, and blanks were then added to the plate and 
incubated at room temperature for one hour shaking at 850 rpm, covered. Following three 
washes, detection antibodies were then diluted and added to each well. The plate was incubated 
as above. Following three washes, diluted SA-PE was added to each well and incubated at room 
temperature for 20 minutes on shaker. The plate was then washed three times and resuspended in 
assay buffer and beads were quantified using a Bio-Plex® MAGPIX™ (Bio-Rad).  
 
Flow cytometry 
BAL cells or cells from digested lung (1x106 total) were spun at 300xg for 3 minutes, 
resuspended in PBS, and pelleted once more. Cells were then resuspended in PBS containing 2% 
heat-inactivated fetal bovine serum and 0.4 μg of anti-CD16/CD32 (eBioscience, clone: 93). 
Following a 15 minute incubation at 4°C, cells were stained with the following antibodies: 
SiglecF-PE (BD Pharmigen™, clone: E50-2440), CD11b-APC (BioLegend, clone: M1/70), 
GR1-PE-Cy7 (BD Pharmigen™, clone:RB6-8C5), CD11c-FITC (eBioscience, clone: N418), and 
F4/80-APC-e780 (eBioscience, clone: BM8). Following an hour incubation at 4°C, cells were 
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washed with PBS, pelleted, and fixed (BD CytoFix™). Cells were then analyzed using a BD 
LSRII Flow Cytometer with compensation via OneComp eBeads (eBioscience).  
 
Eosinophil culture and Pneumocystis killing assay 
Bone marrow-derived eosinophils were generated using a previously described protocol (121, 
125). Briefly, bone marrow was isolated from naïve BALB/c mice and cells plated at 1 x 106 
cells/ml in RPMI 1640 containing 20% FBS (Irvine Scientific, Santa Ana, CA), 2 mM 
Glutamine, 25 mM HEPES, 1X MEM nonessential amino acids, 1 mM sodium pyruvate (all 
from Life Technologies BRL, Rockville, MD), 50 μM β-mercaptoethanol (Sigma-Aldrich, St. 
Louis, MO), 100 ng/ml stem cell factor and 100 ng/ml FLT3-L (both from Peprotech). After 4 
days, cells were replated in the above media supplemented with 10 ng/ml IL-5. After 10 days, 
bone marrow cells were fully differentiated into eosinophils. As previously reported (125), 
samples of 1x105 cells were taken for RNA analysis each time media was changed for real time 
PCR analysis of Epx for eosinophil development and Mpo (Applied Biosystems) for neutrophil 
development. In addition, cells were cytospun onto glass slides, Giemsa stained and analyzed for 
morphology and purity by a murine pathologist in the Comparative Pathology Laboratory at the 
University of Alabama at Birmingham. On the tenth day, bone marrow-derived eosinophils were 
enumerated and utilized in experiments. Bone marrow-derived eosinophils (1 x 105) were then 
co-cultured with 1 x 103 Pneumocystis cysts in 100 μL for 18 h at 37°C and 5% CO2 alone or in 
the presence of 10 ng/mL of IL-4 and IL-13. Controls included P. murina cultured in the absence 
of eosinophils as well as in the presence or absence of IL-4 and IL-13. Total RNA was isolated 
from the contents of each well using TRIZOL LS reagent (Invitrogen, Carlsbad, CA) and 
Pneumocystis SSU burden was calculated as above. Percent killing was defined as previously 
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described (87).  
 
pIL5 and pCMV hydrodynamic injection 
An untagged, murine IL-5 expression vector (pIL5, Origene, MC208784) and an empty vector 
pCMV6 control (Origene, PS100001) were grown in Mix and go E. coli (Zymo Research) in 200 
mL of LB containing kanamycin and were prepared using an EndoFree Plasmid Maxi Kit 
(Qiagen) per manufacturer’s instructions. Following quantification of vector, 10 μg of vector was 
added to 2 mL of Ringer’s solution (0.9% NaCl, 0.03% KCL, and 0.016% CaCl2) and injected 
intravenously via the tail vein within 5 seconds, as previously described (126, 127).  
 
IL-5 ELISA 
Serum IL-5 was quantified using BioLegend ELISA MAX™ Mouse IL-5 ELISA kit per 
manufacturer’s instructions. Briefly, a 96-well plate was coated with capture antibody and stored 
overnight at 4°C. Following washes with PBS + 0.05% Tween-20, the plate was blocked with 
assay diluent for 1 hour at room temperature. Serum samples (diluted 1:20) and IL-5 standard 
were diluted in assay diluent, added to the plate, and incubate overnight at 4°C. Detection 
antibody and diluted Avidin-HRP were then added to the plate, with washes in between 
additions, and the plate was developed with TMB substrate in the dark. Absorbance was then 
measured at 450 nm.  
 
Lung digestion 
The right superior lobe of lung was physically digested using scissors, followed by an hour and a 
half incubation in collagenase/DNase in a 37°C shaker at 250 rpm. Single cell suspensions were 
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then strained using a 70 μm filter, pelleted, and then resuspended in 10 mL PBS. Following 
enumeration using Trypan Blue, cells were stained for flow cytometry as described above.   
 
Histology 
The left main bronchus was clamped using forceps and 250 μL of 10% formalin was injected 
into the bronchus. The lung tissue was then submerged in 10% formalin, paraffin-embedded, and 
processed by the Children’s Hospital of Pittsburgh Histology Core. Sections were then stained 
from H&E and PAS.  
 
Statistics 
All statistics were performed using GraphPad Prism 6. Briefly, an unpaired, two-tailed Student’s 
T test with a p<0.05 considered significant was used for all studies except for the BALB/c pIL-5 
treatment. Given the non-Gaussian distribution for the BALB/c pIL-5 treatment, a Mann-
Whitney nonparametric rank test was performed with a p<0.05 considered significant. For 
studies with three groups, a one-way ANOVA with Tukey’s multiple comparisons was used with 
a p<0.05 considered significant. A Kruskal-Wallis nonparametric test with Dunn’s multiple 
comparison’s test was used for gene expression analysis in the BALB/c primary challenge 
experiment with a p<0.05 considered significant. Linear regression was also performed using 
Prism and Pearson’s correlation coefficient calculations were performed.  
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2.4 RESULTS 
2.4.1 RNA sequencing of whole lung identifies an eosinophil signature early in 
Pneumocystis infection 
To further understand the role of CD4+ T-cells in Pneumocystis infection, we examined 
Pneumocystis burden in wild type and GK1.5 treated, CD4-depleted C57/Bl6 mice. In this study, 
at day 14 using quantitative real time PCR, wild type mice begin to clear infection as CD4-
depleted mice had a higher fungal burden at this time point (Figure 2-1A).  As an unbiased 
approach to investigate potential mechanisms of fungal clearance, we used RNA sequencing of 
whole lung at this time point to examine the signatures of potential effector cells. Strikingly, 
several genes associated with eosinophil function and recruitment, such as Prg2 (major basic 
protein), Il5ra (IL-5 receptor alpha), Ccr3, Ccl11 (eotaxin-1), Ccl24 (eotaxin-2), were all 
significantly upregulated at day 14 of infection in wild type animals (Figures 2-1B and 2-1C). 
Another specific eosinophil marker, eosinophil-associated ribonculease 2 (Ear2), was also 
significantly upregulated in wild type animals, while less specific eosinophil-associated 
ribonucleases (Ear5, Ear10, Ear11) also had higher expression in wild type animals. 
Importantly, in addition to a robust eosinophil signature at day 14 in wild type animals, IL-5 had 
significantly higher expression in wild type animals at the transcriptional level at day 7 and day 
10 post-infection with Pneumocystis (Figure 2-1D). Importantly, prg2, an eosinophil associated 
gene, had a 10-fold increase in expression at day 14 by qRT-PCR, similar to that detected by 
RNA sequencing (Figure 2-1D). Furthermore, protein levels of IL-5 and eotaxin-1 (CCL11) 
were significantly higher in wild type animals at day 14 when compared to CD4-depleted mice 
(Figure 2-1E).  
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Figure 2-1. RNA sequencing of whole lung shows a prominent CD4-dependent eosinophil signature at day 14 
of Pneumocystis infection. A. Wild type or GK1.5 treated CD4-depleted C57BL/6 mice were infected with 2.0 x 
106 cysts/ml of Pneumocystis and were sacrificed at day 3, 7, 10, or 14 following infection (n=5 at each time point). 
Pneumocystis burden was calculated by qRT-PCR of the small subunit ribosomal RNA and a significant decrease 
was seen at day 14 (p<0.01 by Student’s t-test). B. RNA sequencing of whole lung RNA at day 14 in GK1.5 treated 
and wild type mice shows increase in expression in genes associated with eosinophils (n=4 in each group). C. 
Histogram of expression values from heat map in B with * indicating p<0.05 by Student’s t-test.  D. Il5 expression 
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over the course of Pneumocystis infection normalized to Hprt and GK1.5 day 3 (fold change) shows increase of il5 
at day 7 and 10 in wild type mice (* p<0.05, Student’s t-test). Similar to the expression pattern seen by RNA 
sequencing, a ten-fold increase in Prg2 is seen at day 14 by qRT-PCR (p>0.05). E. IL-5 and Eotaxin-1 (CCL11) 
protein levels in lung homogenate at day 14 as determined by luminex (* p<0.05). 
2.4.2 Eosinophils are present in bronchoalveolar lavage fluid early in Pneumocystis 
infection 
To further clarify the CD4+ T-cell dependent eosinophil response to Pneumocystis infection, we 
sought to define the cell populations in the bronchoalveolar lavage (BAL) fluid of wild type and 
CD4-depleted animals at day 14. Cell populations in naïve mice were also analyzed. A 
population of cells with high side scatter was present in animals with intact CD4+ T-cell 
responses, but absent in naïve and CD4-depleted animals infected with Pneumocystis (Figure 2-
2A, left panel). After gating on all cells, a population of SiglecF+CD11b+ cells was noted in the 
wild type animals, but this population was substantially reduced back to naïve levels in animals 
treated with GK1.5 (Figure 2-2A, right panel). The SiglecF+CD11b+ population represented over 
60% of cells in BAL fluid in wild type mice, while less than 2% of cells were SiglecF+CD11b+ in 
mice treated with GK1.5 (Figure 2-2B). Additionally, the RNA from BAL cell pellets was 
enriched for transcripts associated with eosinophils; Epx and Prg2 expression was nearly 1000-
fold higher in BAL cell pellets from wild type mice when compared to naïve and CD4-depleted 
mice (Figure 2-2C).  
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Figure 2-2. CD4-dependent recruitment of eosinophils to the lung at day 14 of Pneumocystis infection. A. 
Bronchoalveolar lavage (BAL) of naïve (uninfected), wild type, and GK1.5 treated CD4-depleted mice 14 days 
post-inoculation with Pneumocystis shows a large population of cells with high side-scatter in wild type mice (left 
panel). The cells were gated as shown (left panel), and a SiglecF+CD11b+ population was seen in the wild type, but 
not the naïve or GK1.5 treated animals (right panel). B. Significant increase in percentage of SiglecF+CD11b+ cells 
in wild type animals compared to naïve and GK1.5 treated animals (n=4-5, **** p<0.0001 by one-way ANOVA 
with Tukey’s multiple comparisons). C. qRT-PCR for Epx (top) and Prg2 (bottom) on RNA extracted from BAL 
cell pellets shows significant increase in expression in wild type animals compared to naïve and GK1.5 treated 
animals (* p<0.05 by one-way ANOVA with Tukey’s multiple comparisons). 
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2.4.3 Eosinophils contribute to control of Pneumocystis infection both in vitro and in vivo 
To determine the role of eosinophils in Pneumocystis infection, we used a loss-of-function 
approach and infected eosinophilopoiesis-deficient Gata1tm6Sho/J mice and BALB/c controls. 
Gata1tm6Sho/J mice had an increased Pneumocystis burden at day 14 post infection compared to 
control BALB/c mice (Figure 2-3A). BALB/c mice had a substantial increase in Epx expression 
and a modest increase in Prg2 expression compared to Gata1tm6Sho/J mice (Figure 2-3B). 
Eosinophils cultured from BALB/c bone marrow also demonstrated anti-Pneumocystis activity in 
vitro (Figure 2-3C). Furthermore, bone marrow derived eosinophils displayed increased 
Pneumocystis killing activity when co-cultured with IL-4 and IL-13 (Figure 2-3D).  
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Figure 2-3. Eosinophils contribute to control of Pneumocystis infection both in vitro and in vivo. A. BALB/c 
and Gata1tm6Sho/J knockout mice were infected with Pneumocystis and sacrificed at day 14 post-infection and SSU 
burden was quantified by qRT-PCR (** p<0.01 by Student’s T test). Uninfected BALB/c mice have no detectable 
Pneumocystis burden. B. qRT-PCR for Epx (left) and Prg2 (right) on RNA from whole lung shows significant 
increase in BALB/c mice infected with Pneumocystis compared to uninfected BALB/c and infected Gata1tm6Sho/J 
knockout mice (* p<0.05 by Kruskal-Wallis test with Dunn’s multiple comparisons test). C. Bone marrow derived 
eosinophils from BALB/c mice demonstrate anti-Pneumocystis activity when co-cultured in vitro for 24 hours at an 
eosinophil to P. murina cyst ratio of 100:1 (*** p<0.0001, Student’s t-test). D. Bone marrow derived eosinophils 
show enhanced killing activity when co-cultured with Pneumocystis in the presence of 10 ng/ml of IL-4 and IL-13 
compared to Pneumocystis alone (** p<0.01 by Student’s T test). 
 
2.4.4 Hydrodynamic injection of IL-5 promotes Pneumocystis clearance in CD4-depleted 
C57BL/6 and Rag1-/- mice 
To induce eosinophilia prior to Pneumocystis infection, we employed hydrodynamic injection 
with either a plasmid expressing IL-5 (pIL5) or an empty plasmid control (pCMV) in C57BL/6 
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mice treated with GK1.5 or Rag1-/- mice three days prior to infection (Figure 2-4A). At day two 
following infection, mice treated with pIL5 had over a log-fold increase in serum IL-5 (Figure 2-
4B). At day 14 of infection, treatment with pIL5 resulted in an increased abundance of a high 
side scatter population and a SiglecF+CD11b+ population in both CD4-depleted C57BL/6 and 
Rag1-/- mice (Figure 2-4C). While these populations were present by flow cytometry in the 
groups treated with pCMV alone (Figure 2-4C, left panel), C57BL/6 and Rag1-/- mice treated 
with pIL5 had significantly more SiglecF+CD11b+ cells as measured by both percentage and total 
cell number recovered from the lung (Figure 2-4D).  
Strikingly, both the CD4-depleted C57BL/6 and Rag1-/- mice receiving pIL5 had a 
statistically significant reduction in Pneumocystis burden by day 14 of infection when compared 
to mice treated with pCMV (Figure 2-4E). While the average difference in burden was 
approximately a half-log in both cohorts, some individual mice had greater than a log-reduction 
in Pneumocystis burden with pIL5 treatment (Figure 2-4E).  Recruitment of eosinophils to the 
lung could also be observed by H&E staining in mice receiving pIL5 (Figure 2-4F). The pIL5 
treated mice also had a ten-fold increase in expression of Epx and Prg2 in whole lung RNA 
when compared to pCMV treated mice (Figure 2-4G).  
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Figure 2-4. Treatment of CD4-depleted C57BL/6 and Rag1-/- mice with pIL5 results in eosinophilia in whole 
lung and decreased Pneumocystis burden. A. Schematic showing timing of hydrodynamic injection of either 
pCMV or pIL5 (day -3 and 4) and Pneumocystis inoculation (day 0) into GK1.5 treated C57BL/6 (B6) or Rag1-/- 
mice. B. Serum IL-5 ELISA at day 2 post infection shows log-fold increase in IL-5 in pIL5 treated animals (n=4-7, 
dotted line represents limit of detection). C. Digested whole lung shows a high side scatter population in the pIL5 
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groups compared to the pCMV treated groups (left panel). The cells were gated as shown (left panel), and a 
SiglecF+CD11b+ population was seen in both the B6 and Rag1-/- mice treated with pIL5 at day 14 post infection 
(right panel). D. pIL5 treatment resulted in a statistically significant increase in percentage (top) and total number 
(bottom) of SiglecF+CD11b+ cells (* p<0.05, ** p<0.01 by Student’s t-test). E. pIL5 treatment results in statistically 
significant reduction in Pneumocystis burden as measured by qRT-PCR of small subunit ribosomal RNA at day 14 
post infection (* p<0.05, *** p<0.001 by Student’s t-test). F. H&E staining on paraffin-embedded lung sections 
demonstrating eosinophils (black arrowheads) in both the B6 and Rag1-/- mice treated with pIL5 at 60X 
magnification. G. qRT-PCR for Epx (left) and Prg2 (right) on RNA extracted from whole lung shows significant 
log-fold increase in expression in pIL5 treated animals compared to pCMV treated mice (* p<0.05 by Student’s T 
test). 
 
Furthermore, although pIL5 treatment increased eosinophilic lung inflammation, this was 
not associated with Type 2 immune inflammation as measured by goblet cell hyperplasia or 
mucin expression (as measured by qRT-PCR of Clca3, Muc5ac and PAS staining) or Il13 
expression in the pIL5 treated C57BL/6 mice (Figure 2-5). 
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Figure 2-5. Airway markers of pathology are reduced following pIL5 treatment. A. pIL5 treatment in B6 mice 
resulted in reduced Clca3, Muc5ac, and Il13 expression in whole lung homogenate when compared to pCMV 
treated mice (*, **, and *** represent p<0.05, p<0.01, p<0.005 by Student’s T test). Muc5b expression was not 
significantly different in pIL5 treated animals. B. PAS staining of airways shows reduced mucus production in pIL5 
treated B6 mice when compared to mice receiving pCMV at 10X magnification. 
 
2.4.5 IL-5 mediated decrease in Pneumocystis burden is abrogated in eosinophil-deficient 
Gata1tm6Sho/J mice 
To verify the effect of pIL5 required eosinophilopoiesis, we used a genetic approach. CD4-
depleted BALB/c mice were treated with pIL5 as described above and similar levels of IL-5 
were induced in the serum (Figure 2-6A). Similarly, increased eosinophils were noted in the 
lung digest of pIL5 treated BALB/c mice (Figure 2-6B). pIL5 treated BALB/c mice had a 
statistically significant increase in total number and a trend towards higher percentage of 
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SiglecF+/CD11b+ cells compared to pCMV treated BALB/c mice (Figure 2-6C). Furthermore, 
upon sacrifice, BALB/c mice treated with pIL5 had nearly a 50% reduction in Pneumocystis 
burden when compared to pCMV treated animals (Figure 2-6D, p=0.04). Burden in this case 
was normalized to the pCMV group as the inoculums over three independent experiments varied; 
however, a similar reduction in burden was noted with C57BL/6 and Rag1-/- mice (Figure 2-
6E). Also noteworthy, four pIL5 treated mice had no induction of serum IL-5 and lacked 
eosinophils in the lung at day 14 by flow cytometry, likely due to technical variation. If only 
mice that responded to pIL5 treatment were included in the analysis, the mean percentage of 
Pneumocystis remaining in pIL5 treated mice would be 26% compared to 100% of pCMV 
treated mice (p<0.0002). pIL5 treatment was also associated with significant increases in 
eosinophil associated genes such as Epx and Prg2 (Figure 2-6E).  
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Figure 2-6. pIL5 treatment can reduce Pneumocystis burden in CD4-depleted BALB/c mice.  A. Serum IL-5 
ELISA at day 2 post infection shows log-fold increase in IL-5 in pIL5 treated BALB/c mice (n=4, dotted line 
represents limit of detection). B. Digested whole lung shows a high side scatter population in the pIL5 groups 
compared to the pCMV treated groups (left panel). The cells were gated as shown (left panel), and a 
SiglecF+CD11b+ population was seen in the BALB/c mice treated with pIL5 (right panel). C. pIL5 treatment 
resulted in an increase in percentage (top) and total number (bottom) of SiglecF+CD11b+ cells. D. pIL5 treatment 
results in reduction in Pneumocystis burden as measured by qRT-PCR of small subunit ribosomal RNA (p=0.08 by 
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Student’s t-test). E. qRT-PCR for Epx (left) and Prg2 (right) on RNA extracted from whole lung shows significant 
log-fold increase in expression in pIL5 treated animals compared to pCMV treated mice (* p<0.05 by Student’s T 
test). 
 
The increased Pneumocystis killing in mice that recruited eosinophils to the lungs is also 
evident in the strong negative correlation that exists between Pneumocystis burden and total 
SiglecF+CD11b+ recruited cells in both C57BL/6 and BALB/c mice (Figure 2-7, p<0.05). 
 
Figure 2-7. Eosinophil number correlates with Pneumocystis killing in vivo. A. Correlation between the log of 
total SiglecF+CD11b+ cells with the log of Pneumocystis SSU burden demonstrates a strong negative correlation in 
B6 mice. Solid line represents linear regression of data points and dashed lines represent 95% confidence interval 
(r=-0.9485, p=0.0003 by Pearson’s correlation). B. Similar correlation was noted in BALB/c mice, despite one pIL5 
mouse recruiting few eosinophils (r=-0.8871, p=0.0033 by Pearson’s correlation). 
 
In contrast, Gata1tm6Sho/J mice, which are deficient in eosinophilopoiesis, were CD4-
depleted and treated with pIL5 or pCMV as described. Treated Gata1tm6Sho/J mice failed to show 
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an effect of pIL5 on fungal burden, despite similar levels of IL-5 compared to previous mouse 
strains (Figure 2-8A and 2-8B). Consistent with no reduction in fungal burden, there was no 
observable eosinophil recruitment was detected in the lungs of Gata1tm6Sho/J mice, as neither a 
high side-scatter population nor a SiglecF+CD11b+ was noted by flow cytometry (Figure 2-8C 
and 2-8D). Furthermore, there was no induction of Epx or Prg2 in the Gata1tm6Sho/J mice treated 
with pIL5 (Figure 2-8E). 
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Figure 2-8. pIL5 treatment cannot rescue eosinophil-deficient Gata1tm6Sho/J knockout mice. A. Serum IL-5 
ELISA at day 2 post infection shows nearly a log increase in Gata1tm6Sho/J pIL5 treated animals (n=4, dotted line 
represents limit of detection). B. pIL5 treatment does not reduce Pneumocystis burden at day 14 post infection in 
Gata1tm6Sho/J mice as measured by qRT-PCR of small subunit ribosomal RNA. C. Digested whole lung shows no 
difference in high side scatter populations (left panel) or SiglecF+CD11b+ cells (right panel) independent of pIL5 
treatment status. D. pIL5 treated Gata1tm6Sho/J mice showed no difference in percentage (top) or total number 
(bottom) of SiglecF+CD11b+ cells. E. qRT-PCR for Epx (left) and Prg2 (right) on RNA extracted from whole lung 
shows no increase in eosinophil associated genes in Gata1tm6Sho/J mice. 
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2.5 DISCUSSION 
The current study utilized an unbiased RNA sequencing based approach towards evaluating the 
role of CD4+ T-cells in Pneumocystis infection and suggested that CD4+ T-cells can recruit 
eosinophils to the lung by day 14 of infection by RNA sequencing. Eosinophils were also shown 
to have a role in immunity against Pneumocystis in a primary challenge model of eosinophil-
deficient mice and in an eosinophil-based Pneumocystis in vitro killing assay. Furthermore, 
induction of eosinophilia via hydrodynamic injection of pIL5 was capable of reducing 
Pneumocystis burden in vivo in both CD4-depleted C57BL/6 and Rag1-/- mice. Finally, the same 
technique was able to reduce Pneumocystis burden in CD4-depleted BALB/c mice but failed to 
provide any therapeutic benefit in CD4-depleted Gata1tm6Sho/J mice, further implicating 
eosinophils as a novel cell population responsible for in vivo antifungal activity.  
CD4+ T-cells have been established as crucial mediators of Pneumocystis due to the high 
incidence of Pneumocystis in HIV/AIDS patients with low CD4+ T-cell counts (1, 128). One 
clear role of CD4+ T-cells in response to Pneumocystis is to stimulate antibody responses by 
providing co-stimulatory signals to B cells (79, 129). Antibodies against Pneumocystis are 
protective; however, at day 14 of infection, prior to antibody production, Pneumocystis burden 
has already plateaued in wild type animals, suggesting an antibody-independent function for 
CD4 cells (129). As such, CD4+ T-cells appear to recruit eosinophils early in infection while B 
cells are undergoing maturation into antibody-producing plasma cells and provide preliminary 
control of Pneumocystis burden. Importantly, IL-5 transcription and eosinophil recruitment 
appear to be dependent on CD4+ T-cells in this model, as such markers do not appear until after 
activation of the adaptive immune response at day 7 post-infection.  
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Eosinophils, classically recognized as mediators of immunity against helminths, have 
recently been implicated in host defense against a variety of pathogens, including bacterial and 
viral infections (98). Recently, the Steele lab demonstrated that eosinophils contribute to host 
defense against the fungal pathogen Aspergillus fumigatus through a secretory factor, as 
eosinophils could mediate fungal killing when separated using transwells (121). The current 
study extends these findings by demonstrating that eosinophil-deficient mice are more 
susceptible to Pneumocystis infection and that eosinophils display antifungal activity in vitro. 
Additionally, treatment of bone marrow derived eosinophils with IL-4 and IL-13 greatly 
enhanced killing of Pneumocystis, suggesting that Th2 cytokines in the lung may augment 
eosinophil-dependent antifungal activity.  
There are also several lines of evidence that connect Pneumocystis related pathology and 
eosinophils in both human disease and mouse models. First, eosinophilia in the bronchoalveolar 
lavage fluid of HIV-positive patients with Pneumocystis pneumonia has been well documented; 
however, whether a correlation exists between high eosinophil counts and lower Pneumocystis 
burden in these patients is unknown (130, 131). Secondly, patients with a history of 
Pneumocystis or bacterial pneumonia had a significantly higher rate of physician-diagnosed 
asthma, a disease that has a well-established eosinophilic component in regards to pathogenesis 
(66). Murine models of Pneumocystis have also shown STAT6, a transcription factor required 
for Th2 responses, is necessary for the development of airway hyperresponsiveness early in the 
course of infection (129). While eosinophilia was also documented early in this murine model, 
the study further links a Th2 response, and potentially eosinophilia, with pathology in the context 
of Pneumocystis infection (129). Additionally studies have shown that CD8+ T-cells may 
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moderate the interactions between CD4+ T-cells and eosinophils, although all three cell types 
may contribute to Pneumocystis driven pulmonary pathology (132). 
However, the current study suggests that eosinophils are more than just the byproduct of 
a misguided immune response that drives airway hyperresponsiveness and pathology. The 
current study demonstrates that eosinophils have antifungal effects against Pneumocystis 
infection in vitro and in vivo and appear to be recruited to the lung by CD4+ T-cells early in 
infection. Additionally, the role of eosinophils as a potential therapeutic in the setting of 
HIV/AIDS may warrant further exploration, as IL-5 mediated eosinophilia can provide reduced 
Pneumocystis burden even in the setting of complete loss of T cells and B cells. Furthermore, 
such robust eosinophilia actually appeared to mitigate airway pathology (e.g. mucus production) 
suggesting that Pneumocystis burden may play an equally important role in driving airway 
hyperresonsivness.  These findings provide evidence that the specific pathways responsible for 
protective and pathologic effects in Pneumocystis pneumonia may be independent and may allow 
for the targeted use of eosinophil-based treatments for Pneumocystis while avoiding concurrent 
pathology. 
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3.0  A NOVEL CD4+ T-CELL DEPENDENT MURINE MODEL OF PNEUMOCYSTIS 
DRIVEN ASTHMA-LIKE PATHOLOGY 
Adapted from: A novel CD4+ T-cell dependent murine model of Pneumocystis driven asthma-
like pathology 
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3.1 INTRODUCTION: IMMUNOBIOLOGY OF ASTHMA 
Asthma affects over 300 million people worldwide and is characterized by bronchial 
hyperreactivity, mucus production, and airway remodeling (133). Asthma is highly prevalent, 
particularly in Western cultures, affecting over 1 in 10 children and 1 in 12 adults (134). In total, 
the medical costs and indirect costs of asthma in the United States exceed $18 billion dollars per 
year (133, 134). Symptoms of asthma include shortness of breath, chest tightness, wheezing, 
cough with sputum production, and nighttime awakenings with any of the above symptoms. 
Often, these patients can require hospitalization for a wheezing episode. However, outside of 
admissions, patients are often maintained on a bronchodilator, as well as an anti-inflammatory 
steroid inhaler.  
Clinically, asthma is diagnosed primarily by spirometry and is defined as a forced 
expiratory volume in one second (FEV1) below 70% predicted (which accounts for various 
factors, such as height, weight, sex, etc.). A decreased FEV1 is diagnostic of obstructive lung 
disease, and in the case of asthma, represents the underlying airway remodeling and mucus 
plugging as a result of hyper-secretion. Other spirometry analyses can include decreased forced 
expiratory flow 25-75% (FEF25-75), which would be further indicative of obstruction in the 
smaller to medium sized airways. Additionally, patients with severe asthma can have such 
obstruction in their bronchi that air is retained or trapped in the lung; air trapping can increase 
the total lung capacity (TLC) and the amount of air remaining in the lungs following maximal 
expiration (residual volume, RV). These measurements are acquired by a technique known as 
plethysmography and are less routinely performed than spirometry.  
 Severe asthma is defined as poor symptom control with frequent severe exacerbations 
requiring systemic steroids or hospitalization. Additionally, patients with severe asthma have a 
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FEV1<80% predicted immediately following treatment with a bronchodilator (135). Asthma, 
however, is more and more being recognized as a heterogeneous disorder. For one, genome wide 
association studies have associated certain genes, such as IL33, SMAD3, and HLA-DQ, with the 
presence of asthma in all age groups (136). Furthermore, meeting the clinical definition of severe 
asthma does not paint the entire picture. One study used data from 856 asthmatic patients (such 
as demographics, spirometry, atopy, treatment, etc.) and found that asthma can divided into five 
clusters (137). This heterogeneity extends further than clinical data, as various –omics 
approaches are being applied to patients with asthma. One study used transcriptomics on nasal 
epithelium followed by hierarchical clustering and was able to identify a subset of patients with a 
high Th2-skew (138). A population of asthma patients with high Th2 gene activation could also 
be detected by transcriptomics techniques on sputum samples and bronchial epithelial brushes 
(139, 140).  
While these unbiased approaches unveiled novel players in the field of asthma, it has 
long been known that Th2 responses play a critical role in asthma. In fact, one early study of 
patients with mild asthma demonstrated the presence of IL-4+ and IL-5+ CD4+ T-cells in the 
bronchoalveolar lavage fluid (141). One possible detrimental effect of these Th2 cells in the lung 
is the promotion of IgE class-switched antibodies. IgE can bind Fc receptors on mast cells, and in 
the presence of cognate antigen result in the release of pathologic mediators of allergic airway 
inflammation such as histamine (134). The presence of antigen-specific IgEs is routinely 
diagnosed clinically via skin prick testing or by serum analysis. Antigen-specific IgEs are 
indicators of allergic sensitization to particular airborne substances (tree pollen, house dust mite, 
cockroach antigen, etc.). 
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The Th2 response in the lung has other consequences outside of IgE antibody formation. 
IL-13, another hallmark type II cytokine, can directly lead to bronchial hyperreactivity and 
airway hyperresponsiveness (142). Furthermore, IL-13 can initiate the process of goblet cell 
hyperplasia, essentially leading to increased epithelial differentiation to the goblet cells that 
produce mucus (143). Th2 cells can also produce IL-5, a cytokine that acts in the bone marrow to 
cause eosinophilopoiesis (see chapter 2). Eosinophils can then be recruited into the lung via local 
production of eotaxins – CCL11, CCL24, and CCL26 – and release of pro-inflammatory 
mediators can lead to increased bronchial reactivity in some cases (144). Murine models of 
allergic inflammation, however, have led to conflicting evidence of the pathologic role of 
eosinophils. The TgPHIL mouse developed by Lee et al., had decreased airway resistance 
following OVA challenge compared to wild type mice (145). Contrastingly, the dblGATA1 
knockout mice deficient in eosinophilopoiesis had similar airway hyperresponsiveness compared 
to wild type mice following OVA challenge (146). One study attributed this discrepancy to the 
underlying genetic strain used to generate each model organism (147). In a second model of 
allergic inflammation, intranasal administration of house dust mite extract exacerbated airway 
resistance in both TgPHIL and dblGATA1 knockout mice, but to a lesser extent than wild type 
mice (148). Importantly, the Th2 response and the associated mucus production appeared to be 
independent of eosinophils (148).  
Another cell type in the lung is capable of mediating type II pathology, the innate 
lymphoid cell type II (ILC2). ILC2s are not part of the adaptive immune system, as these cells do 
not possess antigen-specific recognition receptors (149). However, ILC2 cells mirror the 
response generated by Th2 cells, as ILC2s can produce IL-5 and IL-13 early in the context of 
infection (150). Interestingly, ILC2s respond to the epithelial derived cytokines IL-33, IL-25, and 
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thymic stromal lymphoprotein (TSLP) and can drive airway eosinophilia and mucus production 
(151, 152). The redundancy in cytokines produced between Th2 and ILC2 cells has led to the 
examination of the role of ILC2s in allergic airway disease. Accordingly, ILC2s have been 
implicated in pathogenesis of allergic airway inflammation in response to papain, a protease-
dependent airway irritant, and in an acute model of Alternaria, a fungal allergen (153, 154). In an 
acute model of OVA and house dust mite exposure, ILC2 cells appear to produce IL-5 and IL-13 
in a similar, if not greater, quantity compared to Th2 cells (155). ILC2s also appear to have the 
ability to facilitate Th2-response development, by secreting IL-13 and presumably by altering the 
local cytokine milieu to a more Th2-biased polarizing environment (156). In addition to secretion 
of Th2-skewing cytokines, ILC2 cells are capable of directly priming Th2 cells through major 
histocompatibility class II:T-cell receptor interactions, further suggestive of a role for ILC2s in 
the optimal Th2 response (157).  
While all of these type II cells (Th2, eosinophils, ILC2s) collaborate to contribute to 
asthma pathology, they may represent a specific subtype of allergic airway disease. Revisiting 
the transcriptomic data described above, a high Th2 signature could only be found in less than 
50% of asthma patients, suggesting other immunologic lineages are involved in asthma 
pathogenesis (140). One such cell implicated in the development of severe asthma is the Th17 
cell. Th17 cells are thought to participate in host defense against extracellular pathogens, 
primarily through neutrophil recruitment, modulation of antimicrobial peptide expression, and 
alterations in epithelial barrier integrity (158). This inflammatory response characterized by 
neutrophil recruitment is present in a subset of patients with late-onset, severe forms of asthma 
(159–161). IL-17A, the prototypical cytokine produced by Th17 cells, has been shown to directly 
cause contraction of bronchial smooth muscle cells (162). Further indicative of the severe nature 
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of asthma caused by Th17 cells, one study in a murine model demonstrated that transfer of Th17 
cells led to increased bronchial hyperreactivity that was steroid-insensitive (160).  
While a litany of aspects of the immune system can contribute to the immunopathology 
of asthma, the triggers of this maladaptive response are the real culprits behind the 
pathophysiology. Viral pathogens appear to be a major exacerbating factor leading to wheezing 
in young children. Human respiratory syncytial virus (RSV), for example, has been well 
established as a pathogen capable of causing acute wheezing, cough, and mucus production 
resembling asthma-like pathology in children (163). Furthermore, children diagnosed with RSV 
bronchiolitis had a higher prevalence of asthma (39%) compared to control children (9%) 18 
years after infection with RSV (164). Children with early RSV infection were also more likely to 
have evidence of IgE antibodies to environmental exposures compared to healthy controls (164). 
RSV induces a potent Th2 response in the lung and can potentially skew the immune responses 
to future environmental allergens (165–167). Other viral pathogens, such as human 
metapneumovirus and rhinovirus, are also major causes of acute wheezing episodes in children 
and may lead to Th2-driven pathology in the lung (168–170). 
A variety of non-viral airborne exposures can exacerbate asthma, including non-
infectious particles (house dust mite, cigarette smoke) and infectious airborne fungal spores 
(151). Fungal sensitization in asthma patients is common, as some studies found between 35-
70% of severe asthmatics had evidence of anti-fungal IgE antibodies (171–173). There are a 
number of fungal species associated with asthma, such as Aspergillus, Alternaria, Penicillium, 
Fusarium, and patients are routinely screened for allergic sensitization by skin test or blood IgE 
levels (171). Interestingly, asthma patients with fungal IgE sensitization have more severe 
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disease as measured by diminished lung function and increased hospital admissions (170, 171, 
174).  
Exposure to these fungal species likely occurs early and in the home. One study found 
that dust obtained from homes with an asthmatic child contained a fungal protease, 
aspergillopepsin, found in the Aspergillus niger (175). Porter et al. then elegantly demonstrated 
that protease-deficient strains of Aspergillus were unable to cause changes in airway resistance, 
while wild type strains induced allergic airway inflammation (175, 176). Wild type Aspergillus 
niger was not alone in inducing allergic inflammation; one study demonstrated that exposure to 
over 12 strains of fungi led to varying degrees of Th2 responses and increases in airway 
resistance (177). Importantly, mice lacking CD4+ T-cells were unable to control fungal burden 
and dissemination, suggesting that the Th2 response, at least in regards to a few fungal species, 
was protective (177). 
3.2 RATIONALE AND HYPOTHESIS 
Given the strong eosinophilic response to Pneumocystis in the lung and the abundance of 
exposure to Pneumocystis amongst the population, we hypothesized that Pneumocystis may 
generate a type II response capable of modulating a similarly type II driven disease of the lung, 
asthma. 
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3.3 METHODS 
Mice 
C57BL/6, BALB/c, Gata1tm6Sho/J, Rag1-/- and Rag2-/-Il2rg-/- mice were all ordered from The 
Jackson Laboratory. Mice were all 6-8 week old and sex-matched. Colonies were maintained in 
the Rangos Research Building Animal Facility and use was approved and performed in 
accordance with the University of Pittsburgh Institutional Care and Use Committee.  
 
Pneumocystis inoculation 
Pneumocystis murina was harvested from the lungs of an infected Rag2-/-Il2rg-/- mouse and mice 
were challenged with 2.0 x 106 cysts/mL as previously described(83, 123). CD4-depletion with 
GK1.5 antibody was performed as described previously(83, 124).  
 
RNA isolation and qRT-PCR 
The right middle lobe was homogenized in Trizol® (Life Technologies) followed by subsequent 
RNA isolation, per manufacturer’s instructions. One μg of RNA was then converted to cDNA 
using iScript™ (Bio-Rad). Gene expression analysis was performed using SsoAdvanced™ qRT-
PCR universal probes supermix (Bio-Rad). Murine primers included: Il4, Il5, Il13, Clca3, 
Muc5ac, Prg2 (Applied Biosystems). Pneumocystis SSU primer/probe sequences were described 
above in section 2.3.   
 
 
 
 
 60 
RNA sequencing 
Sample preparation and RNA sequencing was performed as described previously (25994969) 
and are publicly available through the Sequence Read Archive BioProject (number: 
PRJNA276259). Data were filtered on a quality score of 10 and mined for genes associated with 
type II immune responses: Il33, Il25, Muc5ac, Clca3, Il9, Il4, Il13, Chi3l3, Chi3l4, Arg1, Il9r, 
Il17rb, Gpr44, Tslp, Il7r, Crlf2, Il1rl1, Acta2. Il9 and Il25 did not pass the quality filter.  
 
RNA sequencing pathway analysis 
The FASTQ files from our previous study were uploaded to Illumina BaseSpace cloud-based 
software, aligned using TopHat version 1.0.0 and assembled with Cufflinks Assembly and DE, 
Version 1.1.0. Pathway analysis was then performed using iPathwayGuide, Version 1.4.0. 
KEGG and Disease pathways were analyzed for significance using a false discovery rate. 
 
Purification of CD4+ T-cells and adoptive transfer 
Spleens from C57BL/6 mice were harvested, physically digested, and passed through a 70-μm 
filter. CD4+ T-cells were isolated using a Stemcell™ EasySep™ Mouse kit (19852) and were 
subsequently enumerated. Each Rag1-/- mouse received 5 x 105 cells in 200 μL via intravenous 
injection. Mice were infected on the day of transfer as described above and sacrificed 6 weeks 
post infection. 
 
Lung protein and Luminex 
The right upper lobe of lung was collected, homogenized in PBS plus protease inhibitor 
(14277300, Roche). The lung homogenate was then centrifuged at 5,000xg for 5 minutes to 
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collect debris and the supernatant was collected. Cytokine analysis was then performed on this 
supernatant with a 23-plex Bio-Plex Pro™ (Bio-Rad), per manufacturer’s instructions.  
 
Ex vivo whole lung cell stimulation 
The right lower and post-caval lobes of lung were collected, physically digested, and incubated 
for an hour and a half at 37°C in collagenase/DNase. Lungs were collected from naïve, HDM-
treated, PC-infected, or HDM-treated and PC-infected mice. Likewise, cells were isolated from 
mice treated with PCAg. Single cell suspensions were then strained using a 70-μm sterile filter, 
treated with red blood cell lysis buffer (NH4Cl), and enumerated. 5 x 105 cells/well were 
stimulated with PBS (no stimulation control), 2.5 μg PCAg or HDM, or 2.5 μL of CD3/CD28 
Dynabeads® (2015-07, Life Technologies). Three days post-stimulation, the cells were pelleted, 
supernatants were harvested and cell pellets were resuspended in Trizol® LS (Life Technologies).   
 
Histology 
The right lung was clamped and the left lung was inflated with 10% formalin through the 
trachea. Following fixation, the lungs were processed, sectioned, and stained with hematoxylin 
and eosin or periodic acid-Schiff staining. 
 
Pneumocystis antigen preparation and treatment 
A lung from a Rag2-/-Il2rg-/- infected with Pneumocystis murina for 8 weeks was strained 
through a 70-μm sterile filter (83, 178). Following centrifugation, the pellet was resuspended in 1 
mL of PBS, layered on top of 30 mL of Centricoll™ (C-0580, Sigma) and centrifuged at 2,000 
rpm for 15 minutes. The material at the interface of the Centricoll™ and PBS was collected, 
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washed twice in PBS, resuspended in 1 mL PBS and sonicated for 30 seconds three times. 
Protein was quantified using a BCA assay. Mice were then anesthetized with isoflurane and 10 
μg of PCAg or HDM was administered intranasally in 50 μL PBS. Mice were sensitized on day 
0, challenged on day 7-11, and sacrificed on day 14. For ILC2 studies, mice were treated every 
three days intraperitoneally with 0.5 mg of anti-ST2 antibody, provided by Dr. Dirk Smith.  
 
ELISAs 
96-well plates were coated overnight in a 9.2 pH carbonate buffer with 150 ng/well of 
Pneumocystis antigen, Aspergillus fumigatus antigen (GM3A01, Greer®), house dust mite extract 
(XPB70D3A2.5, Greer®), or a heat-killed Streptococcus pneumonia preparation. Plates were 
washed 5x with PBST and blocked in PBST with 5% milk for 2 hours at room temperature. 
Serum was diluted 1:64 (IgG assays) or 1:10 (IgE assays) in PBST with 5% milk and 100 μL 
was added to each well and the plate was incubated overnight at room temperature. Plates were 
then washed 5x with PBST and treated with 1:1000 goat anti-mouse IgG-HRP or 1:1000 goat 
anti-moues IgE-HRP (1030-05, Southern Biotech) diluted in blocking buffer. Following a one-
hour incubation at room temperature, plates were washed 5x with PBST, developed with 1x 
TMB solution (BD OptEIA™, 555214), stopped with H2SO4 and read at 450nm. For human 
serum assays, bovine serum albumin was used in place of milk and rabbit anti-human IgG 
(A8792, Sigma®) and goat anti-human IgE (A18793, Life Technologies) were used as secondary 
antibodies. 
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Anti-PCAg Western blotting 
PCAg (5 μg) or murine lung homogenate (10 μg) was denatured at 65° in LDS buffer with β-
mercaptoethanol for 10 minutes and then added to a 4-20% tris-bis gel (Bio-rad) and run at 200V 
for 35 minutes. Following transfer to a nitrocellulose membrane (Bio-rad), the membrane was 
washed for 5 minutes in TBST and blocked at room temperature in TBST with 5% BSA for 2 
hours. Serum samples were diluted 1:100 in TBST with 5% BSA, applied to the membrane, and 
incubated at 4° overnight. Membranes were washed three times with TBST for 5 minutes each, 
followed by addition of secondary antibody (described in ELISA) for one hour at room 
temperature. Membranes were then washed, developed using SuperSignal® West Pico 
Chemiluminescent Substrate (#34080, Thermo Scientific) and luminescence was measured for 1 
second.  
 
Flow cytometry 
Whole lung cells were isolated as described in the ex vivo whole lung cell stimulation methods. 
Briefly, cells were plated, centrifuged, and resuspended in surface antibodies diluted in PBS. 
Following a 1 hour incubation at 4°C, cells were washed and resuspended in the 
streptavidinBV421 (diluted 1:200). Following a 30 minute incubation at 4°C, cells were washed 
and fixed and permeabilized using the eBioscience FoxP3 staining kit per manufacturer’s 
instructions. Intracellular antibodies, anti-CD45.2, and anti-CD90.2 antibodies were added and 
incubated at 4°C for 1 hour. Cells were then washed, resuspended, and analyzed on a BD LSR II 
Flow Cytometer with compensation via OneComp eBeads (eBioscience). Data analysis was 
conducted using FlowJo software (Treestar). 
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Antibodies used in these panels were diluted 1:200 in PBS unless otherwise specified and 
include: GATA3-FITC, diluted 1:5 (BD Pharmingen, Clone: L50-823), TCRβ-PerCP-Cy5.5 
(eBioscience, Clone: H57-597), TCRγδ-PE (eBioscience, Clone: GL3), CD90.2-PE-Cy7, diluted 
1:1500 (eBioscience, Clone: 53-2.1), RORγT-APC (BD Pharmingen, Clone: Q31-378), CD45.2-
APC-e780 (eBioscience, Clone: 104), Streptavidin-BV421 (BioLegend, Cat: 405226), CD11b-
Biotin (eBioscience, Clone: M1/70), F4/80-biotin (eBioscience, Clone: BM8), NK1.1-biotin (BD 
Pharmingen, Clone: PK136), CD11c-biotin (BD Pharmingen, Clone: HL3), CD19-biotin (BD 
Pharmingen, Clone: 1D3), TER119-biotin (BD Pharmingen, Cat: 553672). APC panel: GR-1-
e450 (BD Biosciences, Clone: RB6-8C5), CD11b-APC (Biolegend, Clone: M1/70), F4/80-APC-
e780 (eBioscience, Clone: BM8), SiglecF-PE (BD Biosciences, E50-2440), CD11c-FITC 
(eBioscience, Clone: N418). 
 
Lung Mechanics and Airway Hyperresponsiveness Measurements 
Pulmonary function was assessed during mechanical ventilation of anesthetized (90 mg/kg 
pentobarbital i.p.) and tracheotomized mice using a computer-controlled small-animal 
mechanical ventilator (FlexiVent; SCIREQ, Montreal, Quebec, Canada) as previously 
described(159, 179). Briefly, mice were mechanically ventilated at 200 breaths/min with a tidal 
volume of 0.25mL and a positive end expiratory pressure of 3 cmH2O (mimicking spontaneous 
ventilation). The quasi-static mechanical properties of the lung (compliance and hysteresis) were 
calculated using pressure-volume curves derived from a step-wise inflation of the lung to a 
maximum pressure of 30cmH2O. Newtonian resistance (Rn), tissue damping (G), and tissue 
elastance (H) were assessed prior to and following airway challenge with increasing doses of 
aerosolized methacholine (0, 0.75, 3.125, 12.5, and 50 mg/mL) using the forced oscillation 
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technique and constant phase model as previously described (180, 181). Multiple linear 
regression was used to fit measured pressure and volume in each individual mouse to the model 
of linear motion of the lung. Model fits that resulted in a coefficient of determination less than 
0.8 were excluded. 
 
Clinical measurements 
All human samples were collected via the Severe Asthma Research Program (SARP) and were 
collected at the University of Pittsburgh. Samples were de-identified and the serum ELISAs were 
performed with the disease status blinded from the researcher. Symptom scores and clinical 
measurements were collected in accordance with the Institutional Review Board (IRB0610032) 
as previously described(137).  
 
Statistics 
All statistics were performed using Graph Prism version 6.0f. All data are presented with mean ± 
SEM, with the exception of symptom scores (presented as median). Studies with two groups 
used a simple Student’s t-test. Time course and Flexivent studies were analyzed using a Two-
way ANOVA with multiple comparisons at each time point. Studies with more than two samples 
were analyzed using an ordinary one-way ANOVA with Tukey’s multiple comparisons. 
Cytokine protein levels were analyzed for normality using a D’Agostino and Pearson omnibus 
normality test and were found to be normally distributed. Antibody dilution studies with human 
serum were analyzed with a two-way ANOVA. A Chi-square test was used to analyze patient 
symptom scores. Linear regression was performed, the slope was analyzed for significant 
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difference from zero, and a Pearson’s correlation coefficient was calculated. All statistical 
analyses considered p<0.05 significant.  
 
3.4 RESULTS 
3.4.1 Pneumocystis murina infection induces a robust type II response dependent on CD4+ 
T-cells  
While we have previously shown that Pneumocystis murina infection leads to a CD4+ T-cell 
dependent recruitment of eosinophils (182), several other genes associated with a type II 
response were upregulated in wild type mice compared to CD4-depleted mice treated with 
GK1.5 monoclonal antibody at day 14 post-infection by RNA sequencing  (Figure 3-1A and 3-
1B). In addition to a previously shown increase in IL-5 expression (182), IL-4 and IL-13 were 
also upregulated in a CD4+ T-cell dependent manner (Figure 3-1C). Likewise, markers of goblet 
cell hyperplasia, Muc5ac and Clca3, had increased expression (Figure 3-1C). At the protein 
level, IL-4 production over the course of infection increased in a CD4+-dependent manner, while 
IL-5 had sustained protein levels in wild type but not CD4+-depleted animals (Figure 3-1D). 
Histologically, wild type mice had inflammatory foci at day 7 and eosinophilic perivascular 
inflammation at day 14, while CD4+-depleted animals appeared to have a delayed and reduced 
inflammatory response (Figure 3-1E). Similarly, by day 7 and 14 of infection wild type mice 
had increased goblet cell activation and mucus production, while GK1.5 treated mice had 
minimal mucus detection at day 14 (Figure 3-1F).  
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Figure 3-1. Pneumocystis murina infection induces a CD4+ T-cell dependent type II response. Wild type (WT) 
or GK1.5 treated C57BL/6 mice were infected with Pneumocystis murina and sacrificed at day 3, 7, 10, and 14. A.) 
Whole lung RNA from day 14 was then isolated, sequenced using an Illumina NextSeq 500, and analyzed for 
differential expression of genes associated with a type II response. B.) RNA sequencing expression levels for the 
corresponding genes in the heat map (* p<0.05, Student’s t-test, n=4 per group). C.) Expression of Il4, Il13, Muc5ac, 
and Clca3 over the time course as measured by qRT-PCR demonstrating CD4+ T-cell dependent increase in gene 
expression (* p<0.05 by two-way ANOVA with multiple comparisons, n=5). D.) Protein levels of IL-4 and IL-5 in 
wild type and GK1.5 treated mice during infection. E.) Representative images of H&E staining of sectioned lung 
from WT and GK1.5 treated mice at days 7 and 14, demonstrating increased eosinophilic perivascular inflammation 
in WT mice. F.) Representative images of PAS staining of sectioned lung from WT and GK1.5 treated mice at day 7 
and day 14 demonstrating increased mucus production in WT animals.  
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Moreover, global pathway analysis demonstrated upregulation of KEGG pathways 
associated with immunologic function, as well as pathways associated with allergic rhinitis, 
eosinophilic disorders, and asthma (Figure 3-2). 
 
 
Figure 3-2. Pathway analysis on RNA sequencing shows upregulation of pathways associated with type II 
immunity. A.) KEGG pathways significantly upregulated in wild type mice compared to CD4+ T-cell depleted 
mice. B.) Individual gene expression associated with each KEGG pathway expressed as log(Fold change). C.) 
Disease pathways significantly upregulated in wild type mice compared to CD4+ T-cell depleted mice. D.) 
Individual gene expression associated with each disease pathway log(Fold change). 
 
CD4+ T-cells are also sufficient to produce a type II immune response following 
Pneumocystis infection, as significant increases in Muc5ac, Clca3, Il13, and Prg2 (major basic 
protein, an eosinophil-marker) were observed in lung homogenates of Rag1-/- mice receiving 
adoptive transfer of CD4+ T-cells compared to no transfer controls (Figure 3-3).  
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Figure 3-3. CD4+ T-cells are sufficient to induce type II mediated pathology. A.) Rag1 -/- mice received PBS 
(no transfer, n=4) or 5 x 105 purified CD4+ T-cells (n=4) via intravenous injection and were infected with 
Pneumocystis murina. Six weeks post-infection, Rag1 -/- receiving CD4+ T-cells had increased gene expression of 
type II related genes in lung homogenate (*p<0.05, **p<0.01, Student’s t-test). 
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3.4.2 The immune response to Pneumocystis generates type II mediated lung pathology 
similar to that of house dust mite 
We next sought to determine if concurrent Pneumocystis infection and exposure to a common 
airway allergen, house dust mite (HDM), would lead to a synergistic type II response (Figure 3-
4A), as prior studies have suggested that Pneumocystis infection altered the immune response to 
OVA(183). Mice exposed to Pneumocystis infection or HDM alone generated both anti-
Pneumocystis and anti-HDM IgG and IgE responses in the serum, respectively, while dual-
treated mice generated IgG and IgE to both antigens (Figure 3-4B). Interestingly, even though 
all mice exposed to Pneumocystis infection had cleared the infection by day 28 (data not shown), 
mice infected with Pneumocystis alone had increases in eosinophil and goblet cell hyperplasia 
transcripts (Figure 3-4C). A synergistic response was noted in terms of a specific eosinophil 
marker, Prg2 (Figure 3-4C). The antigen-specific responses of whole lung cells from 
Pneumocystis-infected or house dust mite exposed mice to PC antigen (PCAg) and HDM, 
respectively, were strikingly similar in terms of IL-4, IL-5, IL-10, IL-13, IL-17A, and IFN-γ 
production (Figure 3-4D). Dual-treatment resulted in little additive effects and appeared to 
prime two independent immune responses (Figure 3-4D). Surprisingly, mice that had been 
infected with and cleared Pneumocystis still had detectable mucus in both large and small 
airways (Figure 3-4E). 
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Figure 3-4. Pneumocystis infection and house dust mite treatment induce independent type II responses. A.) 
Mice were untreated (naïve), treated with HDM alone (HDM), infected with Pneumocystis alone (PC), or infected 
with PC and subsequently treated with HDM (n=4 per group). B.) Infection and HDM treatment generate anti-PC 
and anti-HDM IgG and IgE antibodies C.) Increase in type II associated genes in PC infected, HDM treated, and PC 
+ HDM mice in whole lung as measured by qRT-PCR. D.) Ex vivo cells isolated from whole lung were stimulated 
with either HDM or PC Ag for 72 hours and supernatants were analyzed using a Bioplex kit. E.) PAS staining of 
naïve, HDM, PC alone mice, and dual-treated mice demonstrating increased mucus production following each 
treatment. (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, one-way ANOVA with Tukey’s multiple 
comparisons). 
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Given the similarities between the antigen-specific responses to primary Pneumocystis 
infection and HDM treatment, we next evaluated the potential of PCAg to induce a type II 
response and lung pathology (Figure 3-5A). Following sensitization and challenge, mice 
generated anti-HDM and anti-PC IgG and IgE (Figure 3-5B). PCAg treatment did increase 
expression of type II cytokines, mucus-associated genes and Prg2 in a comparable manner to 
that of HDM treatment (Figure 3-5C). The antigen-specific responses to HDM were similar as 
described above (Figure 3-4D), while PCAg exposure induced an antigen-specific release of IL-
4 and IL-5, but not IL-17A (Figure 3-5D). Additionally, both PCAg and HDM treated mice had 
a striking upregulation of mucus production and increased perivascular inflammation on 
histologic sections (Figure 3-5E and 3-5F). 
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Figure 3-5. Exposure to Pneumocystis antigen and house dust mite generate lung pathology. A.) Schematic of 
treatment of mice with 10 μg of HDM and sonicated PCAg on days 0, 7, 8, 9, 10, and 11. Naïve (n=9), HDM (n=6), 
and PC Ag (n=10) were all sacrificed at day 14 and data are from three individual experiments. B.) PCAg and HDM 
exposure generate anti-PC and anti-HDM IgG and IgE responses, respectively. C.) PCAg and HDM increase 
expression of type II related genes by qRT-PCR D.) Ex vivo cells isolated from whole lung were stimulated with 
either HDM or PCAg for 72 hours and supernatants were analyzed for IL-4, IL-5, IL-17A, and IFN-γ. E.) 
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Representative images from PAS and H&E staining from naïve, HDM-treated, and PCAg-treated mice 
demonstrating increased mucus and perivascular inflammation in the HDM and PCAg groups. All images were 
taken on 20x magnification. F.) HDM and PCAg treatment increased the percentage of total airways affected by 
mucus (left) and the area of individual airways PAS positive (right). (* p<0.05, **p<0.01, *** p<0.001, **** 
p<0.0001, one-way ANOVA with Tukey’s multiple comparisons). 
 
 Furthermore, PCAg treated mice had an increase in antigen-specific CD4+ Th2 cells, as 
measured by upregulation of Gata3 expression and GATA3 protein levels (Figures 3-6A-C). 
This was not the case for Th17 cells, as Rorc expression and RORγT protein levels were 
unchanged following stimulation with PCAg (Figures 3-6A-C). Similarly, antigen-specific Th2 
cytokine expression was increased following PCAg stimulation (Figure 3-6D) and eosinophils 
were recruited to the lung (Figure 3-6E). Neutrophils, a hallmark effector cell responding to IL-
17-dependent chemokine expression, were not significantly recruited to the lung following PCAg 
stimulation (Figures 3-6F and 3-6G). Taken together, these results suggest that PCAg mediated 
pathology is mediated by the effector functions of Th2, and not Th17, cells.  
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Figure 3-6. PCAg treated mice have increased Th2 cells and eosinophil recruitment in the lung. A.) Following 
PCAg treatment, lung cells were isolated from lungs of PCAg treated or naïve mice and stimulated with PCAg or 
CD3/CD28 beads for 72 hours and analyzed for expression of Gata3 and Rorc (** p<0.01). B.) Flow cytometry on 
CD4+ T-cells demonstrates an increase in intracellular GATA3, but not RORγT, following PCAg treatment. C.) 
Quantification of Th2 GATA3+ cells and Th17 RORγT+ cells in naïve and PCAg treated mice (p<0.05, Student’s t-
test). D.) qRT-PCR on ex vivo stimulated lung cells shows increases in Il4 and Il13 in response to PCAg and a log 
increase in expression of Il4, Il5, and Il13 following CD3/CD28 stimulation (*p<0.05). E.) Flow cytometry on 
whole lung cells shows an increase in eosinophils (SiglecF+CD11b+) following PCAg treatment. F.) Flow cytometry 
on whole lung cells shows minimal recruitment of neutrophils (CD11b+Gr1+) following PCAg treatment. G.) 
Quantification of eosinophils and neutrophils by flow cytometry shows significant increase in eosinophils following 
PCAg treatment (p<0.01, Student’s t-test).  
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3.4.3 Both Pneumocystis antigen and house dust mite induce pathologic functional 
changes in respiratory mechanics 
To assess functional changes in airway physiology, BALB/c mice were treated with PCAg or 
HDM. Quasi-static lung compliance was decreased with both PCAg and HDM treatment, 
indicative of inflammation in the lungs (Figure 3-7A). Similarly, both PCAg and HDM treated 
mice had significant increases in airway resistance compared to control animals when challenged 
methacholine (Figure 3-7B). PCAg and HDM treatment also similarly increased parameters 
associated with parenchymal resistance (tissue damping) and recoil (tissue elastance) compared 
to naïve mice (Figure 3-7C).  
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Figure 3-7. Pneumocystis antigen and HDM comparably reduce lung function. BALB/c mice (n=6 per group) 
were treated with either HDM or PC Ag on days 0 and 7-11, and were sacrificed on day 14. Naïve BALB/c (n=3) 
mice were analyzed as controls. Data represent the combination of two independent experiments. A.) Following 
anesthetization, tracheotomized mice were ventilated and quasi-static compliance was calculated using pressure-
volume curves. BALB/c mice treated with HDM and PC Ag had reduced compliance (* p<0.05, ** p<0.01 one-way 
ANOVA with Tukey’s multiple comparisons). B.) Newtonian airway resistance was calculated following escalating 
doses of aerosolized methacholine (0, 0.075, 3.125, 12.5, and 50 mg/mL). PC Ag and HDM treated mice had 
increased resistance at higher doses of methacholine compared to naïve BALB/c mice (*** p<0.001, **** 
p<0.0001, two-way ANOVA with multiple comparisons). C.) Parameters associated with alveolar pathology (e.g. 
increased damping or elastance) were measured following treatment with methacholine and were also increased in 
PC Ag and HDM treated mice (* p<0.05, **** p<0.0001, two-way ANOVA with multiple comparisons). 
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As seen previously in C57BL/6 mice, both PCAg and HDM exposure increased 
expression of type II cytokines, mucus-associated genes, and Prg2 in BALB/c mice in an 
equivalent manner (Figure 3-8). 
 
 
Figure 3-8. PCAg and HDM induce similar type II responses in BALB/c mice. A.) BALB/c mice were treated 
with either PCAg or HDM and type II response in whole lung was analyzed by qRT-PCR (n=6 per group). HDM 
and PCAg induce comparable type II responses in BALB/c mice (* p<0.05, ** p<0.01, one-way ANOVA with 
Tukey’s multiple comparisons). 
 
3.4.4 The pathologic response to Pneumocystis antigen requires CD4+ T-cells and 
collaboration with ILC2 cells 
We next sought to determine the role of CD4+ T-cells and ILC2 cells in response to PCAg. As 
expected, anti-Pneumocystis IgG and IgE production were decreased following CD4+-depletion 
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(Figure 3-9A). Furthermore, CD4+-depletion significantly reduced expression of type II 
cytokines (Il4 and Il13), as well as eosinophil genes (Prg2) and mucus associated genes (Muc5ac 
and Clca3) (Figure 3-9B). CD4+-depletion also significantly reduced PAS-positive airways 
indicative of mucus production (Figures 3-9C and 3-9D).  
To assess the role of ILC2 cells as effector cells contributing to allergic inflammation, the 
response to PCAg treatment was also observed in Rag1-/-, lacking T- and B-cells, or Rag2-/-Il2rg-
/-, which lack adaptive immunity as well as NK cells and ILC2s. Further, Rag1-/- mice treated 
with PCAg were also treated with an anti-ST2 antibody, which has been shown to neutralize the 
IL-33/ST2 signaling pathway and ILC2 expansion (184, 185). No significant induction in type II 
cytokines was observed in Rag1-/- or Rag2-/-Il2rg-/- mice treated with PCAg (Figure 3-9B). Rag1-
/- did have a small increase in mucus production that was ameliorated with anti-ST2 treatment, 
suggesting that ILC2 cells may have a minor role in inducing mucus-associated pathology 
(Figures 3-9C and 3-9D). These results demonstrate that CD4+ T-cells, and not ILC2 cells, are 
the primary effector cells responsible for the asthma-like pathology observed following PCAg 
treatment. 
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Figure 3-9. CD4+ T-cells, but not ILC2s, are the primary effectors of PCAg-driven pathology. C57BL/6 mice 
(n=6 per group) were untreated, treated with PC Ag, or treated with both PC Ag and GK1.5 monoclonal antibody 
and sacrificed at day 14. Data represent the combination of two independent experiments. Naïve Rag1-/- mice (n=3), 
Rag1-/- treated with PC Ag (n=3), Rag1-/- treated with anti-ST2 antibody and PCAg (n=4), and Rag2-/-Il2rg-/- treated 
with PC Ag (n=3) were also analyzed. A.) Anti-PC antibody production (IgG and IgE) is dependent on CD4+ T-
cells. B.) Expression of type II immune response genes in whole lung homogenate at day 14 appears to be mediated 
by CD4+ T-cells but not ILC2 cells. C.) PAS staining of whole lung shows CD4+ T-cells drive the mucus response to 
PC Ag, while limited ILC2-dependent mucus production was noted in Rag1-/- mice. D.) PCAg treatment 
significantly increased the percentage of total airways affected by mucus (left) and the area of individual airways 
PAS positive (right) in a CD4-dependent manner.  (* p<0.05, ** p<0.01, **** p<0.0001, one-way ANOVA with 
Tukey’s multiple comparisons). 
 
However, to assess the role of ILC2 cells upstream of the T-cell responses, C57BL/6 
mice were exposed to PCAg and treated with anti-ST2 antibody. PCAg treatment did result in a 
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small expansion of ILC2 cells, which was neutralized by anti-ST2 treatment (Figure 3-10A and 
3-10B). However, in addition to impairing ILC2 expansion, blockade of ST2 also reduced the 
percentage of GATA3+ Th2 cells (Figure 3-10B). Anti-ST2 treatment did not impair production 
of anti-PC IgG or IgE, but did reduce expression of type II cytokines (Il4, Il5, and Il13) and an 
eosinophil-specific marker, Prg2 (Figure 3-10C). However, anti-ST2 treatment was insufficient 
in reducing the mucus response as measured by qRT-PCR and PAS staining of the airways 
(Figure 3-10D). Taken together, these studies demonstrate that the IL-33/ST2 pathway is 
required for expansion of ILC2 and Th2 cells in response to PCAg. Further, these studies are 
suggestive that ILC2 cells may influence the Th2 response, but do not play a significant role in 
driving the pathology to PCAg.  
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Figure 3-10. ST2-antibody treatment partially abrogates the pathologic Th2 response to PCAg. C57BL/6 mice 
were untreated (naïve), treated with PCAg, or treated with PCAg and anti-ST2 blocking antibody (n=6-7). A.) Flow 
cytometry gating strategy for isolating ILC2 cells from whole lung. Cells were gated on lineage negative, γδ-TCR 
negative, CD90 high, TCRβ negative, GATA3 high (n=4). B.) Quantification of ILC2 cells (TCRβ-GATA3+) and 
Th2 cells (TCRβ+GATA3+). C.) Anti-Pneumocystis antigen IgG and IgE responses are unchanged with anti-ST2 
treatment. D.) qRT-PCR for type II immune response genes showing decrease in type II cytokine production in anti-
ST2 treated mice, but no change in mucus associated genes. E.) PAS staining demonstrating mucus production in 
PCAg and PCAg mice treated with anti-ST2. (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, one-way ANOVA 
with Tukey’s multiple comparisons). 
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3.4.5 Eosinophils are dispensable for Pneumocystis antigen driven pathology 
We next sought to characterize the role of eosinophils in the pathologic response to PCAg. 
GATA1tm6Sho/J mice treated with PCAg had increased Clca3, Muc5ac, Il4, Il5, and Il13 when 
compared to naïve GATA1tm6Sho/J mice (Figure 3-11A). Compared to BALB/c mice treated with 
PCAg, GATA1tm6Sho/J mice had significant upregulation of Clca3, Muc5ac, and Il5, but not Prg2. 
GATA1tm6Sho/J mice also had a significant reduction in quasi-static compliance similar to that 
seen in BALB/c mice (Figure 3-11B). Furthermore, GATA1tm6Sho/J mice had exacerbated airway 
resistance in the airways following PCAg compared to naïve GATA1tm6Sho/J mice (Figure 3-
11C). Although there appeared to be an increase in airway resistance in naïve GATA1tm6Sho/J 
mice compared to naïve BALB/c mice, PCAg challenged GATA1tm6Sho/J mice had significantly 
elevated airway resistance similar to that of challenged BALB/c mice. Significant changes in the 
alveolar parameters were also observed following PCAg in GATA1tm6Sho/J mice (Figure 3-11D). 
Histologically, GATA1tm6Sho/J mice had similar mucus production compared to BALB/c mice 
treated with PCAg (Figure 3-11E). 
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Figure 3-11. Eosinophils are dispensable for pathology following PC Ag exposure. BALB/c and GATA1tm6Sho/J 
mice were treated with PC Ag (n=5 for naïve BALB/c, n=8 BALB/c + PC Ag, n=8 for GATA1tm6Sho/J groups) and 
sacrificed at day 14. Data represent the combination of two independent experiments. A.) RNA isolated from lung 
homogenate demonstrates that GATA1tm6Sho/J mice are capable of mounting a type II response comparable to, if not 
greater than, that of BALB/c mice (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, one-way ANOVA with 
Tukey’s multiple comparisons). B.) Follow anesthetization, tracheotomized mice were ventilated and quasi-static 
compliance was calculated using pressure-volume curves. GATA1tm6Sho/J mice treated with PC Ag had reduced 
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compliance (* p<0.05, Student’s t-test). C.) Newtonian airway resistance was calculated following escalating doses 
of aerosolized methacholine (0, 0.075, 3.125, 12.5, and 50 mg/mL). GATA1tm6Sho/J mice, like BALB/c mice, have 
exacerbated airway resistance following PC Ag treatment (*** p<0.001, two-way ANOVA with multiple 
comparisons). D.) Tissue damping and tissue elastance were increased in GATA1tm6Sho/J mice following PC Ag 
treatment (** p<0.01, *** p<0.001, **** p<0.0001, two-way ANOVA with multiple comparisons). E.) PAS 
staining of naïve and PC Ag BALB/c and GATA1tm6Sho/J demonstrates similar mucus production in the PC Ag 
treated groups in both large and small airways. F.) Quantification of PAS demonstrates BALB/c and GATA1tm6Sho/J 
have equally affected airways following PCAg treatment (*** p<0.001, **** p<0.0001, one-way ANOVA with 
Tukey’s multiple comparisons). 
 
3.4.6 Severe asthma patients have increased antibody titers to Pneumocystis 
As prior studies have implicated Pneumocystis as a ubiquitous environmental exposure, we 
sought to determine if differences in anti-Pneumocystis antibodies correlated with asthma status. 
Severe asthma (SA) patients had elevated anti-Pneumocystis IgG levels compared to healthy 
control (HC) patients (Figure 3-12A). Both a single HC patient and a single SA patient appeared 
to recognize similar Pneumocystis antigens by Western blotting; however, the SA patient 
recognized these antigens with greater intensity, corroborating the ELISA findings (Figure 3-
12B). To assess the specificity of these antibody responses, we evaluated antibody production to 
another respiratory pathogen, Streptococcus pneumoniae (SP). Interestingly, SA patients had 
decreased anti-SP antibodies compared to HC patients (Figure 3-12C). Additionally, as 
previously observed in the murine model of Pneumocystis exposure, a subset of SA patients had 
detectable anti-Pneumocystis IgE levels (Figure 3-12D). A strong positive correlation between 
anti-Pneumocystis IgG and IgE was observed, as patients with elevated anti-Pneumocystis IgG 
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were more likely to have increased anti-Pneumocystis IgE levels as well (Figure 3-12E).  To 
rule out the possibility of non-specific binding to fungal antigens, the serum samples were also 
assessed for anti-Aspergillus antibodies and no difference was observed between HC and SA 
patients (Figures 3-12F and 3-12G). Further, no correlation existed between anti-Pneumocystis 
and anti-Aspergillus IgG or IgE (Figures 3-12H and 3-12I). 
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Figure 3-12. Patients with severe asthma have elevated anti-Pneumocystis IgG and IgE levels. A.) Serum 
samples from healthy controls (HC, n=10) and severe asthma patients (SA, n=20) were analyzed for anti-PC IgG at 
various dilutions. SA patients had increased antibody levels against PC (*** p<0.001, two-way ANOVA). B.) 
Detection of anti-PC IgG from a HC patient and a patient with SA demonstrates similar banding patterns, but 
increased intensity in the SA patient. C.) Serum samples from HC and SA patients were also analyzed for IgG levels 
against Streptococcus pneumoniae (SP) and SA patients had reduced antibody levels (**** p<0.0001, two-way 
ANOVA) D.) Anti-PC IgE could be detected in the serum (diluted 1:10) of subset of patients with SA by ELISA. E.) 
Linear regression and Pearson’s correlation analysis demonstrates a strong correlation between anti-PC IgG and 
anti-PC IgE levels in patients (r=0.8594, p<0.0001). F. and G.) SA patients do not have an increase in anti-
Aspergillus IgG and IgE, respectively. H.) No correlation exists between anti-PC IgG and anti-AF IgG (r=0.2724, 
p>0.05). I.) No correlation exists between anti-PC IgE and anti-AF IgE (r= -0.0396, p>0.05). 
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Due to concerns of contaminating mouse proteins within the PCAg preparation, we 
probed mouse lung homogenate with the same human serum samples and found little reactivity 
(Figure 3-13). 
 
Figure 3-13. Serum from a healthy control and severe asthma patient demonstrate limited reactivity to mouse 
lung protein. A.) Serum samples from a healthy control and a patient with severe asthma were probed for reactivity 
against lung homogenate from naïve mice (N) or mice treated previously treated with PCAg (D14). Unlike the 
PCAg western, the same human serum samples displayed a limited reactivity to mouse protein.   
 89 
3.4.7 Severe asthma patients with increased anti-Pneumocystis antibody levels have 
worsened symptomatology and lung function 
We next stratified SA patients into PC-high or PC-low subsets using a z-score approach. Any 
individual with an anti-PC IgG response above a z-score of one (2.02 based on the HC cohort) 
was considered PC-high (n=11); a patient with an ELISA O.D. of 2.02 or less was considered 
PC-low (n=9) (Figure 3-14A). The PC-high group had a significantly higher age at time of study 
compared to the PC-low group, while other demographics were similar (Figure 3-14A). The PC-
low subset was 67% female and 22% ever-smokers, compared to 81% female and 36% ever-
smokers in the PC-high group.  
The SA PC-high subset had worsened symptom scores compared to the PC-low group 
with regards to cough and a trend towards increased shortness of breath (Figure 3-14B). 
Interestingly, SA PC-high patients had a trend towards reduced sputum production compared to 
the PC-low group (Figure 3-14B). On spirometry, PC-high patients had significantly decreased 
FEV1 and had a trend towards decreased FVC and FEF25-75 (Figure 3-14C). SA PC-high 
patients also had increased air trapping on plethysmography, as PC-high patients (n=7) had 
increased total lung capacity and residual volume compared to PC-low patients (n=9) (Figure 3-
14D). 
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Figure 3-14. Severe asthma patients with increased anti-Pneumocystis IgG have worsened symptoms and 
decreased lung function. A.) Patients with severe asthma were stratified into PC-high (n=11) and PC-low (n=9) 
groups by using a z-score of 1 within the HC population with an O.D. of 2.02 serving as the cutoff (dashed line). 
Demographics for these patient populations were similar with the exception of age, as PC-high patients had a 
significantly higher age (* p<0.05, Student’s t-test). B.) Symptomatology as reported by the patients to a standard 
questionnaire shows PC-high patients having increased symptom severity in every symptom except for sputum 
production (* p<0.05, Chi-square analysis). C.) Spirometric assessment of lung function demonstrates PC-high 
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patients had decreased FEV1 (* p<0.05, Student’s t-test), and trends towards decreased FVC and FEF25-75 
compared to PC-low patients. D.) Plethysmography demonstrates PC-high patients have increased TLC and RV 
compared to PC-low patients (* p<0.05, ** p<0.01, Student’s t-test). 
 
Serum IgE levels for PC-low vs. PC-high groups were comparable, and both appeared 
elevated compared to HC patients (Figure 3-15A). Importantly, there did not appear to be a 
difference in allergen skin testing between groups (Figure 3-15B).  
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Figure 3-15. Allergic sensitization in healthy control and severe asthma patients. A.) Serum IgE shows 
elevation in SA patients compared to healthy controls, but no difference based on anti-PC IgG status. B.) Allergen 
skin testing analysis for HC, PC IgG low, and PC IgG high patients. 
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Additionally, there were no differences in blood neutrophils, lymphocytes or eosinophils 
between PC-high and PC-low patients (Figure 3-16A). Similar counts of cells were also 
observed on bronchoalveolar lavage (Figure 3-16B). There were also no observed differences in 
inhaled or oral steroid use or steroid dose between the PC-high and PC-low group (data not 
shown). 
 
Figure 3-16. Peripheral blood and bronchoalveolar lavage cell analysis in healthy control and severe asthma 
patients. A.) Number of neutrophils, lymphocytes, and eosinophils in peripheral blood in HC, PC IgG low, and PC 
IgG high patients (* p<0.05, ** p<0.01, one-way ANOVA with multiple comparisons). B.) Percentage of 
neutrophils, lymphocytes, eosinophils, and macrophages in the bronchoalveolar lavage of HC, PC IgG low, and PC 
IgG high patients. 
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3.5 DISCUSSION 
These results demonstrate for the first time that Pneumocystis infection and antigen treatment 
induces an asthma-like pathologic response in the lung driven by CD4+ T-cells. The ability of 
Pneumocystis to induce a strong Th2 response may have implications in the immunocompetent 
as it has recently been shown that the majority of healthy individuals have detectable anti-
Pneumocystis antibodies (61). Furthermore, colonization of live Pneumocystis within the lung 
may occur as a transitional state of low Pneumocystis burden, with the specific host-pathogen 
interactions (e.g. immunosuppression) ultimately determining the difference between disease, 
colonization, and clearance (186). Indeed, asymptomatic infection with Pneumocystis may have 
immunologic ramifications, as infants with detectable Pneumocystis in the lungs had increased 
mucus production (187, 188), consistent with findings in our murine model.  
The ubiquity in which humans are exposed to Pneumocystis and the specific nature of the 
immune response to Pneumocystis begs the question of how this pathogen and the subsequent 
host response may impact asthma. One prior study has demonstrated that Pneumocystis could 
worsen an ovalbumin murine model of asthma by altering dendritic cell subsets (183). While 
concurrent Pneumocystis infection only slightly modified a HDM model in the current study, 
Pneumocystis appeared to prime an equally potent type II response compared to HDM treated 
mice alone. These findings, coupled with the PCAg model, would suggest that much like HDM, 
Pneumocystis functions as an airway allergen (189, 190). As shown previously with HDM, 
PCAg further exacerbated airway responsiveness in GATA1tm6Sho/J mice (148, 191). The 
necessity of eosinophils in mediating airway hyperresponsiveness has been difficult to show 
definitively though, as variations between knockout-mouse and antigenic model have offered 
differing outcomes (145, 146).  
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There were some unique differences between the HDM and PCAg models. ILC2 cells 
have been shown to be prolific producers of type II cytokines in response to both pulmonary and 
intradermal HDM exposure (155, 192). Similarly, murine models of fungal allergen exposure, 
Alternaria, have also demonstrated a role for ILC2 cells as cytokine producers (153, 193). In the 
current Pneumocystis model, ILC2 cells appeared to have a greater function in maintaining the 
optimal Th2 response as opposed to directly contributing to pathology via cytokine production. 
This priming function has been shown previously to require MHC class II expression on ILC2 
cells, although it is unclear if direct antigen presentation is required in the PCAg model (157, 
194). One further difference between the HDM and PCAg model appears to be the specificity of 
the respective antigens and antibody responses. The antigen-specific recall responses and 
antibody-responses to PCAg and HDM did not cross-react, suggesting that distinct antigens, and 
not molecular patterns such as chitin, are recognized in these two models (195, 196).  
While evidence in the mouse model shows that Pneumocystis infection and exposure can 
lead to lung pathology, this has yet to formally be studied in a population of immunocompetent 
patients with asthma. One study found an association between HIV-positive patients with prior 
pneumonia with either Pneumocystis or a bacterial pathogen and doctor-diagnosed asthma (66). 
A second study in HIV-positive individuals demonstrated that history with Pneumocystis was 
associated with an obstructed spirometry pattern on lung function testing (197). While these prior 
studies focused on fulminant infection in an HIV-positive host, the current study examined 
immune exposure by measuring anti-Pneumocystis antibody levels in the blood of patients with 
and without asthma. Strikingly, a cohort of patients with severe asthma had elevated anti-
Pneumocystis IgG and IgE antibodies in their serum compared to healthy controls. Importantly, 
this did not appear to be the result of non-specific immune activation to all pathogens, as severe 
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asthma patients had decreased antibody responses to S. pneumoniae and similar antibody 
responses to Aspergillus compared to healthy controls. These findings are suggestive of 
increased exposure of Pneumocystis in severe asthma patients compared to healthy individuals; 
whether this is exposure is persistent colonization or transient contact with airborne spores is 
unclear. One possibility is that this increase in Pneumocystis exposure is due to the use of both 
inhaled and oral corticosteroids in severe asthmatics (135).  
Thus, the current study cannot differentiate between a model where Pneumocystis 
exposure increases the likelihood of developing severe asthma and a model where severe 
asthmatics are more likely to be exposed to Pneumocystis as a result of steroid exposure. 
Monitoring Pneumocystis colonization status by molecular techniques could be useful in 
understanding the effects of local immunosuppression on Pneumocystis colonization, and such 
techniques could be applied longitudinally to a healthy cohort of patients to assess the 
development of asthma.  
Importantly, the current study identifies the presence of anti-Pneumocystis IgE in serum 
samples of asthmatic patients. Type-I hypersensitivity to Pneumocystis, therefore, may be 
diagnosed much like that of other allergens routinely tested in the clinical setting. This also raises 
the exciting possibility of intervening with trimethoprim-sulfamethoxazole (TMP-SMX), the 
hallmark of treatment and prophylaxis for Pneumocystis, in severe asthma patients with known 
sensitization and/or colonization with Pneumocystis. While further studies elucidating the 
interplay between Pneumocystis and asthma are essential to inform future clinical investigations, 
the current study demonstrates in both a murine model and in human patients that Pneumocystis 
may lead to the development of lung pathology and thus a clinical phenotype similar to asthma.   
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4.1 INTRODUCTION: IMMUNOLOGY OF INDUCIBLE BRONCHUS 
ASSOCIATED LYMPHOID TISSUE 
The immune system interacts with almost every organ system. Immunologic cells can travel 
through the lymphatic or circulatory system to reach a site of effector function. However, there 
are also dedicated lymphoid organs where immune cells reside. The traditional primary 
lymphoid organs consist of the bone marrow and thymus, where B- and T-cells develop. Here, 
the processes of positive and negative selection occur and lead to the generation of a diverse, 
self-restricted repertoire of adaptive immune cells. Post-development, these cells can traffic to 
secondary lymphoid organs (SLOs). SLOs, consisting of lymph nodes, Peyer’s patches in the 
small intestine, and the spleen, function to house naïve lymphocytes until priming and activation 
by a cognate antigen (198). Once primed, effector lymphocytes can travel to the site of infection 
and/or inflammation and contribute to the ongoing immune response, be it pathologic or 
protective.  
 One illustrative example of the complexities associated with the development of SLOs is 
the lymph node. Lymph nodes appear to begin development in utero and continue in some 
species up to three weeks after birth (199). Following lymphatic development, circulating 
lymphoid tissue-inducer (LTi) cells colonize the rudimentary lymph node (200). LTi cells are 
derived from the fetal liver progenitor and maturation of LTi cells is dependent on the 
transcription factor RORγT (201). LTi cells interact with stromal cells in the lymph node and 
through unknown mechanisms appear to promote the development of high endothelial venules 
(202). These high endothelial venules facilitate lymphocyte entry into the lymph node through a 
peripheral node addressin (PNAd) and L-selectin interaction (203).  
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Once lymphocytes have entered the lymph node, the tumor necrosis factor-lymphotoxin 
family of proteins, including lymphotoxin-alpha (Lta, gene name, LTα, protein name), and 
lymphotoxin-beta (LTβ), are crucial for lymphoid organ development (204). Lta-/- mice, for 
example, fail to develop lymph nodes and Peyer’s patches (205). To compliment this loss-of-
function approach, transgenic mice expressing LTα under a constitutive promoter can direct 
lymphoid neogenesis in organs such as the pancreas and kidney (206). LTα is unique in the sense 
that it can signal through TNFR family members, or it can form a heterotrimer with LTb 
(LTα1LTβ2) and signal through the lymphotoxin receptor LT-βR. Mice treated with an LT-βR 
antibody had decreased lymphocyte homing, PNAd expression, and lymph node number 
compared to isotype treated mice (207). Furthermore, blockade of LT-βR led to the decreased 
production of the lymphoid chemokine family, which act as critical orchestrators of the lymph 
node compartmentalization (204, 207).  
 The lymphoid chemokine family includes CCL19 and CCL21, ligands for the receptor 
CCR7, and CXCL13, a ligand for the receptor CXCR5 (208). CCL19 and CCL21 are 
constitutively expressed by stromal cells and together organize the homing of naïve T-cells and 
dendritic cells to the T-cell zone of the lymph node (209). Moreover, CCL21 is also expressed by 
the high endothelial venules and appears to have a more direct effect in dendritic cell 
immigration into the lymph node (209, 210). CXCL13, on the other had, has a more direct role in 
the recruitment of CXCR5+ B-cells into the follicles (211). CXCL13, like LTα, can be 
overexpressed and appears to be sufficient to generate lymphoid neogenesis (212). These three 
chemokines control the development and homeostasis of the mature lymph node. Once formed, 
the lymph node is an encapsulated, bean-shaped organ containing compartmentalized 
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lymphocytes, antigen-presenting cells, and intricate vasculature systems connecting to both the 
systemic circulation and the lymphatic system. 
 Although T-cell priming in the SLOs happens regularly, ectopic lymphoid structures can 
form in the context of chronic inflammation or persistent antigen (204). These structures, called 
tertiary lymphoid organs (TLOs), can form in non-lymphoid locations through a process called 
lymphoid neogenesis. Lymphoid neogenesis has been shown to occur in almost every tissue, 
ranging from major organs such as brain, lung, liver, and intestine, to the smaller, more 
specialized tissues such as the aorta, salivary glands, and synovial tissue (198). Given such a 
broad range of tissues capable of harboring TLOs, it is not surprising that these ectopic lymphoid 
structures are found in a variety of disease states, such as: arthritis, multiple sclerosis, 
atherosclerosis, inflammatory bowel disease, cancer, hepatitis infection, Lyme disease, 
transplantation, and chronic obstructive pulmonary disease (COPD) (198). Although this is a 
brief overview of the abundance of TLOs in pathologic conditions, the remainder of this 
introduction will focus on TLOs in the lung.   
 The formation of TLOs in the lung has been preferentially referred to as inducible 
bronchus associated lymphoid tissue (iBALT) and much of our understanding of iBALT has 
stemmed from murine studies looking at key mediators of SLO maturation. In one influenza 
model of iBALT, mice lacking SLOs not only generated antigen-specific T- and B-cell 
responses, but also had decreased mortality (213). Moreover, the lymphoid chemokine family 
members CXCL13 and CCL21 were expressed in lungs containing iBALT in a LTα-independent 
manner (213). CXCL13 appears to be the predominant driver of iBALT formation, as mice 
lacking CCR7 spontaneously develop lymphoid follicles in the lung (214). Furthermore, plt/plt 
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mice lacking the genes encoding CCL19 and CCL21 develop iBALT to influenza but appear to 
have altered organization (215).  
Given the crucial role of CXCL13 in iBALT formation, several studies have examined 
the cellular producers of the chemokine. First, Rangel-Moreno et al. demonstrated using bone 
marrow chimera experiments that the predominant producers of Cxcl13 in the lung are non-
hematopoietic cells (215). Using immunofluorescent staining, CXCL13 was localized to the B-
cell follicles following influenza infection, while CCL21 appeared to be expressed by PNAd+ 
high endothelial venules (215). In another model of influenza-iBALT, CD11c+CD11b+ dendritic 
cells expressed Cxcl13 although depletion of these cells did not alter the total expression of 
Cxcl13 (216). Blockade of LT-βR, however, did reduce Cxcl13 expression in the lung (216). 
Interestingly, in patients with COPD, as well as in mice exposed to cigarette smoke extract, 
CXCL13 can be induced in the lung (217). Furthermore, in patients with COPD, CXCL13 
appears to be expressed by follicular B-cells as part of a positive feedback loop; CXCL13 signals 
through CXCR5 to induce LTα, which then signals through LT-βR to induce more CXCL13 
(218). Patients with pulmonary complications of rheumatoid arthritis are also susceptible to 
developing lymphoid follicles. The presence of iBALT in a subset of patients with rheumatoid 
arthritis correlated with expression of CXCL13, as well as other chemokines, and LTα (219).  
 One elegant study by Rangel-Moreno et al. explored a novel regulator of iBALT 
formation: IL-17A (220). Here, the authors administered LPS to neonatal mice followed by 
subsequent challenge with influenza. Neonatal mice were more susceptible to iBALT formation, 
a finding consistent with human biopsy and autopsy data demonstrating the presence of iBALT 
in infants and young children at high frequencies (220–222). The study then went on to exclude a 
role of LTi cells, as Rorc-/- mice were able to develop iBALT. However, Il17a-/- mice, as well as 
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Il17ra-/- mice, had defects in iBALT formation. These two findings are very counterintuitive, as 
Rorc expression is thought to be critical for Th17 cell development (223); it is also possible that 
some compensatory mechanism exists in the Rorc-/- mice, such as alterations in the microbiome 
(224). The study by Rangel-Moreno et al. convincingly implicated a role for IL-17A though, as 
neonatal pulmonary fibroblasts stimulated with IL-17A upregulated Cxcl13 expression and 
appeared to be a critical mediator of initiation of iBALT (220).  
 Although IL-17A emerged as a novel regulator of iBALT formation, IL-17A belongs to a 
broader, more complex family of proteins that signal through the IL-17 receptors. IL-17A can 
form a homodimer or a heterodimer with IL-17F and signal through a heterodimeric complex of 
IL-17RA and IL-17RC (225). Likewise, IL-17F can also homodimerize and signal through the 
IL-17RA:IL-17RC complex. The IL-17RA:IL-17RC complex can signal through the canonical 
NF-κB pathway via ACT1 and induce chemokine, cytokine, and pro-inflammatory gene 
transcription (225). IL-17RC is specific to IL-17A and IL-17F signaling, while IL-17RA is 
ubiquitously expressed on tissues and is more promiscuous. IL-17RA can also heterodimerize 
with IL-17RB to signal in response to the ligand IL-25 (226). IL-25 sufficiently induces the 
production of type II cytokines such as IL-5 and IL-13 via activation of both Th2 and ILC2 cells 
(152, 155, 226). Given the propensity of IL-25 to amplify type II responses, IL-25 has been 
highly studied in relation to asthma and allergic airway disease (227–229). Interestingly given 
the connection to Pneumocystis, patients with asthma have an increased likelihood of developing 
iBALT (230).  
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4.2 RATIONALE AND HYPOTHESIS 
We observed the formation of perivascular lymphocytic clusters following Pneumocystis 
infection that resembled architecture previously described as iBALT. We hypothesized that these 
structures were iBALT composed of CD4+ T-cells and B-cells and that this Pneumocystis driven 
iBALT would be dependent on CXCL13, IL-17A signaling, and lymphotoxin-alpha.   
4.3 METHODS 
Mice 
All mouse colonies were maintained in the Rangos Research Building Animal Facility and use 
was approved and performed in accordance with the University of Pittsburgh Institutional Care 
and Use Committee (Protocol: 14084329 and 16027674). C57BL/6, BALB/c, Cxcr5-/-, Lta-/-, 
Stat6-/-, Gata1tm6Sho/J, Rag1-/- and Rag2-/-Il2rg-/- mice were all ordered from The Jackson 
Laboratory. The Il17ra-/- and Il17rb-/- mice were generated at Amgen. The Il17rc-/- mice were 
generated at GenenTech.  
 
Reagents 
Mice were depleted of CD4+ cells by weekly intraperitoneal injection of 0.3 mg of GK1.5 
monoclonal antibody as previously described (182, 231). CD20+ cells were depleted using 
intraperitoneal injections of 0.1 mg 5D2 monoclonal antibody every three days. Recombinant IL-
17A and IL-13 (R&D Systems) was used at a final concentration of 100ng/mL. Recombinant IL-
6 (R&D Systems) was used at a final concentration of 40 ng/mL.  
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Pneumocystis inoculation 
Pneumocystis murina was harvest from the lungs of an infected Rag2-/-Il2rg-/- mouse. Following 
straining through a 70-μm sterile filter, mice were challenged with 2.0x106 cysts/mL as 
previously described (83, 123).   
 
Immunofluorescence staining and histologic analysis  
The left lobe was fixed by injecting 10% formalin into the left main stem bronchus. Lung tissue 
was processed, paraffin-embedded, and sectioned. Hematoxylin and eosin staining was 
performed by the Children’s Hospital of Pittsburgh Histology Core. For immunofluorescence, 
slides were hydrated in PBS and were blocked for 30 mins at room temperature in Fc block (10 
ug/mL) and 5% vol/vol normal donkey serum in PBS. Slides were then incubated in primary 
antibody diluted in PBS for 30 minutes at room temperature: anti-PNAd, anti-Lyve-1, 
proliferating cell nuclear antigen (PCNA), peanut agglutinin (PNA), anti-B220, anti-CD3, anti-
CXCL13, anti-CD21, anti-CD35, anti-FDC-M1. Images were collected with Zeiss Axioplan 2 
microscope and the outline tool in Zeiss Axiovision software was used for morphometric 
analysis. I would also like to take this time to acknowledge our collaborator, Dr. Javier Rangel-
Moreno. I want to avoid feeling like Jeremy Grey, who once said “the painting was a gift and 
I’m taking it with me.” The pictures from Dr. Rangel-Moreno are an incredible gift and are only 
included in my dissertation, as the data he provided are instrumental in telling the story of the 
Pneumocystis driven iBALT. To Dr. Rangel-Moreno, thank you sincerely.  
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qRT-PCR 
The right middle lobe was homogenized in Trizol® (Life Technologies) followed by RNA 
isolation per manufacturer’s instructions. Following quantification using a Nanodrop 2000 
(Thermo Scientific), 500 ng of RNA was converted to cDNA using iScript™ (Bio-Rad). Gene 
expression analyses were then perfomed using SsoAdvanced™ qRT-PCR universal probes 
supermix (Bio-Rad). Murine primers included: Ccl19, Ccl21, Ifng, Prg2, Il6, Il17a, Ccl11 
(Applied Biosciences) and Cxcl13, Il5, Il13, and Cxcl1 (IDT). Pneumocystis SSU burden was 
quantified as described previously (231).  
 
Ex vivo antigen restimulation assay 
The right lower lobe of lung was collected, physically digested, and incubated in 
collagenase/DNase for one hour at 37°C as described previously(182, 231). Single cell 
suspensions were then strained using a 70-μm sterile filter. Red blood cells were lysed using a 
NH4Cl solution and the cells were enumerated using Trypan Blue staining. Cells were then 
plated at 5x105 cells per well, stimulated with either 5 μg Pneumocystis antigen or 2.5 μL of 
CD3/CD28 Dynabeads® (2015-07, Life Technologies). Following 72-hours, the cells were 
pelleted and the supernatants were collected. The remaining cells were resuspended in Trizol® 
LS (Life Technologies) for RNA isolation.  
 
Flow Cytometry 
Whole lung cells were isolated prepared as described in the ex vivo whole lung cell stimulation 
methods. Briefly, cells were plated, centrifuged, and stimulated with 50 ng/mL PMA and 750 
ng/mL ionomycin for 4 hours. After one hour, 1 μL GolgiStop (BD Pharmingen) was added. 
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Following incubation, cells were then washed, and resuspended in surface antibodies diluted in 
PBS at 1:200 unless otherwise specified. Surface staining included: CD3-Alexa700 (eBioscience, 
Clone: 17A2) TCRβ-PerCP-Cy5.5 (eBioscience, Clone: H57-597), TCRγδ-FITC (eBioscience, 
Clone: GL3), CD90.2-PE-Cy7, diluted 1:1500 (eBioscience, Clone: 53-2.1), CD11b-Biotin 
(eBioscience, Clone: M1/70), F4/80-biotin (eBioscience, Clone: BM8), NK1.1-biotin (BD 
Pharmingen, Clone: PK136), CD11c-biotin (BD Pharmingen, Clone: HL3), CD19-biotin (BD 
Pharmingen, Clone: 1D3), TER119-biotin (BD Pharmingen, Cat: 553672). Following a 1 hour 
incubation at 4°C, cells were washed and resuspended in the streptavidin-BV421 (diluted 1:200). 
Following a 30 minute incubation at 4°C, cells were washed and fixed and permeabilized using 
the eBioscience FoxP3 staining kit per manufacturer’s instructions. Intracellular antibodies, anti-
IL-17A-APC (eBioscience, clone: 17B7) and anti-IL-13 (eBioscience, clone: eBio13A) 
antibodies were added and incubated at 4°C for 1 hour. Cells were then washed, resuspended, 
and analyzed on a BD LSR II Flow Cytometer with compensation via OneComp eBeads 
(eBioscience). Data analysis was conducted using FlowJo software (Treestar). 
 
Pulmonary fibroblast culture and stimulation 
Whole lung cells were isolated as described above and plated at a 1:10 dilution in 24-well plates. 
Cells were incubated for three days at 37°C to allow for adherence, washed once with PBS, and 
left to grow in complete IMDM until reaching 50-70% confluence. The cells were then 
stimulated with the various cytokine mixtures described above and incubated at 37°C for 6 or 24 
hours. Supernatants were collected for use in a CXCL13 ELISA (BioLegend®). The cells were 
then harvested in 1 mL Trizol and RNA isolation and qRT-PCR was performed as described 
above.  
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Statistics 
All statistical analyses were performed using GraphPad Prism version 6.0f. All data are 
presented as mean ± standard error of the mean (SEM). Studies with two groups were analyzed 
with a Student’s t-test. Studies with three or more groups were analyzed using an ordinary one-
way ANOVA with Tukey’s multiple comparisons. All statistical analyses considered p<0.05 
significant.  
4.4 RESULTS 
4.4.1 Inducible bronchial associated lymphoid tissue develops following Pneumocystis 
infection and exposure 
Over the course of murine Pneumocystis infection, we observed perivascular lymphocytic 
follicle formation beginning at day 7, expanding at day 14, and contracting by day 28 (Figure 4-
1A). The lymphocytic follicles appeared to have other characteristics of inducible bronchus 
associated lymphoid tissue at day 14. For one, PNAd+ high endothelial venules, described in 
both lymph nodes and iBALT structures, were detectable outside of the follicle (Figure 4-1B). 
Furthermore, Lyve-1+ lymphatic vessels were also present in the surrounding areas of the follicle 
(Figure 4-1B). Importantly the formation of iBALT following Pneumocystis infection was not 
an artifact of oropharyngeal infection with a large inoculum. C57BL/6 mice co-housed with a 
Pneumocystis infected Rag2-/-Il2rg -/- double knockout mouse for two weeks also had formation 
of perivascular follicles four-weeks post-exposure (Figure 4-1C). Formation of iBALT 
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following co-housing required adaptive immunity, as Rag1-/- mice did not have lymphoid 
follicles following co-housing (Figure 4-1C). Interestingly, both C57BL/6 and Rag1-/- mice co-
housed with an infected Rag2-/-Il2rg -/- mouse had detectable Pneumocystis burden four weeks 
removed from exposure (Figure 4-1D).  
We also sought to characterize the lymphoid populations contained within the structures. 
In C57BL/6 mice inoculated with Pneumocystis oropharyngeally, these structures contained 
proliferating cell nuclear antigen (PCNA) positive B220+ B cells as well as intrafollicular CD3+ 
T-cells (Figure 4-1E). CD4+ T-cells are crucial for the development of these structures, as 
depletion with an anti-CD4 monoclonal antibody (GK1.5) completely abrogated the 
accumulation and proliferation of B-cells (Figure 4-1F). Likewise, depletion of B-cells with an 
anti-CD20 monoclonal antibody (5D2) reduced the accumulation of lymphocytes in the lung 
(Figure 4-1G). Quantification of these iBALT structures demonstrated that both CD4+ and 
CD20+ depletion resulted in the reduction of lymphoid follicle size, number, and area occupied 
per lung section (Figure 4-1H).  
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Figure 4-1. Inducible bronchus associated lymphoid tissue (iBALT) forms following Pneumocystis infection 
and exposure. A.) iBALT development over the course of Pneumocystis infection. B.) Immunofluorescent staining 
of an iBALT structure 14 days post-infection with Pneumocystis demonstrating the presence of PNAd+ high 
endothelial venules and Lyve-1+ lymphatic vessels. C.) C57BL/6 mice co-housed for two weeks with a 
Pneumocystis infected Rag2-/-Il2rg-/- mouse have iBALT structures four weeks following separation. D.) C57BL/6 
mice co-housed for two weeks with a Pneumocystis infected Rag2-/-Il2rg-/- mouse have detectable Pneumocystis 
burden. ** p<0.01 by one-way ANOVA with Tukey’s multiple comparisons. E.) Immunofluorescent staining of 
rapidly dividing B-cells (PCNA+B220+) cells and CD3+ T-cells in the lung of a C57BL/6 mouse 14 days after 
Pneumocystis infection. F.) iBALT structures are reduced following CD4+ T-cell depletion with GK1.5 monoclonal 
antibody. G.) iBALT structures are reduced following CD20+ B-cell depletion with 5D2 monoclonal antibody. H.) 
Quantification of iBALT structures in C57BL/6 mice, C57BL/6 mice treated with GK1.5, and C57BL/6 mice treated 
with 5D2. * p<0.05, **** p<0.0001 by one-way ANOVA with Tukey’s multiple comparisons. 
 
Fungal exposure of any species was not sufficient to induce iBALT, as Aspergillus 
infected mice did not have lymphoid follicles in the lung 14 days post-infection (Figure 4-2A). 
 110 
At this time point, Aspergillus burden was undetectable, as were any residual inflammatory 
changes (Figure 4-2B).  
 
 
Figure 4-2. Aspergillus infection does not result in formation of iBALT. A.) H&E staining reveals little 
inflammation 14 days post-infection with Aspergillus fumigatus (AF). B.) qRT-PCR on whole lung reveals no 
changes in Cxcl13, Ccl19, Ccl21, Il6, Il13, or Il17a 14 days post-infection with Aspergillus.  
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4.4.2 CXCR5, but not lymphotoxin-alpha, is required for Pneumocystis iBALT formation 
Ligands for both CXCR5 (CXCL13) and CCR7 (CCL19 and CCL21) have previously been 
implicated in the formation of inducible bronchus associated lymphoid formation in both mice 
and humans (215–217). Over the course of Pneumocystis infection, CXCL13, but not CCL19 or 
CCL21, was induced concomitantly with iBALT formation (Figure 4-3A) However, CXCL13 
induction was absent in GK1.5 treated mice, suggesting CD4+ T-cells regulate expression of the 
chemokine (Figure 4-3A). Likewise, wild type mice that developed iBALT following exposure 
to a Pneumocystis-infected Rag2-/-Il2rg -/- mouse had increased CXCL13, but not CCL19 or 
CCL21 expression (Figure 4-3B). Further implicating CXCL13 as a crucial mediator of 
Pneumocystis iBALT formation, Cxcr5-/- mice lacked organized follicles in the lung 14 days 
post-infection (Figures 4-3C and 4-3D). 
Lymphotoxin-alpha has been previously implicated as an upstream mediator iBALT 
formation in response to influenza (220) and as a regulator of Cxcl13 production following 
smoke exposure in mice (232). Strikingly, Lta-/- mice had enhanced iBALT formation with 
rapidly dividing B-cells and architecture similar to that of C57BL/6 mice (Figure 4-3E). 
Likewise, both Cxcr5-/- and Lta-/- mice had comparable levels of Cxcl13 production compared to 
C57BL/6 mice (Figure 4-3F). Both Cxcr5-/- and Lta-/- mice, which are devoid of all secondary 
lymphoid organs, were also capable of controlling Pneumocystis burden similar to that of wild 
type mice, suggesting these iBALT structures are sufficient, but not required, to provide anti-
fungal immunity (Figure 4-3G). Taken together, these results demonstrate that CXCR5-
signaling is required for Pneumocystis iBALT formation in a lymphotoxin-alpha independent 
manner.  
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Figure 4-3. CXCR5, but not lymphotoxin-alpha, is required for Pneumocystis iBALT formation. A.) Cxcl13 is 
induced over the course of Pneumocystis infection in C57BL/6 mice in a CD4+ T-cell dependent manner. Ccl19 and 
Ccl21 expression levels are unchanged throughout Pneumocystis infection. * p<0.05 by multiple t-tests. B.) 
C57BL/6 mice co-housed with a Pneumocystis infected Rag2-/-Il2rg-/- mouse for two weeks, followed by four weeks 
of separation, upregulate Cxcl13 but not Ccl19 or Ccl21. * p<0.05, ** p<0.01, *** p<0.001 by one-way ANOVA 
with Tukey’s multiple comparisons. C-E.) Immunofluorescent staining of C57BL/6, Cxcr5-/-, and Lta-/- mice 14 days 
post-Pneumocystis infection demonstrating iBALT formation in C57BL/6 and Lta-/- mice and unorganized follicle 
structure in Cxcr5-/- mice. F.) Cxcl13 expression is similar in C57BL/6, Cxcr5-/-, and Lta-/- mice. G.) C57BL/6, 
Cxcr5-/-, and Lta-/- mice control Pneumocystis burden at 14 days post-infection compared to CD4-depleted mice. *** 
p<0.001, **** p<0.0001 by one-way ANOVA with Tukey’s multiple comparisons. 
4.4.3 Pneumocystis iBALT is dependent on IL-17R family member signaling 
We next evaluated members of the IL-17 family, IL-17RA, IL-17RB, and IL-17RC, in 
Pneumocystis driven iBALT formation. IL-17A signals through a heterodimer of IL-17RA and 
IL-17RC, while the Th2-promoting cytokine IL-25 (IL-17E) signals through an IL-17RA and IL-
17RB heterodimer (225, 226). IL-17A has been previously implicated in Cxcl13 induction and 
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iBALT formation in neonatal LPS-influenza and tuberculosis models of immunopathology (220, 
233). Similar to those models, Pneumocystis iBALT was disrupted in Il17ra-/- mice compared to 
wild type controls, as Il17ra-/- mice had a drastic reduction in PCNA+-B220+ cells and little 
organization of T-cell and B-cell zones (Figures 4-4A and 4-4B). Surprisingly, Il17rb-/- mice 
also had disrupted iBALT organization (Figure 4-4C). Likewise, Il17rc-/- mice had reduced 
iBALT size and abnormal architecture (Figure 4-4D). Upon quantification, Il17ra-/-, Il17rb-/-, 
and Il17rc-/- mice all had reduced follicle number and size, as well as area occupied within the 
lung (Figure 4-4E). In concordance with the histologic data, Il17ra-/-, Il17rb-/-, and Il17rc-/- mice 
had reduced expression of Cxcl13 in the lung (Figure 4-4F).  
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Figure 4-4. IL-17R family members are required for the development of Pneumocystis iBALT. A-D.) 
Immunofluorescent staining of C57BL/6, Il17ra-/-, Il17rb-/-, and Il17rc-/- mice, respectively, 14 days following 
Pneumocystis infection demonstrates decreased iBALT formation (top). Il17ra-/-, Il17rb-/-, and Il17rc-/- mice all have 
reduced proliferating B-cells (middle) and disorganized T-cell and B-cell zones (bottom). E.) Quantification of size, 
number, and area occupied by iBALT structures. * p<0.05, ** p<0.01, **** p<0.0001 by one-way ANOVA with 
Tukey’s multiple comparisons. F.) Cxcl13 expression is reduced in Il17ra-/-, Il17rb-/-, and Il17rc-/- mice. ** p<0.01, 
**** p<0.0001 by one-way ANOVA with Tukey’s multiple comparisons. 
 
We next assessed the T-cell responses from each genotype at day 14 post-infection. 
Il17ra-/- and Il17rb-/- mice had diminished expression of Il5 following ex vivo stimulation with 
Pneumocystis antigen (Figure 4-5A). Il17rc-/- mice had Il5 expression comparable to that of 
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C57BL/6 mice, suggestive of intact Th2 priming and differentiation (Figure 4-5A). Importantly, 
cells from Il17ra-/- and Il17rb-/- mice did not appear to be intrinsically defective in Th2 
polarization, as non-specific stimulation with CD3/CD28 was capable of inducing robust Il5 
expression (Figure 4-5A). Similarly, cells from Il17ra-/- and Il17rb-/-, but not Il17rc-/- mice, had 
striking defects in Il13 expression comparable to CD4-depleted mice (Figure 4-5B). Again, the 
capacity of these cells to make Il13 was not defective following CD3/CD28 stimulation (Figure 
4-5B). In contrast, Th17 polarization was reduced in cells from Il17ra-/- and Il17rc-/- mice, which 
are defective in IL-17A signaling (Figure 4-5C). However, cells from Il17rb-/- mice had intact 
antigen-specific production of IL-17A (Figure 4-5C). Production of the Th1 cytokine, 
interferon-γ (Ifng), appeared to be slightly reduced in all genotypes (Figure 4-5D).  
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Figure 4-5. Defective Pneumocystis specific T-cell responses in Il17ra-/-, Il17rb-/-, and Il7rc-/- mice.  A-D.) Whole 
lung cells were isolated 14 days post-Pneumocystis infection from each genotype and were stimulated with either 
Pneumocystis antigen or CD3/CD28. Expression of Il5, Il13, Il17a, and Ifng was measured by qRT-PCR. E.) Il17ra-
/- mice have increased Pneumocystis burden comparable to that of CD4-depleted animals, while Il17rb-/- and Il17rc-/- 
have a trend towards increased burden. F.) Eosinophil recruitment as measured by Prg2 expression is diminished in 
Il17ra-/- and Il17rb-/- mice. ** p<0.01, **** p<0.0001 by one-way ANOVA with Tukey’s multiple comparisons. 
 
Strikingly, Il17ra-/- mice had Pneumocystis burden levels comparable to that of CD4-
depleted mice, while both Il17rb-/- and Il17rc-/- had trends towards increased burden at day 14 
post-infection (Figure 4-5E). As we have shown previously that eosinophils are protective in 
response to Pneumocystis (182), we next examined the expression of the eosinophil marker 
major basic protein (Prg2). Both Il17ra-/- and Il17rb-/- had significantly reduced expression of the 
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eosinophil marker Prg2 similar to that of CD4-depleted animals (Figure 4-5F). On the contrary, 
Il17rc-/- mice had similar eosinophil recruitment compared to C57BL/6 mice (Figure 4-5F). 
Eosinophils did not seem to actively participate in the formation of iBALT, as dblGATA1-/- mice 
formed lymphoid follicles and expressed Cxcl13 in a manner similar to that of BALB/c controls 
(Figure 4-6A). Furthermore, in agreement with previously published data in a sterile 
Pneumocystis antigen model (231), the T-cell responses were unperturbed in dblGATA1-/- mice 
(Figure 4-6B). 
 
 
Figure 4-6. Eosinophils are dispensable for Pneumocystis iBALT formation. A.) Pneumocystis dependent 
iBALT formation is present in both BALB/c and GATA1-/- mice fourteen days post-infection by H&E staining. B. 
Cxcl13, Il13, and Il17a expression is similar in BALB/c and GATA1-/- mice.  
 
To confirm that these antigen-specific responses were CD4+ T-cell responses, we 
examined the nature of IL-17A and IL-13 producing cells early in Pneumocystis infection. Mice 
infected with Pneumocystis had significant increases in both IL-17A and IL-13 single-producing 
αβ T-cells compared to naïve controls (Figures 4-7A-4-7C). Furthermore, IL-17A and IL-13 
double-producing cells also expanded following Pneumocystis infection (Figure 4-7D). γδ T-
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cells and ILCs, however, appeared to have unchanged production of IL-17A and IL-13 following 
Pneumocystis infection (Figures 4-7A-4-7C). Likewise, at day 14 post-infection, αβ CD4+ T-
cells greatly outnumbered both innate lymphoid cells and γδ T-cells in the lungs (Figure 4-7E).  
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Figure 4-7. αβ T-cells produce IL-17A and IL-13 following Pneumocystis infection. A.) Representative flow 
cytometry plot of IL-17A and IL-13 producing cells in naïve and Pneumocystis infected mice at day 7 post-
infection. Pneumocystis infection results in expansion of CD3+TCRb+ cells expressing both IL-17A and IL-13, while 
no change was observed in the γδ T-cell (GL3+) or ILC (Lin-CD90+) compartments. B.) Quantification of IL-17A+ 
cells demonstrating expansion of αβ T-cells, but not γδ T-cells or ILCs. **** p<0.0001 by Student’s T-test C.) 
Quantification of IL-13+ cells demonstrating expansion of αβ T-cells but not ILCs. D.) αβ T-cells expressing both 
IL-13 and IL-17A were also expanded following Pneumocystis infection. * p<0.05 by Student’s t-test. E.) αβ T-cells 
are the vast majority of cells present in the lung at day 14 post-Pneumocystis infection. **** p<0.0001 by one-way 
ANOVA with Tukey’s multiple comparisons.  
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As both Il17ra-/- and Il17rb-/- mice had reduced antigen-specific Th2 responses and 
iBALT development, we next sought to confirm the role of IL-25 in iBALT formation. C57BL/6 
mice were treated with an anti-IL25 monoclonal antibody, and at day 14 post-infection with 
Pneumocystis, anti-IL25 treatment reduced lung inflammation, as well as the structural 
organization of iBALT (Figures 4-8A and 4-8B). Both the size and total area of iBALT follicles 
were reduced following anti-IL25 treatment, while number of follicles was unchanged (Figure 
4-8C).  
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Figure 4-8. Treatment with anti-IL25 antibody reduces Pneumocystis driven iBALT formation. A-B.) iBALT 
structures on H&E and immunofluorescent staining is reduced in C57BL/6 mice receiving anti-IL25 antibody 
compared to untreated C57BL/6 mice. C.) Quantification of iBALT structures demonstrates reduced size and area 
occupied in mice receiving anti-IL25 compared to untreated mice.  
 
Altogether, these results suggest that Il17ra-/- and Il17rb-/- mice had defective Th2 
priming and iBALT in part due to defective IL-25 signaling, while Il17ra-/- and Il17rc-/- mice 
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unsurprisingly have defective Th17 responses. Importantly, disruption of either the Th2 or Th17 
responses alone was capable of reducing iBALT structures. 
 
4.4.4 IL-13 and IL-17A synergistically induce Cxcl13 expression 
Formation of Pneumocystis iBALT is dependent on CXCL13 production, but surprisingly both 
mice lacking IL-17 signaling and Th2 cell polarization have defective Cxcl13 expression. To 
assess the mechanism of Cxcl13 induction, we first determined that the CXCL13 protein was 
localized to the center of the lymphoid follicles (Figure 4-9A). CXCL13 was undetectable in the 
airway epithelium and vascular endothelium (Figure 4-9A). Another known producer of 
CXCL13, CD21+CD35+FDC-M1+ follicular dendritic cells, were also absent in the 
Pneumocystis-driven follicles (data not shown). These histologic findings suggest that a stromal 
cell, such a pulmonary fibroblast, was the primary cellular source of CXCL13.  
Based on these data, we hypothesized that Cxcl13 expression in pulmonary fibroblasts 
was being driven by IL-17 and/or the local Th2 response in the lung. Cultured primary 
pulmonary fibroblasts from adult mice responded to both IL-17A and IL-13 six hours following 
stimulation, as the respective conditions led to upregulation of Cxcl1 and Ccl11 (Figure 4-9B). 
However, Cxcl13 was not induced six hours following stimulation with IL-17A, IL-13, or the 
combination of the two cytokines (Figure 4-9B). However, at 24 hours post-stimulation, Cxcl13 
was significantly upregulated in fibroblasts treated with both IL-17A and IL-13 compared to 
single stimulation controls (Figure 4-9C). Cxcl1 induction at this time point had waned, while 
Ccl11 expression remained high in IL-13 treated cells (Figure 4-9C).  
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Figure 4-9. IL-17A and IL-13 synergistically regulate Cxcl13 expression in pulmonary fibroblasts. A.) 
Immunofluorescent staining demonstrates CXCL13 protein in a lymphoid follicle 14 days post-infection with 
Pneumocystis. B.) Pulmonary fibroblasts upregulate Cxcl1 and Ccl11 following a six hour stimulation with IL-17A 
and IL-13, respectively. Cxcl13 expression is unchanged in all conditions at six hours post-stimulation C.) Cxcl1 
expression is reduced at 24 hours post-stimulation, while Ccl11 expression persists. Stimulation with both IL-17A 
and IL-13 leads to upregulation of Cxcl13 at 24 hours post-stimulation. * p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001 by one-way ANOVA with Tukey’s multiple comparisons.  
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The direct induction of Cxcl1 by IL-17A coupled with the delayed induction of Cxcl13, 
led us to hypothesize an indirect effect of IL-17A was synergizing with IL-13. Stimulation of 
pulmonary fibroblasts with IL-17A for six hours induced a four-fold increase in IL-6 production 
(Figure 4-10A). Interestingly, IL-6 coupled with IL-13 induced similar levels of Cxcl13 
expression compared to IL-13 and IL-17A co-stimulated cells (Figure 4-10B). As IL-6 signaling 
leads to activation of STAT3 and IL-13 signaling leads to activation of GATA3 through STAT6, 
we next sought to determine if these transcription factors were required for Cxcl13 induction. 
Stat3fl/fl and Gata3fl/fl fibroblasts were treated with adenovirus-Cre, followed by 24-hour 
stimulation with IL-6 and IL-13 (Figure 4-10C). Strikingly, Cxcl13 expression was attenuated in 
both Stat3fl/fl and Gata3fl/fl fibroblasts, suggesting that both transcription factors are required.  
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Figure 4-10. Cxcl13 expression is dependent on STAT3 and GATA3 activation. A.) Expression of Il6 is 
upregulated in pulmonary fibroblasts following a six-hour stimulation with IL-17A (n=4). B.) Cxcl13 is induced in 
pulmonary fibroblast by 24-hour stimulation with IL-13 in combination with either IL-6 or IL-17A (n=4-10). C.) 
Cxcl13 upregulation is partially blocked by treatment with an anti-gp130 antibody (n=7-9). D.) Cxcl13 expression is 
attenuated in pulmonary fibroblasts from Stat3fl/fl mice following in vitro treatment with adenovirus-Cre (n=4-12). 
E.) Stat6-/- fibroblasts fail to upregulate Cxcl13 following stimulation with IL-17A and IL-13 (n=3-6). F.) Cxcl13 
expression is attenuated in pulmonary fibroblasts from Gata3fl/fl mice following in vitro treatment with adenovirus-
Cre (n=3-4). Data are shown as mean ± standard error of the mean. * p<0.05, ** p<0.01, **** p<0.0001 by one-way 
ANOVA with Tukey’s multiple comparisons. 
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4.5 DISCUSSION 
The current study demonstrates that Pneumocystis infection via either oropharyngeal inoculation 
or natural transmission results in induction of CXCL13 and iBALT formation. Furthermore, the 
Pneumocystis-dependent iBALT structures required signaling through IL-17 family members for 
formation, and mice with either defective Th17 or Th2 responses failed to induce CXCL13 
expression and develop iBALT. Finally, pulmonary fibroblasts from adult mice stimulated with 
both IL-17A and IL-13 synergistically upregulate CXCL13 expression in a STAT3- and 
GATA3-dependent manner.  
 Importantly, this study identifies a novel fungal pathogen capable of inducing iBALT. 
Previously studied models include bacterial (Pseudomonas) and viral (influenza, modified 
vaccinia virus Ankara (MVA)) infection and subtle differences have begun to emerge in iBALT 
formation depending on the pathogen of interest (213, 216, 234, 235). For example, 
Pseudomonas iBALT formation requires CXCL12-producing stromal cells, while MVA induces 
iBALT through a CXCL13-producing follicular dendritic cell dependent mechanism (234). 
Likewise, CXCL13 expression has been implicated in influenza-mediated iBALT formation 
(213, 215, 216). However, unlike MVA infection, CXCL13 expression in response to influenza 
is mediated primarily by a stromal, and not hematopoietic, source (215). Influenza mediated 
iBALT requires additional soluble factors, such as lymphotoxin-alpha, for development. 
Blockade of the receptor for lymphotoxin-alpha (LTβR) was sufficient to reduce influenza 
driven-iBALT and neonatal Lta-/- exposed to LPS and then influenza failed to develop iBALT 
(216, 220). Pneumocystis, on the other hand, requires CXCL13 signaling, but not lymphotoxin-
alpha, for iBALT formation. These findings further highlight the need to study iBALT in a 
pathogen-specific manner, as differences in mechanism may arise from differences in pathogen.  
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 Furthermore, despite the requirement for CXCL13 in both the neonatal LPS-influenza 
and Pneumocystis models, the mechanism of Cxcl13 transcript induction appears to be different. 
Rangel-Moreno et al. elegantly demonstrated that neonatal pulmonary fibroblasts upregulate 
Cxcl13 expression following stimulation with IL-17A (220). However, in adult pulmonary 
fibroblasts, IL-17A stimulation is not sufficient to upregulate Cxcl13. Surprisingly, IL-13 and IL-
17A, products of the mixed Th2 and Th17 inflammatory response generated by Pneumocystis, 
potently induce Cxcl13 expression in adult pulmonary fibroblasts. The mechanism of IL-13 and 
IL-17A synergy appears to be dependent on the hallmark downstream transcription factors, 
STAT3 and GATA3. These findings suggest that transcriptional regulation of Cxcl13 is 
tightened over the course of development, perhaps through epigenetic modifications, or that 
neonatal fibroblasts have differing baseline activation of either STAT3 or GATA3.   
 The synergistic induction of Cxcl13 highlights a unique aspect of Pneumocystis driven 
inflammation. Strikingly, mice lacking either IL-17A signaling (Il17ra-/- and Il17rc-/-) or IL-25 
signaling (Il17ra-/- and Il17rb-/-) failed to upregulate Cxcl13 and subsequently form iBALT. 
Although IL-17A signaling has previously been implicated in iBALT formation (220, 233), 
Il17rb-/- mice with intact IL-17A responses, but defective production of Il5 and Il13, failed to 
form iBALT. Several studies in mice lacking Th2 cells (e.g. Stat6-/- and CD4-cre Gata3fl/fl mice) 
are pending and will be crucial in verifying the role of Th2 cells in the mechanism of iBALT 
formation. Importantly, IL-13 was produced solely by TCRβ+ cells and not ILC2s, further 
strengthening the role of Th2 cells in induction of Cxcl13. Together, these results demonstrate 
for the first time that Th2 responses can be required for iBALT formation.  
 While mechanistic studies in the murine model clearly indicate that natural transmission 
of Pneumocystis can induce iBALT, the incidence of iBALT formation in humans exposed to 
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Pneumocystis is unknown. Several key populations have been shown previously to develop 
iBALT: infants (222), and patients with COPD (218, 236), asthma (230), or pulmonary 
complications of rheumatoid arthritis (219). Importantly, colonization of Pneumocystis in all of 
these populations has been documented. Infants are nearly ubiquitously colonized with 
Pneumocystis by the age of 4 months; furthermore, Pneumocystis colonization in young children 
correlates with the increase in a mucus-associated gene, suggestive of a pathologic immune 
response (187, 188, 231). Likewise, patients with COPD and Pneumocystis have more severe 
disease and increases in proteases and inflammatory markers (68, 237, 238). While colonization 
has yet to be fully studied in asthma, a subset of patients with severe asthma have increased anti-
Pneumocystis IgG and IgE antibodies, which correlates with worsened disease (231). Finally, 
patients with rheumatoid arthritis can have asymptomatic colonization of Pneumocystis, or 
depending on the therapeutic regimen, can become immunosuppressed enough to become 
susceptible to Pneumocystis pneumonia (239, 240). In all of these pathologic conditions, the 
correlation between Pneumocystis colonization or infection and iBALT formation is unknown. 
However, future studies examining the causality of Pneumocystis in iBALT formation in humans 
would be highly informative in supporting and/or validating the novel findings in a murine 
model of Pneumocystis exposure.   
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5.1 INTRODUCTION 
As mentioned in Chapter 1, Pneumocystis jirovecii pneumonia remains one of the most common 
serious opportunistic infections in individuals with HIV/AIDS (1, 128, 241). Pneumocystis 
pneumonia mortality rates in the HIV-positive patients have remained largely unchanged over 
the past twenty years, despite the implementation of combined antiretroviral therapy in 
developed countries (2). Additionally, Pneumocystis infections are re-emerging in the clinical 
setting of immunosuppressive therapy for hematologic malignancy and post-transplantation 
rejection (13, 14). Alarmingly, HIV-negative patients with Pneumocystis pneumonia tend to have 
worse clinical outcomes, such as increased mechanical ventilation and mortality, when compared 
to HIV-positive patients (29).  
The mainstay of treatment and prophylaxis for Pneumocystis is trimethoprim-
sulfamethoxazole (TMP-SMX), which inhibits folate synthesis and de novo nucleic acid 
synthesis in microbial organisms (94, 242). Unfortunately, TMP-SMX has numerous side 
effects, which prove to be intolerable in up to 20% of patients, and TMP-SMX cannot be used in 
patients with sulfa allergies (94, 95). Second line agents, such as dapsone, are less effective and 
more toxic than TMP-SMX and tend to target similar microbial pathways (94, 95).  
Of greater concern is the emergence of mutations in the Pneumocystis enzymes, 
dihydropteroate synthase (Dhps) and dihydrofolate reductase (Dhfr), targeted by TMP-SMX. 
Interestingly, the Dhps gene appears to be under greater selective pressure compared to the Dhfr 
gene. Out of a cohort of 37 patients, 16 had mutations in the Dhps gene compared to one 
synonymous substitution in the Dhfr gene (243) Interestingly, certain geographic areas, such as 
San Francisco, appear to have higher rates of resistant strains, suggestive of transmissibility of 
these Dhps mutant strains (244). In one recent observational clinical study, over 80% of patients 
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had detectable mutations in the Dhps gene and these patients had a greater likelihood of 
requiring mechanical ventilation and mortality (245). However, it is also worth noting that the 
majority of patients with Dhps mutations in this study survived despite TMP-SMX being utilized 
as the primary therapeutic agent, raising the question of the clinical relevance of these mutations 
clinically (245). Despite unclear clinical significance, Saccharomyces cerevisiae complemented 
with the mutated Pneumocystis Dhps gene clearly grow better in the presence of TMP/SMX 
(246). Although Dhps mutations are far more common, more recent studies are also finding 
evidence of mutations in the Dhfr gene that correlate with failure of TMP/SMX prophylaxis 
(247).  
Given the challenge of using conventional therapies and the emerging risk of increased 
antimicrobial resistant Pneumocystis strains, discovery of novel therapeutic targets is imperative. 
Kinases are especially attractive candidates for rationale drug development, as these proteins are 
highly conserved and play important roles in proliferation, cellular signaling, and stress 
responses. One kinase family in particular, the phosphoinositide-3-kinase (PI3K) family, may be 
an attractive drug target, as these kinases mediate cell proliferation and survival, and as such, 
have been exploited in the development of recent anti-cancer therapeutics (248, 249). 
Most antifungals utilized clinically target enzymes associated with cell wall or nucleic 
acid synthesis. To our knowledge, kinases have not been targeted clinically in fungal infections. 
However, in vitro studies are suggestive of a possible therapeutic effect of targeting kinases. One 
interesting study performed by De Souza et al. demonstrated that Aspergillus nidulans contained 
128 kinases. The authors went on to characterize functional mutations for each kinase (250). 
Importantly, deletion of two VPS kinases (vps34 and vps15) resulted in defective endosomal 
trafficking and A. nidulans growth arrest (250). In S. cerevisiae, deletion of VPS34 leads to 
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defective vacuolar sorting and decreased growth at high temperature or in high salt (251). The 
drastic effects of VPS34 deletion have been attributed to the dual roles of VPS34 as both a 
protein kinase and a PI3K (252). VPS34 appears to be a highly conserved protein throughout 
evolution, and orthologs of the fungal VPS34 proteins are present in mammals (253). Recently, 
the VPS34 protein from Drosophila was crystallized and the structure of the binding pockets 
were mapped (254, 255).  
5.2 RATIONALE AND HYPOTHESIS 
Given the use of anti-kinase therapeutics used clinically, we hypothesized that the Pneumocystis 
kinome may be targeted for the development of anti-fungal compounds. To test this hypothesis, 
we utilized a top-down approach, beginning with genome annotation and ultimately leading to 
selection of a viable druggable target (Figure 5-1).  
 
Figure 5-1. Top-down approach to identifying proteins within the kinome to target pharmaceutically.  
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5.3 METHODS 
Pneumocystis kinome annotation and characterization 
A collection of all hypothetical Pneumocystis murina proteins was downloaded from the Broad 
Institute Pneumocystis sequencing project. Each hypothetical protein was analyzed using the 
NCBI Blast algorithm and the closest annotated ortholog to each protein was recorded. Every 
Pneumocystis protein with a predicted kinase function or domain was then aligned using Clustal 
Omega Alignment algorithms and a phylogenetic tree was created using MEGA5 software using 
the Maximum Likelihood method based on the JTT matrix-based model. Each kinase was then 
analyzed again with NCBI Blast restricted to the following taxa: Pneumocystis (taxid: 4753), 
Saccharomyces cerevisiae (taxid: 4932), Schizosaccharomyces pombe (taxid: 4896). Percent 
identity and e-value were then recorded. This process was repeated for all identifiable cyclins 
and major surface glycoproteins within the Pneumocystis murina genome and 50 randomly 
selected non-kinase Pneumocystis murina genes.  
 
Pneumocystis murina time course 
All animal procedures were approved by the University of Pittsburgh Institutional Care and Use 
Committee. Ten C57Bl/6 female mice were CD4-depleted using GK1.5 monoclonal antibody as 
previously described (83, 123, 182) and were subsequently challenged with 2.0 x 106/mL 
Pneumocystis murina cysts using oropharyngeal inoculation. Ten C57Bl/6 female mice were 
inoculated at the same time, but were not CD4-depleted. Five mice from each group were then 
sacrificed at day 10 and day 14, and lung RNA was purified using Trizol® Reagent (Life 
Technologies). Briefly, lungs were homogenized and following the addition of chloroform, RNA 
in the aqueous phase was collected and precipitated in isopropanol. Following centrifugation, the 
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RNA was washed with 75% ethanol, centrifuged again, and then resuspended in nuclease-free 
water. Following incubation at 55°, RNA was quantified using a Nanodrop and 1 μg of RNA was 
converted to cDNA using iScript™ cDNA synthesis kit per manufacturer’s instructions (Bio-
Rad). Pneumocystis burden was then quantified using SsoAdvanced qRT-PCR universal probes 
supermix (Bio-Rad) as well as primers and a probe specific for Pneumocystis murina large 
subunit (LSU) rRNA with a standard curve of known Pneumocystis LSU rRNA concentrations. 
Prior to sequencing, the RNA was further purified using a Qiagen RNA cleanup kit with DNAse 
treatment. An Aglient assessment of RNA purity was performed with an Agilent Tape Station 
2200.  
 
RNA sequencing 
RNA sequencing was performed as described in Chapter 2. Following sequencing, the samples 
were aligned to the Pneumocystis murina genome using Genesifter. For the adult case of 
Pneumocystis pneumonia, .fastq files were downloaded and aligned to the Pneumocystis jirovecii 
genome (256). 
 
VPS34 cloning  
Pneumocystis murina VPS34 was cloned from the cDNA above using Phusion High-fidelity 
polymerase (Thermo-Scientific). VPS34 Pneumocystis murina primers:  
Forward- 5’-CACCATGGGAAATTCTACATATTCTTTTTGTACTTCATCTCAACTAC; 
Reverse- 5’-AAAGTCGACTCAGCTTCTCCAATATTGTGCGATATTATGAACTC. VPS34 
from S. cerevisiae was cloned from genomic DNA using the following primers:  
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Forward- 5’-CACCATGTCACTGAACAACATAACATTCTGTGTCTC; Reverse- 5’- 
AAAGTCGACTCAGGTCCGCCAGTATTGTGCCAGATTATGTAAATG. Overlap extension 
PCR was performed to create the domain mutants. Briefly, the 5’ S. cerevisiae forward primer 
and the 3’ P. murina reverse primer were used. For the HC mutant, the domains were cloned 
using the overlapping primers: Reverse in the S. cerevisiae domain 5’-
GTTAGGTTTTAGCTCTCTGTCCAAGTTTGCATTTTTAGATGC and Forward in the P. 
murina domain 5’- GCATCTAAAAATGCAAACTTGGACAGAGAGCTAAAACCTAAC. For 
the C mutant, the following primers were used: Reverse in the S. cerevisiae domain 5’- 
GCCAGCAATTCTGCCTGTCTTTGATCGTTCAGTATATTC and Forward in the P. murina 
domain 5’- GAATATACTGAACGATCAAAGACAGGCAGAATTGCTGGC. Once the two 
domains were cloned, the samples were ligated and amplified using a 30-cycle PCR reaction 
with Phusion polymerase. PCR products were gel purified using a QIAQuick Gel extraction kit 
(Qiagen) per manufacturer’s protocol. Purified PCR products were inserted into pENTR™/D-
TOPO® vector following manufacturer’s instructions (Life Technologies). Briefly, the 
pENTR™/D-TOPO® vector was incubated with PCR product in a salt buffer for 30 minutes, 
followed by transformation with One Shot® Max Efficiency® DH5α™ competent cells and 
overnight growth at 37°. Colonies were selected and 5 mL starter cultures were prepared 
following overnight growth using a QIAprep Spin Miniprep Kit (Qiagen) per manufacturer’s 
protocol. The indentity of the insert was then confirmed by M13 PCR screen and by sequencing 
(GENEWIZ®). The domain mutants were then inserted into pYES-DEST52 destination vector 
using an LR Recombination reaction. Following isolation of vector from starter cultures 
(QIAprep) the products were again verified via PCR and sequencing.  
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Δvps34 growth rescue 
To transform yeast, wild-type and Δvps34 strains of S. cerevisiae were grown overnight at 30° in 
yeast extract peptone dextrose (YPD) media. The cultures were then pelleted and resuspended in 
5 mL of YPD. The cultures were then incubated at 30° for 4 hours prior to centrifugation for 3 
mins at 3000 rpm. Cells were resuspended in 5mL of distilled water, centrifuged, and 
resuspended in 5 mL of 1x Te/LiAc buffer. Following centrifugation, pellets were resuspended 
in 1.1 mL of 1x Te/LiAc buffer and incubated for one hour at room temperature. Ten μL of 
sonicated salmon sperm DNA and approximately one μg of each vector (VPS34 or control) were 
added and cells were incubated at room temperature for 30 minutes. Following incubation, 750 
μL of 9:1 PEG:10xTe/LiAc was added to each tube, followed by a 30 minute incubation at room 
temperature, and a ten minute incubation at 42°. Cells were spun at 5000 rpm for 2 minutes, 
decanted, and resuspended in appropriate selection media, plated, and grown overnight at 30°. 
Following initial colony selection, each strain was grown at 26°, 30°, and 37°.   
 
Pneumocystis killing assay 
Pneumocystis murina was purified from a frozen Rag2-/-Il2rg-/- double knockout lung, 
resuspended to a final concentration of 2.0 x 106 cysts/mL in PBS, and 1.0 x 105 cysts were 
added to a 96-well plate. Fifty μL of 20 μM stock compounds in PBS were added to each well. 
Equivalent quantities of Pneumocystis murina input were harvested at the time of plating, while 
the remainder of the wells were incubated for 24 hours at 37°. RNA was isolated using Trizol® 
LS Reagent as described above.  
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In silico modeling of VPS34 
The crystal structure of the Drosophila VPS34 protein was downloaded from NCBI Structure 
Summary (MMDB). Using MacPyMOL software, the catalytic subunits of the Pneumocystis 
VPS34 was modeled using the Drosophila VPS34 as a scaffold. After building the model, 
individual amino acids, as well as three-dimensional rendering, were performed on MacPyMOL 
software suite. Analysis of the chemical library of Dr. Xie was performed in the Xie lab as 
previously described.  
5.4 RESULTS 
5.4.1 Initial characterization of the Pneumocystis murina kinome 
One hurdle to compiling and characterizing the Pneumocystis murina kinome is the fact that the 
recently released genome remains largely unannotated (Figure 5-2).  
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Figure 5-2. Annotation of the Pneumocystis murina genome.  A.) Representative image of the original annotation 
of the 3615 hypothetical proteins within the Broad Institute Pneumocystis murina genome. B.) Following NCBI 
Blast analysis for each individual hypothetical protein, the Pneumocystis genome was fully annotated.  
 
To annotate the kinome, we analyzed each of the 3615 hypothetical proteins in the Broad 
Institute Pneumocystis murina genome using the NCBI BLAST algorithm. Each Pneumocystis 
murina protein was compared to orthologues in similar fungal species (e.g. Schizosaccharomyces 
pombe, Saccharomyces cerevisiae, Aspergillus nidulans, etc.) and a gene name for each protein 
was recorded. 
Upon annotation of the Pneumocystis murina genome, a total of 120 kinases were 
identified and further evaluated (table not included due to size). Using the NCBI BLAST 
algorithm, each kinase was characterized for percent identity and E-value (NCBI’s measure of 
homology) when compared to Pneumocystis jirovecii, S. pombe, and S. cerevisiae. Each 
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Pneumocystis kinase protein sequence was aligned using Clustal Omega alignment algorithms 
and the evolutionary history of these kinases was detailed using MEGA5 software (Figure 5-3). 
Importantly, several conserved kinase families that have been well studied in model organisms 
were clustered together using these methods. Nineteen CMGC kinases (cyclin-dependent, 
mitogen-activated, glycogen synthase, and cyclin-dependent protein kinase-like kinases) were 
found in 3 clusters, while 10 CAMK kinases (Ca2+/calmodulin-dependent protein kinases), 9 
AGC kinases (protein kinase A, G, or C), and 10 STE kinases (sterile kinases) clustered with 
their related kinase family members. Interestingly, 12 PIKK kinases (phosphoinositide-3-kinases 
(PI3K) and PI3K-like kinases) resided in the genome, but these proteins seemed more scattered 
throughout the evolutionary tree when compared to the other protein kinase families.  
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Figure 5-3. Molecular Phylogenetic analysis of the Pneumocystis kinome. Clustal Omega was used to align the 
119 predicted kinases in the Pneumocystis murina genome and the evolutionary history was inferred by using the 
Maximum Likelihood method based on the JTT matrix-based model (257). The tree with the highest log likelihood 
is shown. The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. 
Evolutionary analyses were conducted in MEGA5 (258). Individual protein kinase families (CMGC, CAMK, AGC, 
STE, and PIKK) are colored.  
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To establish the level of conservation for the entire kinome, we compared the 
Pneumocystis murina kinome to Pneumocystis jirovecii, S. pombe, and S. cerevisiae to see how 
conserved each kinase was in relation to its ortholog in those species. On average, kinases 
between Pneumocystis murina and Pneumocystis jirovecii had 72.8% identity, while these same 
kinase were less conserved between Pneumocystis murina and S. pombe (49.9% identical) and S. 
cerevisiae (45.8%) (Figure 5-4A). A similar trend was noted with each E-value, a more 
comprehensive measure of conservation, as kinases were highly conserved between 
Pneumocystis murina and Pneumocystis jirovecii (Figure 5-4B).  
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Figure 5-4. The Pneumocystis kinome is conserved between fungal species and in comparison to other protein 
families. The percent identity (A) and E-value (B, shown in log scale) were calculated for each predicted kinase in 
comparison to Pneumocystis jirovecii, S. cerevisiae, and S. pombe, with an e-value of -180 representing the 
maximum level of conservation. The identity (C) and E-value (D) of each P. murina kinase, cyclin family member, 
major surface glycoprotein family member, and fifty genes selected at random were calculated in relation to P. 
jirovecii. 
 
Along with examining the conservation between other genera and species, we sought to 
characterize how conserved the kinome was in relation to other protein families between 
Pneumocystis murina and Pneumocystis jirovecii. Cyclins, a protein family known to have a high 
degree of conservation (259), and the kinome had similar means of percent identity (75% vs. 
72.8%) and E-values (-158 vs. -157.2) (Figures 5-4C and 5-4D). The kinome also appears to be 
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more conserved in comparison to other genes; 50 non-kinase genes selected at random had lower 
percent identities and E-values when compared to the kinome. Finally, there is a unique gene 
family within Pneumocystis, known as the major surface glycoprotein family, which tends to be 
more divergent and undergo genetic variation. Interestingly, these MSG proteins were less 
conserved than randomly chosen genes and the kinome.  
After characterizing the kinome as a whole, we next sought to determine if a particular 
protein kinase family was more conserved, as a member of such a family might be a therapeutic 
target. Importantly, the CAMK, AGC, PIKK, CMGC, and STE kinases were all similarly 
conserved with the majority of the kinases in each family demonstrating high conservation by E-
value (Figures 5-5A and 5-5B). Similar to the kinome as a whole, these results suggest that 
individual protein kinase families share a high level of conservation.  
 
 
Figure 5-5. Kinase families are conserved within the Pneumocystis kinome. Percent identity (A) and E-value (B, 
shown in log scale) of each Pneumocystis murina kinase within the CAMK, AGC, PIKK, CMGC, and STE kinase 
families when compared to the ortholog within the Pneumocystis jirovecii genome. An E-value of -180 represents 
the maximum level of conservation. 
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5.4.2 The Pneumocystis kinome is expressed during murine and clinical infection 
To better select potential therapeutic targets, we next sought to assess the expression of each 
kinase in several different models of Pneumocystis infection. First, we examined the kinome 
expression profile in the lung 10 and 14 days following infection with Pneumocystis murina in 
both wild-type (WT) and CD4-depleted mice treated with GK1.5 monoclonal antibody (Figure 
5-6A). Pneumocystis burden is similar in WT and GK1.5-treated mice at day 10 (Figure 5-6B). 
However, in CD4-depleted mice, several kinases from a variety of families are more highly 
expressed than in WT controls. Similarly, at day 14 when Pneumocystis burdens are divergent, 
there is a cluster of kinases that are more highly expressed in CD4-depleted mice. Strikingly, 
there are also kinases that are expressed at higher quantities in WT mice at day 10, suggesting 
that the transcriptome of Pneumocystis may be altered when challenged with an immune 
response. There are also patterns that appear independent of CD4-status, as two groups of 
kinases are more highly expressed at day 10 and day 14 regardless of GK1.5 treatment. Taken 
together, these data suggest that the kinome is dynamically expressed over the course of 
infection and may be sensitive to immune pressure.  
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Figure 5-6. The Pneumocystis kinome is expressed during models of infection and during clinical infection. A.) 
Expression map of the Pneumocystis kinome at 10 and 14 days following infection in GK1.5 treated CD4-depleted 
vs. wild type mice. B.) Pneumocystis burden of wild type and GK1.5 treated mice at days 10 and 14 as measured by 
qRT-PCR. C.) Venn diagram demonstrating overlap in kinase expression during a murine model of Pneumocystis 
infection and a patient with clinical Pneumocystis infection. D.) Expression of each kinase in the CAMK, CMGC, 
STE, AGC, and PIKK families during the course of infection in wild type (WT) and GK1.5 treated mice at day 10 
and day 14 post-infection.  
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We next sought to determine if the expression of the Pneumocystis kinome could be 
detected in a patient with fulminant Pneumocystis pneumonia secondary to immunosuppressive 
drug therapies for chronic lymphocytic leukemia (256). Out of the 97 kinases expressed in 
murine infection, 91 were also expressed in this patient with Pneumocystis pneumonia (Figure 
5-6C). Interestingly, nine kinases were uniquely expressed in this patient compared to the murine 
model of infection.  
Given the abundance of kinases expressed during both murine and clinical infection, we 
again looked at individual kinase families to identify possible expression patterns (Figure 5-6D). 
Again, there was heterogeneity in terms of expression depending on the immune status and day 
of infection within protein kinase families. Interestingly, there appeared to be very few kinases 
that were expressed evenly despite immune pressure or status of infection. One PIKK family 
member, VPS34, a class III PIKK family member, was highly expressed in wild type and CD4-
depleted animals at all four time points. Class I and class II kinases within the PIKK family have 
multiple different proteins, suggesting that there may be redundancy among the classes. As 
VPS34 represents the single class III PIKK family member, we hypothesized that this may be a 
viable drug target with little compensatory mechanisms in Pneumocystis. Furthermore, VPS34 is 
highly conserved among fungal species, suggestive of a critical function (Table 5-1). Finally, the 
Drosophila VPS34 protein structure has recently been crystallized, which can be used as a 
template for accurate in silico modeling.  
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Table 5-1. Bioinformatic analysis of the conservation of VPS34 between species. 
Predicted 
kinase 
name 
PNEG 
name 
PNEJI 
name 
% homology 
between 
murina and 
jirovecii  
(E-value) 
S. 
cerevisia
e 
homolog
ue 
% homology 
between 
murina and 
cerevisiae 
(E-value) 
S. pombe 
homologue 
% homology 
between 
murina and 
pombe 
(E-value) 
VPS34 
protein 
kinase 
PNEG_0
3203 
PNEJI1_0
00867 
80% (0.0) Vps34p 40% (0.0) NP_594699.1 50% (0.0) 
 
5.4.3 Evaluation of VPS34 as a therapeutic target 
Based on the data presented above, we next sought to evaluate the function and druggability of 
the Pneumocystis VPS34 protein by complementing Δvps34 S. cerevisiae strains. Several 
attempts to express the full length Pneumocystis VPS34 were unsuccessful in Δvps34 S. 
cerevisiae despite the expression vector and transformation system working sufficiently for other 
Pneumocystis proteins. Interestingly, we hypothesized that lack of expression may have been due 
to missing regulatory elements in the Pneumocystis gene. Closer analysis of the VPS34 locus in 
S. cerevisiae indicated two large regions of amino acid sequences that were absent in both the 
Pneumocystis murina and Pneumocystis jirovecii genes (Figure 5-7A). However, the majority of 
residues were conserved in the 3’ catalytic domain of VPS34 across species (Figure 5-7A). To 
circumvent the inability to express the full length Pneumocystis VPS34, we designed domain 
mutants (Figure 5-7B). The HC mutant contained the 5’ N-terminal domain from S. cerevisiae 
and the helical and catalytic domains from Pneumocystis. The C mutant contained only the 
catalytic domain from Pneumocystis VPS34. These constructs are fully cloned and sequenced, 
and complementation studies in Δvps34 S. cerevisiae are underway. Prior to complementation 
with the various Pneumocystis constructs, we optimized the expression system by transforming 
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Δvps34 S. cerevisiae with the full length VPS34 from S. cerevisiae (Figure 5-7C). Adding back 
VPS34 in this system rescued the growth defect of Δvps34 at 37°C (Figure 5-7C).  
 
 
Figure 5-7. Schematic for complementation of Pneumocystis VPS34 in Δvps34 S. cerevisiae. A.) Alignment of 
VPS34 amino acid sequences from P. murina, P. jirovecii, and S. cerevisiae showing two large amino acid segments 
missing in the Pneumocystis sequences B.) Schematic of fusion proteins containing either both the helical and 
catalytic domains from Pneumocystis (middle) or the catalytic domain alone (lower). C.) Optimization of the VPS34 
expression system in Δvps34 S. cerevisiae showing rescue of the growth defect with full length VPS34 from S. 
cerevisiae.  
 
While in vitro studies to examine the function of Pneumocystis VPS34 were underway, 
we next sought to determine the druggability of Pneumocystis VPS34 via in silico analysis. The 
catalytic domain of Pneumocystis VPS34 was modeled using the crystal structure of Drosophila 
VPS34, which demonstrates high structural similarity (Figure 5-8A). The binding pockets 
between Drosophila and Pneumocystis, however, contained four amino acid substitutions: L744 
to V613, Y746 to F615, V774 to I616, I822 to A692 (Figure 5-8B). Three-dimensional 
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rendering demonstrated that Drosophila VPS34 binding pocket appeared to be more compact 
due to a higher degree of electrostatic interactions compared to Pneumocystis VPS34 (Figure 5-
8C). 
 
 
Figure 5-8. Modeling of the Pneumocystis VPS34 binding pocket. A.) The catalytic domain of Pneumocystis 
VPS34 (green) modeled off the crystallized Drosophila VPS34 (cyan). B.) Map of the binding pocket showing four 
amino acid substitutions in the Pneumocystis (green) VPS34 compared to the Drosophila protein (cyan). C.) Three-
dimensional reconstruction of Drosophila (left) and Pneumocystis (right) VPS34 showing a more open, less compact 
binding pocket in the Pneumocystis VPS34.  
 
 To screen novel compounds to target Pneumocystis VPS34, a library of over 22,000 
chemicals created by the laboratory of Dr. Xiangqun Xie was screened in silico for binding to the 
VPS34 pocket (Figure 5-9A). While there were several hits, eight compounds (14, 16b, 17, 24, 
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41, 45, 81, and 203) were selected for further analysis as antifungals. Each compound has a 
unique chemical structure that is undisclosed at this point for possible proprietary reasons. 
Interestingly, two compounds, 16b and 24, reduced Pneumocystis viability by nearly 50% in 
vitro (Figure 5-9B).   
 
 
Figure 5-9. In silico analysis of potential inhibitors of VPS34 and in vitro killing assay. A.) Compounds 
interfacing with the VPS34 binding pocket in silico. B) Pneumocystis murina cultured with eight compounds (14, 
16b, 17, 24b, 41, 45, 81, and 203) for 24 hours at 37°C. Following incubation, RNA was isolated and Pneumocystis 
burden was calculated by qRT-PCR.  
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5.5 DISCUSSION 
The current study demonstrates a novel top-down approach to design novel therapeutics against 
Pneumocystis pneumonia. Annotation of the 3615 genes within the Pneumocystis genome allows 
for more thorough, rational target selection. Here, we evaluated the Pneumocystis kinome, which 
contains over 100 proteins that are dynamically expressed throughout infection. As a proof-of-
principle, we further demonstrated that by targeting a conserved, highly expressed kinase, 
VPS34, using in silico analysis and drug design, we could identify novel inhibitors against 
Pneumocystis. 
 These techniques could be of the utmost importance as antibiotic resistance continues to 
emerge. Prophylaxis and treatment for Pneumocystis relies heavily on trimethoprim-
sulfamethoxazole (TMP-SMX), which targets the nucleotide synthesis pathway (94, 95, 243). 
However, documented resistance to TMP-SMX has begun to become more prevalent in patients, 
leading to increased failure of prophylaxis (242, 243, 247, 260, 261). Additionally, TMP-SMX 
has over a 20% treatment failure rate, as use is limited by sulfa allergy and other unwanted side 
effects (94, 95). Second-line therapies, such as dapsone, are less effective and tolerable than 
TMP-SMX (94, 95). Together, these clinical problems necessitate the discovery of novel 
antifungal targets.  
 While the current study only examines a single target, VPS34, several novel findings lay 
the groundwork for possible high-throughput screening. Pneumocystis, at present, remains 
unculturable in vitro and 99% of the inoculum will die within 24 hours as measured by qRT-
PCR. This remains a large limitation in the field and greatly hinders the development of any high 
throughput assay. Here, we utilized a complementation approach in Saccharomyces cerevisiae to 
demonstrate functionality of the Pneumocystis protein VPS34. This technique, coupled with the 
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in silico analysis of protein structure, could lead to an assay where druggability of specific 
Pneumocystis proteins is assessed in vitro in S. cerevisiae. As S. cerevisiae mutants can have 
growth phenotypes, using a spectrophotometer could allow for assessment of broth density in a 
96-well or 384-well plate, allowing for high-throughput screening. Likewise, using a luminescent 
or fluorescent S. cerevisiae could allow for quantification of growth visually (262, 263).  
Given the identification of one potential target, further studies are needed to assess the 
viability of a strategy to drug Pneumocystis VPS34. VPS34, a hallmark PI3K, is expressed in 
most species and any compound directed towards the Pneumocystis VPS34 may have unwanted 
off-target effects. Both in vitro studies on mammalian cell lines and in vivo safety studies need to 
be performed prior to developing VPS34 inhibitors. Indeed, current PI3K inhibitors used 
clinically are directed at cancerous cells, suggesting that these compounds can target mammalian 
cells (248, 249). Furthermore, as existing PI3K inhibitors have yet to be screened for antifungal 
activity, it is possible that a currently used chemotherapy for cancer may actually have anti-
Pneumocystis effects. This, of course, would again be limited by unwanted side effects, but it 
does raise the possibility of repurposing an already approved drug as a novel antifungal.  
While the top-down approach successfully identifyied a single target, annotation of the 
Pneumocystis genome should facilitate antifungal development. For example, the use of 
unbiased screens to identify novel targets may no longer be required (264), as researchers 
interested in pathway ‘X’ or protein ‘Y’ can now query a fully annotated genome. Likewise, 
known inhibitors of proteins can be screened for anti-Pneumocystis activity if the protein is 
contained within the genome and is expressed during infection. Together, the current study 
furthers our knowledge of Pneumocystis biology and demonstrates that a top-down approach of 
genome annotation can identify novel drug targets.   
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6.0  USING TRANSCRIPTOMICS AND PROTEOMICS TO IDENTIFY NOVEL 
LIFE-CYCLE SPECIFIC VACCINE CANDIDATES FOR PNEUMOCYSTIS 
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6.1 INTRODUCTION 
Pneumocystis (PC) is a fungal species that is best known for causing an opportunistic pneumonia 
in immunocompromised individuals, such as patients with HIV/AIDS (265). Even after the 
advent of highly active antiretroviral therapy (HAART), Pneumocystis pneumonia (PCP) 
remains one of the most feared complications of HIV/AIDS. One retrospective study 
demonstrated that PCP prior to HAART had a mortality rate of 10.1%; following the 
implementation of HAART, the mortality rate of PCP was modestly reduced to 9.7% (2). 
Furthermore, another retrospective study in the early 2000’s demonstrated that overall PCP 
mortality in HIV-patients was 11.6%, while the mortality rose to 29% in patients requiring 
intensive care (266). Although HAART has helped reduce the incidence, PCP remains the most 
common AIDS-defining opportunistic infection in the United States (1).  
PC is also emerging in the clinical setting in the HIV-negative patient population. A 
study conducted in Sweden demonstrated that 75% of patients presenting to the hospital with 
PCP were HIV-negative (13). Another study conducted in the U.K. between 2000-2010 found 
that the number of hospital episodes of PCP more than doubled during the study period, with 
transplant and hematologic malignancy patients representing the highest risk groups (14). 
Furthermore, patients receiving certain immunosuppressive medications such as methotrexate, 
steroids, or TNF-antagonists also have an increased susceptibility to PCP; these newer 
immunosuppressive agents are often the hallmark of treatment for conditions like rheumatoid 
arthritis, autoimmune conditions, and post-transplant rejection (30, 267–270). Perhaps more 
troubling, HIV-negative patients infected with PC tend to have worse outcomes such as higher 
mechanical ventilation and mortality rates when compared to HIV-positive patients (29, 30).  
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The current standard of care for prophylaxis and treatment of PC is trimethoprim-
sulfamethoxazole (TMP-SMX). However, approximately 8% of patients have sulfa allergies and 
are unable to take TMP-SMX (96). Furthermore, one out of five patients will fail to complete the 
therapeutic course of TMP-SMX due to adverse effects (94, 95). Interestingly, HIV infection 
seems to increase the likelihood of having an adverse reaction to sulfa drugs, again limiting the 
use of TMP-SMX (97). Another growing concern is the emergence of TMP-SMX resistance 
strains of PC due to mutations in dihydrofolate synthase (242). Second line therapies, such as 
pentamidine, tend to have increased treatment failure rates and adverse events (94, 95). 
Although treating PC remains a clinical challenge, it is clear that an intact immune 
system is capable of resolving PC infection. The HIV epidemic highlighted the importance of 
CD4+ T cells in maintaining immunity against PC. Additionally, several lines of evidence 
suggest that an intact B cell response, facilitated by CD4+ T cells, is crucial in eliminating PC. 
First, patients with common variable immunodeficiency and other inherited forms of 
hypogammaglobulinemia are susceptible to developing PCP (271). Second, patients with 
mutations in IL-21 receptor are susceptible to numerous opportunistic pathogens, including PC 
(78). IL-21 is a hallmark cytokine produced by T follicular helper cells, which are important for 
shaping a high-affinity antibody response (272). Third, patients treated with Rituximab, an anti-
CD20 antibody, frequently develop PCP. These findings are also corroborated in several mouse 
models, as B cell deficient mice, IL-21 receptor knockout mice, and mice treated with an anti-
CD20 antibody are unable to clear PC infection ((79, 178), unpublished data). Together, these 
findings all demonstrate that a humoral immune response is a crucial component of maintaining 
immunity against PC. 
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Ideally, a vaccine could be developed which induces a humoral immune response capable 
of protecting patients with profound immunosuppression. For example, the use of HAART can 
potentially reconstitute the immune system to the point where vaccination can induce a 
protective response even after the CD4+ T cell count drops precipitously (273–275). 
Furthermore, a vaccine to protect non-HIV infected patients against PC, in theory, would be 
easier to implement because these patients have induced immunosuppression in the clinic. To 
generate such an immune response would require the presence and identification of strong 
antigenic proteins on the surface of PC. Thus, discovering and evaluating the immunogenic 
potential of novel antigens on PC, along with characterizing the immune response these antigens 
generate, are the crucial first steps in therapeutic and vaccine development.  
6.2 METHODS 
Separation of cysts and trophs 
Total PC was isolated from whole lung of a PC infected RAG2/γ-common chain double knockout 
mouse and stained with CD45, PC antisera (total PC), an anti-PC antibody (6F5), and a dectin-
Fc fusion protein (a complex produced in our laboratory) (127). Cysts stained CD45-PC+Dectin+ 
while trophs stained CD45-PC+Dectin- and were sorted accordingly. RNA was extracted using 
Trizol and was sequenced was performed as described in prior chapters.  
 
Meu10 and GSC-1 Elispot and peptide immunization 
A total of eight fungal proteins were chosen for epitope analysis based on surface peptide 
identification (Table I, Supplemental Table 1). Potential MHCII-binding peptides were predicted 
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for each potential protein antigen using the Immune Epitope Database and Analysis Resource T 
cell epitope prediction tools for peptide binding to MHC class II molecules 
(http://tools.immuneepitope.org/mhcii).  This tool employs a consensus approach to predict 
MHC Class II epitopes based upon Sturniolo, ARB, and SMM_align algorithms (276). For each 
gene product, the predicted peptide binding results for mouse MHC Class II were sorted by top 
percentile using the consensus score, and 10-14 of the highest ranked peptides with a unique 
Average Relative Binding (ARB) matrix core sequence were selected for each of the 8 fungal 
surface protein candidates. A total of 96 peptides were chosen for peptide synthesis and 
screening (Table II). C57/BL6 wild type mice were inoculated with P. murina for two weeks. 
Total lymphocytes include T cells, B cells, and antigen-presenting cells from lung draining 
lymph node of P. murina inoculated mice were collected. Total lymphocytes were resuspended 
in complete IMDM medium (Invitrogen, Grand Island, NY), and then distributed at 200,000 
cells/well in 96 well manufactory pretreated of mouse Interferon gamma (IFN-), Interleukin-5, 
and IL-17 ELISpot plates (R&D, Minneapolis, MN). Cells were then incubated at 37°C in 5% 
CO2 in the presence of each identified peptides pools at 1 µg/ml for four days. PC antigen and 
ovalbumin (OVA) proteins were used as positive and negative controls. Spot frequency of IFN-
, IL-5, and IL-17 were developed following the manufacturer’s instructions and spot forming 
units were scanned and calculated by Cellular Technology Ltd’s plate reader and its spot 
calculation software. For peptide immunization, mice were immunized with remaining peptides 
complexed in Sigma Adjuvant system and injected intraperitoneally. Serum was collected 14 
days after injection.  
 
 
 158 
ELISAs 
Antigens (Pneumocystis, Meu10, GSC-1, cell lysates at a concentration of 150 ng/well) in 
coating buffer were then added to a 96-well plate and incubated at 4° overnight. Plates were then 
washed, blocked with PBST plus 5% dry-milk, and stained with 1:1000 diluted P. murina 
convalescent serum or naïve serum overnight at 4°. Plates were then washed, stained with goat 
anti-mouse IgG (Southern Biotech), washed, and developed with TMB substrate. Absorbance 
was measured at 450 nm and groups were compared using unpaired Student’s t-test. 
 
DNA vaccination 
Mice were anesthetized with a combination of ketamine and xylizine. Vector (100 μg/mouse) 
was then injected intramuscularly into the tibialis anterior every two weeks for a total of three 
doses. Pneumocystis inoculation was performed as described in previous chapters. 
 
Pneumocystis staining  
P. murina samples were heat-fixed onto glass slides, followed by further fixation using ice-cold 
methanol. Slides were washed with PBS and blocked for 15 minutes in PBS with 5% dry milk. 
Anti-Meu10 serum (generated from mice immunized with the Meu10 peptide pool) was diluted 
1:1000 in PBS and added to the slides for 15 minutes. Following PBS washes, slides were 
stained with 1:1000 diluted goat anti-mouse IgG conjugated to DyLight 488 (Thermo Scientific). 
Slides were washed with PBS, counterstained with DAPI (1:2000 for 15 minutes), washed again 
and coverslips were mounted with VectaMount™ AQ mounting media (Vector Laboratories). 
Slides were visualized using 63X magnification. 
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Expression of recombinant GSC-1 and protein immunization 
Briefly, GSC-1 was cloned into the pYES-DEST52 expression vector and sequence confirmation 
was obtained from Genewiz. S. cerevisiae was then transformed (as described on pg. 134) and 
GSC-1 expression was induced by growth in S.C. –ura media containing galactose. Following 
24-hours, the yeast was pelleted via centrifugation and lysed using a BeadBeater for 3 mins in 
ice. The lysate was then applied to a nickel-affinity column, and was cycled through at 1 
mL/min. Flow through was obtained at each step. Elution was performed in an imidazole 
solution and buffer exchange was performed to resuspend the protein in PBS. A BCA assay was 
performed to calculate the concentration of protein and GSC-1-Myc tag was confirmed via 
Western blot. Mice were then immunized with 150 ng of GSC-1 complexed 1:1 in alum via 
intraperiotneal injection.  
 
Co-housing 
Mice were immunized with recombinant GSC-1 complexed in alum. Mice were then CD4-
depleted as described in above chapters, and co-housed with a Pneumocystis infected Rag2-/-
Il2rg-/- double knockout mouse for four weeks. Mice were then sacrificed and lung tissue was 
processed as described above.  
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6.3 RESULTS AND DISCUSSION 
We first sought to identify extracellular antigens using a surface biotinylation process on 
recovered, viable Pneumocystis. Following biotinylation, mass spectrometry was performed on 
the samples and specific extracellular proteins were identified as described previously (264). 
Following characterization of extracellular proteins on Pneumocystis, we next wanted to identify 
the life form on which these proteins are expressed. Purified Pneumocystis was obtained from 
bronchoalveolar lavage fluid from an infected Rag2-/-Il2rg-/- and cysts were labeled using a 
dectin-1:Fc construct (127), while trophs were dectin negative (Figure 6-1A). Following 
separation, RNA was isolated and sequenced. Interestingly, of the proteins identified via surface 
proteomics, Meu10 seemed to have increased expression on trophs, while GSC-1 transcript was 
enriched in the cyst (Figures 6-1B and 6-1C). 
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Figure 6-1. RNA sequencing of separated cysts and trophs. A.) Gating strategy on separating cysts and trophs. 
Whole Pneumocystis was stained with PC anti-sera and was CD45-. Cysts were sorted on Dectin+, while trophs were 
Dectin-. B.) Meu10 had a 1.3-fold higher expression on trophs, while GSC-1 had a 1.3 fold higher expression on 
cysts (* denotes p<0.05). 
 
  After identifying two differentially expressed targets, Meu10 and GSC-1, we next sought 
to characterize the immunogenicity of each protein. T-cells from a Pneumocystis infected mouse 
recognized peptides from both Meu10 and GSC-1 and released IFN-γ, IL-5, and IL-17 (Figures 
6-2 A-C). These results suggest that both Meu10 and GSC-1 are antigens recognized by antigen-
specific T-cells during the course of Pneumocystis infection.  
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Figure 6-2. Meu10 and GSC-1 are antigens seen during natural infection. Lymphocytes collected from 
Pneumocystis infected mice were either stimulated with Meu10 peptides, GSC-1 peptides, OVA peptide, or were 
unstimulated (NS). Meu10 stimulation resulted in a statistically significant increase in IFN-γ positive cells (p<0.05), 
while GSC-1 stimulation resulted in a trend towards greater IFN-γ positive cells (p=0.09) as calculated by a 
Kruskal-Wallis nonparametric ANOVA with Dunn’s multiple comparison test. IL-5 and IL-17 production appeared 
to be nonspecific. 
 
As Meu10 and GSC-1 appeared to be T-cell epitopes, we next sought to determine if B-
cells recognized either protein over the course of infection. Following immunization with Meu10 
and GSC-1 peptides, a significant increase in anti-Pneumocystis IgG over adjuvant alone control 
was observed (Figure 6-3).  
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Figure 6-3. Meu10 and GSC-1 immunization produces anti-Pneumocystis IgG. Meu10 and GSC-1 immunized 
mice had significantly higher anti-PC antibodies as measured by ELISA. * denotes p<0.05, ** denotes p<0.01 as 
determined by a one-way ANOVA with Holm-Sidak’s multiple comparisons. 
 
While the immunogenicity of Meu10 and GSC-1 made both targets viable vaccine 
candidates, the above data is limited by the peptide-based approach. To examine if Meu10 
protein was immunogenic, 293T cells were transfected with an expression vector containing the 
nucleotide sequence for the Meu10 ectodomain. Meu10 was readily expressed in 293T cells 
(Figure 6-4A). As further evidence that Meu10 is recognized during natural Pneumocystis 
infection, serum from infected animals bound Meu10 lysate significantly more than serum from 
a naïve animal (Figure 6-4B). Furthermore, when mice were immunized intramuscularly with 
the Meu10-containing expression vector, sera could recognize both the cyst and the troph form 
of Pneumocystis (Figure 6-4C).   
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Figure 6-4. Meu10 is an extracellular antigen capable of inducing a humoral immune response. A.) 
Recombinant myc-tagged Meu10 protein identified by SDS-PAGE and Western blotting in transfected 293 cell 
lysate. B). Anti-PC serum recognizes Meu10 lysate by ELISA compared to naïve serum (top panel, p=0.0009). 
Further normalization of the data to non-transfected 293 lysate (background) demonstrates that anti-PC serum 
recognizes Meu10 greater optical density (O.D.) than naïve serum (bottom panel, p=0.024). C.) Immunofluorescent 
staining of whole PC with anti-Meu10 serum binds to both the PC cyst (top row) and troph (middle row). Naïve 
serum (bottom row) demonstrated very little specific binding. 
 
As this DNA vaccine approach was immunogenic, we next immunized mice three times 
with our Meu10 expression vector, followed by CD4-depletion and challenge with Pneumocystis 
(Figure 6-5A). Following 6 weeks of infection, Meu10 immunized mice had significantly 
reduced burden by qRT-PCR compared to mice receiving an empty vector control (pBUD) 
(Figure 6-5B). These findings were corroborated via a histologic approach, as GMS staining was 
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significantly reduced in Meu10 immunized mice (Figure 6-5C). As seen previously, Meu10 
immunization generated anti-Pneumocystis IgG by ELISA (Figure 6-5D).  
 
 
Figure 6-5. Meu10 DNA vaccination provides protection against Pneumocystis challenge and generates 
Meu10-specific antibodies. A.) Vaccination scheme demonstrating three vaccination doses, followed by CD4-
depletion with GK1.5 monoclonal antibody treatment, and Pneumocystis challenge. B.) Quantitative reverse 
transcription PCR (qRT-PCR) of large subunit (LSU) rRNA of lung homogenate following vaccination and 
challenge. C.) Histological analysis of Meu10 DNA vaccination demonstrates that Meu10 provided significant 
protection. D.) Meu10 pBudCE4.1 was transfected into 293 cells and lysates were used to coat ELISA plates. Serum 
collected at the time of sacrifice showed that Meu10 vaccinated animals had significantly increased O.D. when 
normalized to empty pBud 293 lysate. * denotes p<0.05 as determined by a one-way ANOVA with Holm-Sidak’s 
multiple comparisons test.   
 
As the DNA vaccination approach appeared to be successful in providing limited 
protection against Pneumocystis challenge, we next sought to use a protein-based approach. 
Expression of Meu10 recombinant protein, however, was unsuccessful in both yeast and bacteria 
(data not shown). To further validate our DNA vaccine findings, we then immunized mice with 
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the MHC-restricted Meu10 peptides designed for the ELISpot assay (Figure 6-2). Following 
immunization, mice receiving Meu10 peptides had significantly reduced Pneumocystis burden 
(Figure 6-6A). Upon histologic quantification, Meu10 immunization reduced GMS staining 
Pneumocystis significantly (Figures 6-6B and 6-6C). Again, Meu10 immunization led to 
significantly increased anti-Pneumocystis IgG levels comparable to that of C57BL/6 mice 
(Figure 6-6D).  
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Figure 6-6. Vaccination with Meu10 peptides decreases Pneumocystis burden and results in Pneumocystis-
specific antibody generation. Mice received two doses of Meu10 peptides + Sigma Adjuvant System® i.p. followed 
by CD4-depletion with GK1.5 and challenge with Pneumocystis. A.) qRT-PCR on lung homogenate following 4 
weeks of infection demonstrates that Meu10 vaccinated mice had significant decrease in Pneumocystis burden when 
compared to mice receiving adjuvant alone. B.) Histologic analysis of lungs stained with GMS demonstrating 
Meu10 vaccination provides significant protection. C.) Pneumocystis antigen ELISA demonstrating that Meu10 
vaccinated mice had significantly higher anti-Pneumocystis IgG. * denotes p<0.05 as determined by a one-way 
ANOVA with Holm-Sidak’s multiple comparisons test. 
 
 168 
After demonstrating Meu10 immunization provided limited protection using two 
vaccination strategies, we next sought to determine the protective capabilities of GSC-1. Using a 
comparable DNA vaccine approach, GSC-1 was unable to provide protection following 
challenge with Pneumocystis (data not shown). We next turned to a recombinant protein 
approach. The ectodomain of GSC-1 was successfully cloned and expressed in S. cerevisiae at 
24-hour post-galactose induction (Figure 6-7A). Furthermore, GSC-1 ectodomain protein was 
recognized by convalescent sera, indicating this portion of GSC-1 is recognized during natural 
Pneumocystis infection (Figure 6-7B).  
 
 
Figure 6-7. GSC-1 protein is seen during natural Pneumocystis infection. A.) Expression of the ectodomain of 
GSC-1 (approximately 67 kDa) in S. cerevisiae. Protein was purified using a nickel affinity-column and was 
detected using an anti-myc Western blot. B.) Purified GSC-1 is recognized by convalescent Pneumocystis sera. ** 
p<0.01 by Student’s t-test.  
 
Immunization with GSC-1 induced a strong antibody response that was enhanced 
following a second immunization (Figure 6-8A). Furthermore, anti-GSC-1 sera collected 
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following the second immunization was capable of recognizing the Pneumocystis cyst, while 
anti-OVA sera did not (Figure 6-8B). Following CD4-depletion and Pneumocystis challenge, 
however, GSC-1 immunization failed to provide protection as measured by Pneumocystis burden 
(Figure 6-8C).  
 
 
Figure 6-8. GSC-1 protein immunization induces a strong antibody response, but fails to provide protection. 
A.) Anti-GSC-1 antibodies are elicited following GSC-1 immunization and boost. B.) Serum from GSC-1 
immunized mice recognizes the surface of the Pneumocystis cyst, while serum from OVA immunized animals does 
not. C.) Pneumocystis burden is unaffected by GSC-1 ectodomain immunization. 
 
GSC-1 protein immunization failed to provide protection against challenge with both 
Pneumocystis cysts and trophs. However, RNA sequencing data suggests that GSC-1 is 
expressed on transmissible form of Pneumocystis, the cyst. Prior work by Andrew Limper’s lab 
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also demonstrated that GSC-1 is expressed exclusively by the cyst (277). We therefore 
hypothesized that GSC-1 immunization would block transmission in a co-housing model. Mice 
were immunized with two doses of GSC-1 or OVA in alum and GSC-1 immunization again 
elicited a strong anti-GSC-1 IgG response (Figure 6-9A). Following CD4-depletion, immunized 
mice were co-housed with a Pneumocystis infected Rag2-/-Il2rg-/- mouse for four weeks. In the 
first preliminary experiment, GSC-1 immunized mice had noticeably reduced Pneumocystis 
burden compared to OVA immunized mice (Figure 6-9B).  
 
 
Figure 6-9. GSC-1 immunization blocks transmission of Pneumocystis infection. A.) GSC-1 immunization 
induces anti-GSC-1 IgG production. B.) Pneumocystis burden is reduced following GSC-1 immunization and 
subsequent CD4-depletion and co-housing with an infected Rag2-/-Il2rg-/- mouse. 
 
Taken together, these results demonstrate the identification of two novel vaccine targets 
for Pneumocystis pneumonia. Meu10 and GSC-1, which appear to be life-form specific based on 
RNA sequencing data, are both recognized by T- and B-cells during natural infection. 
Furthermore, immunization with both proteins appears to be immunogenic as measured by 
production of anti-Pneumocystis, anti-Meu10, and anti-GSC-1 IgG production. Meu10 
immunization was capable of providing limited protection against Pneumocystis challenge, while 
 171 
GSC-1 immunization could block transmission of Pneumocystis but failed to reduce burden in a 
challenge model.  
 These findings, while still preliminary, are encouraging for a number of reasons. First, 
the validation of both Meu10 and GSC-1 demonstrates the ability of unbiased, -omic based 
approaches towards discovering novel antigens. Meu10 and GSC-1 were identified as candidates 
based on life-form specific transcriptomics and surface proteomics, two techniques that were 
previously never applied to Pneumocystis. This was especially important in the setting of an 
unannotated genome (which was the case when this project was initiated). Second, each antigen 
was capable of inducing anti-Pneumocystis IgG using various vaccine strategies and in isolation, 
both Meu10 and GSC-1 provided benefit to the host. Meu10 antibodies were capable of reducing 
Pneumocystis burden in a challenge model; however, this raises the possibility that passive 
transfer of anti-Pneumocystis antibodies into an infected host may be therapeutic. Discovery of 
high-affinity monoclonal antibodies targeting infectious diseases is an area of active research, as 
administration of a biologic agent could vastly enhance treatment regimens currently comprised 
of antibiotics. GSC-1, on the other hand, was more effective at blocking transmission than 
reducing burden. Future studies will examine the length of GSC-1 provided protection and 
possibly translate these findings to a non-human primate model.  
However, these antigens may be best utilized in a collaborative setting, where dual 
vaccination could target both the cyst and the troph life-form. The life cycle of Pneumocystis is 
complicated (see Chapter 1) and it is possible that a multivalent vaccine targeting multiple life 
forms would provide the best protection. Unfortunately, these vaccine studies are time-intensive 
and a multivalent approach, although tenable, was not performed during the course of my thesis. 
Our future studies will therefore explore the synergistic or additive effects of adding multiple 
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antigens in each vaccination. Furthermore, as our knowledge of the microbiology of 
Pneumocystis expands, identification of further antigens could aid in rationale, multivalent 
vaccine development. 
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7.0  OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
The findings contained in this dissertation describe the early immune response to Pneumocystis 
infection and exposure. What fascinated me about these projects was how an incredible 
opportunist like Pneumocystis generates such a strong, protective immune response that can 
eliminate the pathogen, but can also result in damage to the host. While we describe several 
novel facets of the immune system in response to Pneumocystis, there are additional studies that 
could compliment the projects contained in this thesis or lead to entirely new avenues of 
research. 
 My thesis work truly began with the Pneumocystis time course experiment, which led to 
the discovery of a strong eosinophilic signature in the lungs of infected, but not CD4-depleted, 
mice (Figure 2-1). While that project culminated with the use of hydrodynamic injection to drive 
eosinophilia and reduce Pneumocystis burden, the true antifungal mechanism of eosinophils 
remains unknown. Murine eosinophils have been previously shown to have fungicidal properties 
against Aspergillus fumigatus in a manner that did not require contact (121). These studies are 
highly suggestive of a cytotoxic mediator released via degranulation, but as described in Chapter 
2, these eosinophilic granules are highly complex. More detailed in vitro studies could be 
performed with recombinant major basic protein, eosinophil peroxidase, eosinophilic cationic 
protein, and eosinophil-derived neurotoxin to see if any or all of these proteins contain antifungal 
properties. Other proteins within eosinophils, such as eosinophil associated ribonucleases, have 
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been shown to have anti-viral properties against respiratory syncytial virus (RSV) (personal 
communication S. Cormier). As transcripts for eosinophil associated ribonucleases were highly 
upregulated in Pneumocystis infected lungs, this protein family could also be a potential target 
for in vitro screening of antifungal activity. These in vitro studies will be limited by the fact that 
99% of Pneumocystis dies within 24-hours outside of a suitable host. While Pneumocystis killing 
assays in vitro are possible with sufficiently high inoculums, a second technique would be to 
give recombinant proteins oropharyngeally to a Pneumocystis infected mouse and monitor 
burden in vivo. This type of in vivo killing assay has been performed by our group previously 
with an antimicrobial peptide; however, it is also possible that these eosinophilic granule derived 
proteins would cause host damage as well (109). Studies examining the antifungal properties of 
these eosinophil-derived proteins could also be performed in vitro with a culturable fungus, such 
as Aspergillus. Furthermore, the mechanistic studies could also be performed with recombinant 
human eosinophilic proteins or human eosinophils. These further studies would be especially 
interesting, as identification of a fungicidal protein could potentially lead to a novel therapeutic 
avenue for Pneumocystis pneumonia.  
 While the exact mechanism of the anti-Pneumocystis effects of eosinophils was not 
elucidated in the current study, driving eosinophilia was sufficient to reduce Pneumocystis 
burden (Figure 2-4). In natural infection, CD4+ T-cell release of IL-5, coupled with the 
induction of eotaxin-1 (CCL11), appears to be the major driver of eosinophilia (Figure 2-1). 
However, eosinophils have been shown to respond to a number of cytokines, such as GM-CSF, 
IL-4, IL-13, and IL-33 (98). Furthermore, eosinophils have a number of chemoattractant 
receptors, as well as pattern recognition receptors that may be directly triggered by pathogen-
associated molecular patterns (PAMPs) on Pneumocystis itself (98). One component of the 
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Pneumocystis cell wall, chitin, triggers airway eosinophilia and allergic airway inflammation in 
mice (278–280). Much like the in vivo studies described above with granule proteins, giving 
recombinant proteins in the airway and monitoring eosinophil influx could elucidate which 
chemokines, cytokines, or PAMPs drive eosinophil recruitment. These studies could also be 
performed in an in vitro transwell system with possible chemoattractants in the basolateral 
chamber, with the primary outcome measure of eosinophil transmigration (281). Eosinophil 
activating cytokines could also be studied in an in vitro assay, as various doses of cytokine (e.g. 
GM-CSF) could be added and changes in Pneumocystis burden could be monitored.    
 Understanding the molecules responsible for driving pulmonary eosinophilia could also 
be informative in the clinical setting. A subset of patients with HIV/AIDS, particularly those 
with lower CD4+ T-cell counts, can have an increased absolute eosinophil count in the periphery 
(282). AIDS patients with peripheral eosinophilia rarely have active urinary or gastrointestinal 
parasitic infection, although eosinophilia was correlated with increased anti-parasitic antibody 
titers, lower CD4+ T-cell counts, and prior diagnosis of an AIDS-defining infection (283). Of 
course, this exact cohort of AIDS patients with low CD4+ T-cell counts is the one most 
susceptible to Pneumocystis pneumonia. All of the above studies beg the question: do patients 
with HIV/AIDS and peripheral eosinophilia have decreased incidence of Pneumocystis 
pneumonia?  
While it is unfortunate that this particular study has yet to be performed, a few different 
outcomes are possible. First, it is possible that peripheral eosinophilia in AIDS patients does not 
alter the incidence of Pneumocystis infection. One such reason for this finding could be that 
peripheral eosinophilia does not correlate to pulmonary eosinophilia. While driving eosinophilia 
in our murine model certainly resulted in more eosinophils in the bronchoalveolar lavage fluid, 
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this may not be the same in humans with AIDS. It could therefore be the case that patients with 
peripheral eosinophilia and Pneumocystis pneumonia could benefit from inhaled delivery of a 
chemoattractive substance capable of recruiting the eosinophils to the lung. Another alternative 
explanation is that an eosinophil activating factor may be lacking in patients with such profound 
immunodeficiency. Similar human eosinophil antifungal assays as described above could be 
performed with samples from these AIDS patients with peripheral eosinophilia to determine if 
these cells are defective in fungal killing. This could again lead to discovery of activation factors 
capable of stimulating these cells in vivo to further combat the fungal burden in the lungs.  
 However, a second outcome in the hypothetical study examining peripheral eosinophilia 
and Pneumocystis pneumonia incidence is that patients with peripheral eosinophilia may have 
transient colonization, but not fulminant infection, with Pneumocystis. Perhaps the eosinophils 
are sufficient to keep Pneumocystis burden contained, but not clear infection. This outcome has 
some preliminary evidential support, as one small study found increased bronchoalveolar lavage 
eosinophils in patients harboring Pneumocystis infection (130). However, the study by Fleury-
Feith et al. did not examine if a negative correlation between eosinophil number and 
Pneumocystis burden existed. It may therefore be possible that eosinophils, which act as a 
protective and temporary bridge until the adaptive immune system responds in the murine model, 
exist in equilibrium in the context of Pneumocystis colonization or infection in an 
immunocompromised patient. The peripheral eosinophilia in this case is not protective per se, 
but could be used to raise clinical suspicion of Pneumocystis pneumonia in addition to parasitic 
infections.   
A third speculative outcome for this proposed study is that peripheral eosinophilia does 
decrease the incidence of Pneumocystis pneumonia. This outcome would certainly be consistent 
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with the murine studies contained in this dissertation and would further justify exploring the use 
of eosinophils as a therapeutic agent against Pneumocystis. Biologic therapies such as treatment 
with recombinant IL-5 could therefore be used in severe or TMP-SMX resistant Pneumocystis 
pneumonia cases and could represent a new pathway of targeted pharmaceuticals. Furthermore, 
peripheral eosinophilia could then be used as a biomarker to identify patients at lower risk of 
developing Pneumocystis infection.  
The concept of potentially exploiting eosinophils as immunologic mediators against 
fungal infection was and continues to be limited by the pathologic role of eosinophils in allergic 
airway inflammation. A subset of patients with asthma has increased eosinophilia and a strong 
type II immune signature (137, 140, 284). In eosinophilic asthma patients, blockade of IL-5 
signaling significantly reduced steroid dependence and exacerbations compared to a placebo 
control (285). These findings, coupled with murine studies that implicate eosinophils as pro-
inflammatory airway irritants, suggest that increased eosinophilia is detrimental in the lungs 
(148). Therefore, any proposed therapeutic interventions for Pneumocystis pneumonia that 
induced or stimulated eosinophils would have to be thoroughly vetted for unwanted changes in 
ventilation and airway resistance. Inducing an asthma exacerbation in a patient with a fulminant 
pneumonia would be less than ideal.  
Therefore, a balance would need to be struck between the protective role of Th2 cells and 
subsequent eosinophilia in response to Pneumocystis and the pathologic role of Th2 cells and 
subsequent eosinophilia in asthma exacerbations. Essentially, the immune response to 
Pneumocystis closely mirrors that seen in a subset of asthmatics, which led us to explore the 
question: Could Pneumocystis exposure be contributing to asthma pathogenesis?  
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In our murine model, repetitive exposure of Pneumocystis antigen led to Th2-
polarization, increased airway hyperresponsiveness, and goblet cell hyperplasia similar to that of 
known airway allergen, house dust mite (Figures 3-5 and 3-7). While this model induced robust 
pathology in a CD4+ T-cell dependent manner (Figure 3-9), this may not represent the most 
physiologic form of inoculation. While both primary Pneumocystis infection (Figure 3-1) and 
natural transmission via a co-housing model (data not shown) induce a strong Th2-response, it is 
unclear at this time if either model is capable of inducing the hallmark functional changes of 
airway hyperresponsiveness. In particular, studying the mechanisms of allergic airway 
inflammation in the co-housing model would be fascinating, as this model, despite its technical 
challenges, would represent the mechanism of infection thought to occur in the human 
population.  
The current model of Pneumocystis antigen exposure studied in this dissertation was 
highly informative in a number of ways. First, Pneumocystis antigen model allowed for direct 
comparison to the previously studied and validated model of house dust mite exposure by 
controlling the timing and protein dose of inoculation (286, 287). The immunologic similarities 
between the two models strongly suggest that like house dust mite, Pneumocystis is capable of 
behaving as a common airway allergen. Second, exposure to sterile Pneumocystis antigen 
allowed for the use of knockout mice that would have been otherwise susceptible to 
Pneumocystis infection, such as Rag1-/-, Rag2-/-Il2rg-/-, and Gata1-/- knockout mice. Use of 
genetic tools, coupled with antibody-mediated depletion of CD4+ T-cells, allowed for the 
examination of the cellular populations responsible for the pathology. In the sterile antigen 
model, CD4+ Th2 cells appeared to be the predominant mediator of the detrimental inflammation 
(Figure 3-9). ILC2s, as well as eosinophils, appeared to be largely dispensable as effector cells 
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causing inflammation (Figures 3-9 and 3-11). However, preliminary studies contained in this 
dissertation implicate ILC2s as upstream mediators responsible for maintaining the optimal Th2 
response (Figure 3-10). Therefore, the pathology mediated in this model was largely dependent 
on CD4+ T-cells —the same cell that is critical for the protective response in both mice and 
humans.  
The immunologic sensors that lie upstream of the CD4+ T-cell response remain largely 
unknown. For example, the bronchial epithelial cells and intraepithelial dendritic cells are likely 
the first cells exposed to Pneumocystis in the airway. Understanding the pattern recognition 
receptors (PRRs), such as toll-like receptors (TLRs) and C-type lectin receptors (CLRs), that 
respond to Pneumocystis and initiate the immunologic cascade that follows would be highly 
informative (151, 288, 289). C-type lectin receptors, such as Dectin-1, Dectin-2, Mincle, and 
others, are responsible for sensing sugar and protein moieties contained within fungal cell walls 
(288). Future studies examining the role of these CLRs in initiation of the pathologic response 
would be informative for three reasons. First, by identifying the receptors required for 
recognizing Pneumocystis, mediators downstream of these receptors could then be evaluated for 
a role in the host response against Pneumocystis. Second, if the receptors lead to a pathologic 
response, blocking the accompanying signaling could lead to novel strategies to 
pharmacologically limit such pathology. Third, identifying a receptor would provide further 
information about the ligand from Pneumocystis that triggers such a pathologic response. 
Establishing the pathway of Pneumocystis recognition and identifying targets downstream of the 
initial ligand:receptor interaction would facilitate further understanding of the immune response 
against Pneumocystis, both pathologic and protective.  
 180 
In addition to possible pathogen associated molecular patterns interacting with PRRs, 
other virulence factors from Pneumocystis could contribute to asthma-like pathology. For 
example, in Aspergillus mediated allergic airway disease, fungal proteases appear to initiate the 
inflammatory process in the lung (176, 177). The target of the proteolytic cleavage appears to be 
fibrinogen, which once cleaved, can signal through a TLR4-dependent pathway to upregulate 
mucus production and fibrin clot formation in the airway (290). In an Alternaria model of 
murine allergic airway inflammation, a fungal serine protease triggers the release of IL-33 from 
bronchial epithelial cells and initiates a Th2-skewed response (193). Interestingly, proteolytic 
activity does not appear to be necessary for Pneumocystis driven airway inflammation. The 
genome of Pneumocystis encodes multiple proteases with homology to proteases in Aspergillus 
and Alternaria. However, protease activity in the Pneumocystis antigen preparations was 
assessed by casein zymography and by in vitro cleavage of fluorescently labeled peptides; both 
techniques revealed little proteolytic activity (data not shown). While this lack of proteolytic 
activity could be an artifact of the Pneumocystis antigen purification process, the very same 
antigen preparation was sufficient to induce allergic airway disease. Therefore, unlike 
Aspergillus, which requires protease activity to induce asthma-like pathology, Pneumocystis may 
have a protease-independent mechanism. 
While the novel murine model of Pneumocystis driven allergic airway inflammation is 
highly informative for elucidating mechanisms of disease, it is unable to answer if this 
phenomenon is observed clinically. Pneumocystis exposure is common over time in humans, as 
80% of individuals will have anti-Pneumocystis antibodies by the age of 13 (61). Interestingly, in 
a cohort of adult healthy controls and severe asthmatics, anti-Pneumocystis IgG antibodies could 
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be detected ubiquitously (Figure 3-14). However, the intensity of binding was higher in a subset 
of severe asthmatics, which correlated with worsened lung function (Figure 3-14).  
While this initial study of antibody levels yielded exciting, positive results, measuring 
anti-Pneumocystis IgGs does not accurately reflect infection status. For example, a patient may 
have a robust IgG response against Pneumocystis from multiple prior exposures, but may not be 
actively colonized with Pneumocystis. Therefore, understanding the Pneumocystis colonization 
rates amongst patients with severe asthma would be a next logical step. This could be done in 
several different ways. First, a noninvasive nasal swab could be used to screen for Pneumocystis 
RNA by qRT-PCR. This has been done previously in the laboratory and would be very easy to 
perform in an outpatient or emergency room setting. The second, more invasive option would be 
to collect bronchoalveolar lavage fluid from patients with severe asthma. In addition to 
quantifying Pneumocystis RNA, bronchoalveolar lavage fluid could be assessed for cellular 
infiltrates (e.g. eosinophils) and pro-inflammatory cytokines (e.g. IL-13). Furthermore, 
correlations between Pneumocystis colonization and pulmonary function could be performed at 
the time of screening, similar to that performed in this thesis (Figure 3-14). Either approach 
would provide excellent information regarding the snapshot colonization rates of Pneumocystis 
in patients with severe asthma at a specific time. 
The other variable that these studies would aim to address is the role of steroid use in 
enhancing Pneumocystis exposure. Pneumocystis is a remarkable opportunist that thrives under 
settings of immunosuppression; severe asthmatics, by definition, all have local pulmonary 
immunosuppression at the very least (135). Oral steroid courses are frequently used to treat 
asthma exacerbations and some patients, regardless of asthma severity, see little change in 
disease progression following steroid administration (133, 137). It is therefore possible that 
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Pneumocystis colonization rates in patients with severe asthma would then positively correlate 
with dose of inhaled corticosteroid, length of corticosteroid use, and/or courses of systemic 
steroids. Depending on the cohort, it may also be possible to follow Pneumocystis colonization 
pre- and post-initiation of inhaled corticosteroids in children not otherwise exposed to steroids. 
Of course, defining the relationship between steroid initiation and Pneumocystis may be difficult 
in a clinical setting. Should this be the case, Pneumocystis colonization rates could be assessed in 
our mouse model of natural transmission, with a cohort of mice receiving local or systemic 
steroid exposure.  
While characterizing the one-time colonization rate studies described above would be 
informative to get a greater sense of the prevalence of Pneumocystis colonization, both studies 
would fail to assess causality of Pneumocystis infection. To address that question, a cohort of 
patients would need to be followed from birth or infancy. The study design would include nasal 
screens for Pneumocystis at all routine visits to the pediatrician during the first year of life, 
coupled with assessment of wheezing, cough, rhinitis, etc. The children would then be enrolled 
in the study for years (approximately until adolescence) and diagnosis and severity of asthma 
would be followed. This study, while challenging to execute, would be informative for a number 
of reasons. First, one study in Chile found near universal prevalence of Pneumocystis by qRT-
PCR or immunostaining in infants that passed away at four months of age (187). The proposed 
study above would aim to validate the ubiquity of Pneumocystis colonization in young children 
using non-invasive measures. Second, this study could address the temporal relationship of 
Pneumocystis colonization and development of asthma (or vice versa). This would need to be a 
fairly large study, although the prevalence rate of asthma (~30%) is high enough to make 
enrollment feasible.  
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 All of the above clinical studies examining the role of Pneumocystis in development or 
worsening of asthma are critically important in the sense that if a relationship does exist, this 
would allow for potential therapeutic intervention. Trimethoprim-sulfamethoxazole (TMP-SMX) 
is used clinically for prophylaxis in high-risk patients and for therapy in patients with diagnosed 
Pneumocystis pneumonia (95). While failure of TMP-SMX does occur, the fact that a 
pharmaceutical exists and is deemed safe for long-term use in certain patients, including 
children, offers an exciting possibility that intervention in patients with asthma and Pneumocystis 
colonization could improve disease. Although we are likely several critical studies away from 
initiation of a phase I clinical trial, the ability to prevent or reduce colonization of Pneumocystis 
and reduce disease severity of asthma with TMP-SMX would represent a tremendous 
opportunity to impact clinical care for a large patient population.  
 Another fascinating implication of Pneumocystis exposure occurring early in life is the 
possible relationship to a histologic finding common in infants: inducible bronchus associated 
lymphoid tissue (iBALT). iBALT structures were observed in nearly half of autopsy specimens 
from infants passing away from trauma or congenital defects (222). One study by Emery et al. 
further demonstrated that iBALT formation occurs in the majority infants by the age of 10 weeks 
and is nearly ubiquitously detected in children by three years (221). However, estimations of 
iBALT structure prevalence in adults varies widely, from completely absent in some cohorts to 
detectable in 70% in others (230, 291). Interestingly, the percentage of iBALT in adults does 
appear to rise in patients with pulmonary pathology, such as smoking or asthma (230). iBALT is 
also present in patients with chronic inflammatory processes such as pulmonary complications of 
rheumatoid arthritis and chronic obstructive pulmonary disease (COPD) (219, 230, 236). 
Strikingly, the conditions associated with iBALT formation (e.g. infancy, asthma, autoimmune 
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disease, and COPD) are very similar to the conditions associated with Pneumocystis colonization 
and infection. These connections, coupled with our remarkable histologic findings in our murine 
model of Pneumocystis infection, led us to further explore the formation of Pneumocystis 
dependent iBALT.  
 Much like the earlier studies looking at type II pathology, we were able to demonstrate 
that both inoculation and natural transmission of Pneumocystis lead to the development of 
iBALT (Figure 4-1). Pneumocystis iBALT was dependent on CXCL13, which was regulated by 
both Th17 cytokines (IL-17A) and Th2 cytokines (IL-13) (Figures 4-3 and 4-9). Interestingly, 
as mentioned in Chapter 4, these findings represent the first model of fungal iBALT in mice. 
However, as this iBALT project is more in its infancy than the eosinophil or asthma projects, 
there are a number of future studies to conduct to complete this story.  
 For one, the exact mechanism of Cxcl13 transcript induction requires further exploration. 
While the current studies elucidated two novel transcription factors capable of regulating Cxcl13, 
STAT3 and GATA3, how this mechanism occurs is unknown. For example, the Cxcl13 promoter 
and gene contain both STAT3 and GATA3 binding sites. However, chromatin 
immunoprecipitation assays with anti-STAT3 or anti-GATA3 antibodies would be required to 
assess transcription factor binding to the Cxcl13 promoter. Another hypothesis for the 
requirement of two transcriptions could be that one transcription factor is required for 
modification of the epigenetic landscape of the Cxcl13 promoter, while the other is required for 
initiation of transcription (292). Such modification could include demethylation or deacetylation, 
both of which would make the chromatin more accessible to transcription factor binding. 
Experimentally, the role of demethylation in regulating Cxcl13 expression could be determined 
by performing single cytokine stimulation (e.g. IL-13 or IL-17A alone) coupled with inhibitors 
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of DNA methylation, such as 5-azacytidine (293). Likewise, an inhibitor of DNA acetylation, 
such as trichostatin (294), could be added to cultures of pulmonary fibroblasts with IL-13 or IL-
17A stimulation to assess induction of Cxcl13. 
 Two pieces of evidence support the epigenetic modification hypothesis. First, Rangel-
Moreno et al. has shown previously that IL-17A stimulation alone was able to induce Cxcl13 in 
neonatal pulmonary fibroblasts (220). However, in the current study, Cxcl13 transcript levels 
were unchanged following stimulation of adult pulmonary fibroblasts with IL-17A (Figure 4-9). 
These findings could suggest that the Cxcl13 epigenetic landscape changes, and while open 
during development, becomes more closed in adulthood. Epigenetic changes certainly occur 
during development, as methylation states change greatly in peripheral blood cell populations 
from neonatal cord blood to adulthood (295). Second, using a luciferase reporter system, 
increases in Cxcl13 transcription were observed following stimulation with sodium butyrate, a 
short chain fatty acid that has histone deacetylase inhibitor activity (296). Furthermore, Cxcl13 
transcription was enhanced with pre-treatment with 5-azacytidine and/or trichostatin (296). 
Taken together, these results would suggest that epigenetic modifications may be occurring in 
the Cxcl13 locus.  
 While further in vitro experiments need to be performed to elucidate the precise 
mechanism of Cxcl13 regulation, several questions remain about the development of iBALT in 
vivo. First, although suggested by studies with Il17rb-/- mice, the role of Th2 cells in initiating or 
propagating Pneumocystis iBALT could be further explored. Using CD4-cre Gata3fl/fl mice to 
abolish Th2 differentiation could be a useful system to determine if Th2 cytokines from an αβ T-
cells are required (297). Upstream mediators of the Th2-polarization (e.g. CLRs) as described 
above could then also be evaluated as important initiators of Pneumocystis driven iBALT.  
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 Furthermore, the role of iBALT itself in host defense or Pneumocystis driven pathology 
is unclear. Much like prior publications examining iBALT in influenza (213), mice lacking 
peripheral lymphoid organs (Lta-/-) can clear Pneumocystis pneumonia comparable to that of 
wild type mice (Figure 4-3). However, Cxcr5-/- mice lacking CXCL13 signaling and iBALT also 
clear Pneumocystis adequately (Figure 4-3), suggesting that iBALT is sufficient, but not 
necessary, for immunity against Pneumocystis. In terms of pathology, however, it is unclear if 
these iBALT structures would contribute to the allergic airway inflammation seen following 
repetitive exposure to Pneumocystis antigen. It would be worthwhile to explore changes in 
airway hyperresponsiveness in the Cxcr5-/- and Lta-/- mice to evaluate if the presence of iBALT 
structures contributes to the functional changes associated with Pneumocystis exposure. This 
could also be evaluated on re-exposure to live Pneumocystis infection, as iBALT structures are 
thought to contain memory T-cell responses that would presumably expand upon stimulation 
with the cognate antigen. These studies would undoubtedly begin to address the role of iBALT in 
Pneumocystis-driven allergic airway inflammation, and possibly strengthen the link between 
iBALT and asthma (230, 298).  
Assessing the role of Pneumocystis-driven iBALT in humans would also be highly 
informative, although it would be challenging from the perspective of obtaining a piece of lung 
tissue for histologic analysis. Therefore, it may be worthwhile to retrospectively look at sample 
cohorts previously obtained. For example, the cohort described in the work of Vargas et al. 
detecting colonization of Pneumocystis in deceased infants would a fascinating population to 
examine (187, 188). This cohort has archived histology and RNA samples, both of which could 
be assessed for iBALT and expression of Cxcl13 transcript, respectively. Immunologic markers, 
such as Il13 and Il17a, could also be evaluated. Interestingly, this cohort contains subjects with a 
 187 
range of Pneumocystis burden, so correlations between all of the above markers and fungal 
colonization status could be explored. Mining these previously collected samples would 
represent a crucial first step in examining the role of Pneumocystis colonization in infants 
contributing to iBALT formation.  
 All of the above experiments explored the expansive host response to Pneumocystis and 
elucidated novel protective mechanisms of immunity against the fungus, such as eosinophil-
mediated killing and iBALT formation. The findings contained within this dissertation, therefore, 
could be utilized for the development of novel anti-Pneumocystis therapeutics. However, the 
above studies fail to account for the populations most susceptible to Pneumocystis infection: the 
immunocompromised. The individuals that have the most morbidity and mortality inflicted by 
Pneumocystis uniformly have a suppressed or defective immune response, and thus are unable to 
combat the infection. Therefore, designing a therapeutic that exploits the host response may have 
little benefit in an immunodeficient or immunosuppressed patient.  
 In addition to understanding the host’s immune response, we also utilized a top-down 
approach to discover potential antifungal drug targets within the Pneumocystis genome. 
Following annotation of the Pneumocystis genome, we characterized the Pneumocystis kinome 
(Figure 5-3). The kinome was highly conserved and dynamic throughout Pneumocystis infection 
(Figures 5-4 and 5-5). Finally, we used an in silico approach to target a class III PI3K, VPS34, 
and discovered several compounds capable of killing Pneumocystis in vitro (Figure 5-8).  
 There are several additional experiments that could further the potential use of anti-
VPS34 compounds. For one, although three of the compounds had anti-Pneumocystis effects in 
vitro, there is no guarantee that this is due to targeting VPS34. Pharmaceuticals often have off-
target effects and it is certainly possible that these compounds are perturbing a different system 
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within the fungus. To analyze this possibility, we plan to explore the fungicidal properties of 
these compounds in the S. cerevisiae system (Figure 5-7). Complementation of a Δvps34 strain 
of S. cerevisiae with a vector encoding wild-type S. cerevisiae VPS34 rescued the observable 
growth defect of the yeast. However, similar complementation experiments could be performed 
with the VPS34 from Pneumocystis. Presuming this VPS34 was capable of rescuing the growth 
defect of the Δvps34 strain, we could then use this system to examine the specificity of our 
compounds. Ideally, culture with our anti-VPS34 compounds would inhibit the growth or kill the 
S. cerevisiae expressing Pneumocystis VPS34, but not the S. cerevisiae VPS34 protein. This 
complementation system would also be highly useful in developing a high-throughput screening 
system where efficacy of a compound could be measured by alterations in growth (O.D.), as 
opposed to RNA yield of Pneumocystis.   
 The above complementation system could also be utilized to examine any off-target 
effects these compounds may have on the host VPS34. Addition of a mammalian (mouse or 
human) VPS34 back into the Δvps34 strain would allow for screening of toxicity of the anti-
VPS34 compounds against a non-fungal VPS34. However, it is also possible that these 
compounds have off-target effects extending beyond binding to VPS34. To explore off-target 
toxicity, I would examine the growth rates and apoptosis rates of murine or human cell lines 
grown in the presence of the anti-VPS34 compounds. These experiments would allow for 
examination of toxicity in a broader fashion.  
 While a novel therapeutic against Pneumocystis would be highly utilized and important 
clinically, one of the tenets of providing care to patients at high-risk for Pneumocystis is to block 
transmission. While this can be done via prophylactic administration of trimethoprim-
sulfamethoxazole, adverse side effects as well as difficulty implementing a daily treatment limit 
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the efficacy of such therapy. Towards that end, we sought to identify novel vaccine targets 
capable of inducing protective humoral immunity capable of preventing Pneumocystis infection. 
This approach would utilize a patient’s immune system while intact and would hopefully provide 
protection even after disruption of the immune system by HIV progression or initiation of 
immunosuppressive medications. 
 To identify novel antigens, we used unbiased –omics based techniques. Previously, we 
utilized surface biotinylation and proteomic analysis to identify extracellular proteins (264). 
Here, we explored the ascus and troph specific expression of these extracellular proteins and 
found that two, GSC-1 and Meu10, had enhanced expression in the ascus and the troph, 
respectively, using RNA-sequencing (Figure 6-1). While immunization with Meu10 was capable 
of reducing Pneumocystis burden, vaccination with the extracellular region of GSC-1 was 
capable of preventing Pneumocystis transmission in a co-housing model of infection (Figure 6-
9). 
 The above findings highlight a number of novel aspects of Pneumocystis. First, the ascus 
form of Pneumocystis is transmissible form of the fungus. Pharmacologic depletion of the ascus 
with an echinocandin antibiotic prevented transmission of infection in a murine model (55). The 
findings above further support the notion of the ascus as the infectious form, as prevention of 
ascus transmission was sufficient to limit Pneumocystis infection in an immunocompromised 
mouse. Future experiments will examine the length of protection of GSC-1 immunization in the 
murine co-housing model. In addition to primary vaccination and CD4-depletion, wild-type mice 
could be immunized with GSC-1 and sera could be passively transferred to Rag1-/- mice. The 
recipients of GSC-1 sera could then be co-housed with an infected mouse to demonstrate that the 
protective component of the vaccine is a soluble factor (e.g. antibody). If these experiments 
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further demonstrate that anti-GSC-1 antibodies are protective over a long period of time, the next 
step would be to move to a non-human primate model of immunization and Pneumocystis 
infection.  
Secondly, in the murine model of Pneumocystis infection, immunocompromised mice 
with anti-Meu10 antibodies had reduced Pneumocystis burden by qRT-PCR and histologic 
analysis. These findings suggest that antibodies targeting the trophic form of infection may have 
therapeutic benefit in the setting of a fulminant Pneumocystis pneumonia. Towards that end, the 
effect of passively transferred anti-Meu10 antibodies in the context of high Pneumocystis burden 
in an immunocompromised mouse could be explored. Furthermore, the use of Meu10 in the co-
housing model described above could add to our understanding of Pneumocystis 
transmission/infection, as the protection against the trophic form should not prevent 
transmission.  
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